var title_f23_7_23664="Nasal encephalocele";
var content_f23_7_23664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasal encephalocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nasal cephaloceles are herniations of brain, meninges, and/or cerebrospinal fluid through a defect in the skull. Those containing brain tissue are termed encephaloceles. They may communicate with the subarachnoid space and, occasionally, the ventricular system. The arrow points to&nbsp;an encephalocele&nbsp;underneath the nasal dorsum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Marvin A Fishman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23664=[""].join("\n");
var outline_f23_7_23664=null;
var title_f23_7_23665="Unstable UCL";
var content_f23_7_23665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulnar collateral ligament: Unstable",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Abduction stress placed upon the ulnar collateral ligament in the photograph above reveals increased motion, which may be due to a partial ligament tear. Patient history and comparison with the opposite thumb can determine the nature of such increased motion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23665=[""].join("\n");
var outline_f23_7_23665=null;
var title_f23_7_23666="Periorificial dermatitis - perinasal";
var content_f23_7_23666=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Periorificial dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4AcADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDmRGE7fMf0qVIeQXAx6elTRpnhAeelT7djqoGR1PvQmdTRBsYgqPlB6fSn+UuQoyTjnNWYowc5IyanWMdCvGPzp2FsRxKqxZZcZ6r/AEqWOMOyq3BPJ9vapI42YIAMt1PtViNdoOT97t3NBPoMSMKoAOc/zqeGMKD3/iPrToY1LA4z2FWo4s7vrgk+lCQmMEeWGfu9MYqWJfLVuh6mnKMlQvRc1Nt688HBAHrQMerAkHPzKBwafs3S4AbnofSkjQEMehzyBT2fIAVOTzk9KqwbaIeTGVVlzlcdv51PGcMMlSvcmq9rGAMk5ZuoPT3qwhXZt2gkHr6+mapeZL7DCAZCVYdcj0NSLwRuUEN0x/hTAm45AG0noe2KkQqcrJkYGD8vJNRYTIFnQfJIhzn0pV5ZcMGAOGB7e9MwEyQxBA4GetOjOVzkFx0I/SoTBpdCZEBYbBlsEgE9aaZSJFQfIcYIYcZojAaMyHGVbJFPBj+8qkY7+xrUlDz9zJUKc54odSw+VgCTnPpSEsYRtIypyML1/GpQMtkj7w4NU0mhbFe2XbAyvgEHvwT75/pUo2odoG1Sc8HPFJeI6YHJzgHBzxUUbNkbsDuMHOayvbQvV6luQMGLkhfmwChyDQ25mxM3bP3eopUVSNzIWx1wcDH17VDIMBeTsJ9+KrYhEhOQ20jg8ZPP40xQN204D9OvaoyGVRuz5Z/iz1oiYMQvdePlHJ96XNqVbQkkfaw+XnsSOvqR6UpBLYAG3qCOSPpURiLMpyoP3cA9R9asAL5aqgI2/KDn+lPW4aIbKhIACsxHcHkLViMAgKy4wOMdvXNRSzbArAZ+XA29R9fehHYgso68EGjqGrQ5YSF/djC9weMk+lTE5PyjkHHPY/4UbiTuOEJ6jnFNkUyRqCMMuQV9Kq1thXvuQiZdwA5O7BH9PrUkLozOyry3cf1qsYHLhvkBwfoPpU1rGUJUqQe49PxrC7vqXZW0L1vHvbaCo29OO9TxFV+Uglj+WP8AGoYpAycMAwOOnX1qZsAB/wCHoPU1svIzJVfYOnGe/Q1Tv52SSLYCHY9CcY+gq2ZfNYAKMeuOtVJR++IOT1GT1HrzRPYcd9SCZhMVSRQAvVT1JNWuIYW/eHbnaAf50FIEcYIVMYA7k57UxvmZFC53D8MVnbqXvoRsrY29fWq0yRyJjr/SphC4IRjtcnk9cVHOvlbnCtnGCvepuyrdjkNTtPst5vQEIx/I1PGwKjmtu6tUuoCJB8xHUdq5qZmtZGik6rx9a1ps4cXTvqi7mlzVFbpc5zUouFPQ1tc4XFlnNAqETA0okFArMkNFN3g0ufQ0xWHGkpBS5FIBR3pKKQ0wOUCbRjp9O1CREjc3BP6CrIQZOfur1qWONR80nQckfyFch9FcZDHuO7BC9Oe3qcVZRcgoMY3cHFERXOBhs9hVgLhCoGeMfLVIl3GJGNpYH/PSrBiUsRxtC9u1KilcL2XnnufSpY/mypI5/SgizCBdgBI9wBUwUAA5+9+lIiHZmpYUO/lPc/lTFbqK6cgY5I7URoQAD65zmnKxDBjxjoB0qfbukDKi8n8KGPYYigO+7APXPrQ6/NxwB0qSRR5KgH5s5BH60kYJ3HncRjmhPoF+oqRnkEgYOOTxmjgKAy8txz0FTkEAHC7u3GKryyIrgjr3FU9AWo+MHzFaM4LcfiKm8wx4YBSw5OT1pgKsU2cNjuOnpUjk7ct8x/u4xU7EshmVHkJZQN3XB4zT12FT1BVdrEevrTjtZPlwcjnDZz6E1X8xQ33cY7D+7S2FuOU9CHUr15ODn0qWXDbcNjoQW4xVZwGkQrg9uBzVmJhx5vAPAOOAfWhA9CVeUDBjk8tgYApwKhAGUbfUdD/9ekIUSMFZsZHI7j1ApVKo/wAxwM9CM4/CtCBZIyAAAdqA4yMnGaZEDEwdeDzgnndT2ODlSDg5x2xUfmYO5cDPXjr9aTSKTFU/KcMM5z701WcqwRnIPbj8aRvnbLO24/NyacD5eGZNy9QBzj2pDImB3EFfk756ZNSQqqsxBKjp74/z3pHbeG2k7yeD6j6VIu1S2VLKygN9c/pSSVx30Ezwc4wfbpSs4zuHJBxkin9AuDg+56j0qOVwRtDZCnA9qpuwkrkrKz5cjlByQOnpmnRKADkE454OKrSNhlKMq/LyV46+tTI58sp6DI4+6f8ACpT1BrQnYBcDO5cDJ9Pwp/zbSw+XIwSR1/CqonVxwCpAwwABzUqyYYoOcng9v/rVXMnsKzBCJN2f5dakaPPcnccls/l/9ehI9rEMevGB2qaJDgArg859MiptfcbfYSBAsh+UZPJPYe1WyScLyRzgjtUUZGVLHt0x09qlXLlt3GBwQTj6U46EvUezHaWK459sCmMMkEruHTIX7o/rUo4IYgDBwT1FJtYqWbkKecnrmqkCKNzC7sGRQRxlun5d6fkIixKVUdcAfpVtsZJzkYxhutRldjKCodgfl2dveoas9C07ogZWx1GSfvep/wDrCq0itvOW6dK044d284AUdT3+tUruMbMpk5680pR0Gpa2M+VNhLh8AnkVieIbMXdr5keROvA9/at8xODskGVYdKovlS0TKxizjcR0rHmcHcuUVNWZ5VLqzW8zRSkB1ODz3qeHWkx9/wDWrfxP8NzyWZvdPT99kK6qO/Y+w968ZOqXEEjI7EOpwQeoNdfOrXOJ4fsezx6srfxVYTVFP8VeNQ+IJl6k/nV6DxKwxuJpqUTN0JHsEeoqe4qdL5T3zXlEHicHGWrRt/EiHGX/AFpozdJo9MW6UnrUq3C+tefw+IEP8f61di1xWx89MhwO2EymniUHPNclHq6n+MD3q3Hqi4HzUhchPEjKoJxyaJVJXLZPcCnxYkdVXPTLGp3i3j5TgiuSWq0PdvZ6kFsxEnTkdcDge1aEJOB0A6sfb0qG3hAbkev4Vdhty0YzjGen9aULomTQ5YcR8857ntmpbaEq3bPTmnBBlV3HaSTxVgfIRuUZHBUCtvMzb0EjGMHGT1IzSrkHcpJI4GaRpAWPHfimrKA3Qkk9hQ2kJJkhA3HOQnOe2BSoeBgjGM/hSyI0kfJGDxTVxHjkDjH1pN6jWxIgCtgnjFOibBXjk0cZXoQR0FRt+6O3cM9/Y+lNsLXLMsgRCMseKqwxHzBKxIYHBBHFChi6lioUnnnpVlWCBSg56EfyNLfcPhJWVSx8zH1HbNIFLIAQAM4PY5pQ37vZIo56c05DH5h3ZQk7SAen0qyNSMqyqwIHXqBVN2RJFIcDOe+fy/wrQlBy20kAnoTVWeJd4CsDjOGPYj1zUzQ4vuR5VgNgGR0I6fSpkIfhSGxg7WPQ1WZSG+VQMHPyj2qZVVFJX1yA3f8AGlF9AaQ8yrEoYkqDxjHI71KJVk+Ynr8pbOarSbniDBypz+H402BHiDH7wY4OTgD3o5nfyFZWLhbcCeSw5JA/zio5HC9ByeA3NJEcHhU5J681FIy7wFDYPO3rVOQRRKXy3TCnsBnFBPlsGcFR3IOcfQ0igMvJOB90kUiyPEyjkjoM80rjJTnDdBznGcioFkZmJBU9+D+dTbQOU6njbjp9KXC7TIuARwQOc+9JpsY9ADgFlBPIx2NKfmLA43dzjI+tRtyPkwWz0PFOMwQodoCr+OfrVPzJSIIwYmJJLA9QR69RVhnK52jcjgKQBzgVEUCsRkEf5xUuSvDLkEjgn2qErFvUiRCW/dNxt6elSqxWUbmyD19vemAhlaQAkZGeOfrSuBnKjDDJOfrS22HfuX0O7JBJ9+vFThl69RnqfWqtuwRVfAPseanUD+Hq2SPTjtWqd0ZPRgd5K4yMj8SferCuo+Vuwz06GoFlRSMrknpz1+tSxSbiGVgR1xULcGWsFgVXpjsOTSiME4P38VC74weRjqP8Kb5hIKtjI7gdRWjlYSTLDYGc/P8AXsfpTVJEmOTkcgHtTLeQEDcBjqRUy4b5lA+X+I80t9h7CZZWHlkA9DnnIPYVRG5LoIAWBOFz61ZZyd2wgk8ckBfzpsRMjM/ylunHQf41L10Q1oQT7fmyTkHkntWdcbSdpXPv61o3KjzthO5sZ+Wqbo2c4OOx9KyqXLhZFeaINDslUOGGCCODXz18V/CTaXqE19b/ADxSuXckYCg9AP8AOa+jX3KD3xWL4l0WDXNKmtJ1XDj5WYZ2n1qovow21PkPJzShyOhroPGHh2bQdYntpcKin5M55Fc9RsWPErDnNSLcuvc1XoouK1y9HfyL0dhVqLVpkP36yM0mafMxOCOlg16ZP4v1q/D4kcY3E1xeTTg7Doar2jIdGLPpqONo1cjBboDjqavRL8ikHJ7nFQTYVQX3DHTHrSQSSFihDBQcDHesuZRdmb2vqX4o1G0j86k483ABwBnFJCfmJIKkAAAVYCBlLA84xgVe+pntuNR92SSRgY+tTKpJyTkg96r4AJYrwMHjrU0EhkjI24OC2M0cy2BrsKITt3bgOOM96jEZEhIOMgk1ZEoEeTgtgKAKaCCD/ePGKJJPYE2LCm0AM3AHB9RUnlqzZ64A696hGCBjv15qbzG3A5AA6Y7VSatqDTJBGyxrnruP51Wmi2uX3krnv61JJclYQuOxFKFwoyBuZcjPvRJp6CV1qJHEGVskE4z9KcACCNoUjkc0K4UDYoGMkHNRTyl9wHU8nI60dAs2yxCFaT72cjKjH86WUAsrbdwx2OOB61DGgUgliTjPy8g1I+AyNkFd38ROMe9MVtRQxXOWyOmCKWSQE52gjOCR37VBKxB5jJU9CefamsSisQo2lewxmlKQWJXIyABypOCBzj3pjONqeWvI7Z4/Coi7Ftu4kr2I5FSAF8DAzj3NRcGrDEmXK5zuzwGXI9wanZAWBAHHAqg/EpIydx9e/rVxATGu0hhjpnkUQbejCUbbCSSgSKpxzg4I6/jTCpIKle+cn/PFSsVZgWxu7MTjilwC6kEjPB5ptdwRHlhIqgcY+lPEeHHPPpTXDZK9vypQ3Z2YA9B70bD3Hk4wy5Ge2D/OmBfmaQOSG4Ix0PrQX+Q7my2cHH86b5mDk4bIx1piJg2BkYwcU4lJFTJIfox/rUUeGlZ9w5GW5wD6VHMzKV2HdGent7Zo5rIdixIDkA4Yj7vaiUhgeSO4HfNMDMYzn5ucEHtTZW+QAkEfd596TegLcsQupRyWw/XB45/rQ8mMZ7DBA6Ef41StyNzDGOuM/wAqlQLghzkc5OPpipTbRVrMvRMTAy8+3v7VFHcvEAjsCc43E5zSIVEh3BVXP3lOcf8A1qaUwRvwGUgqxpyvbQSt1Ld0vmWysAMHleasQEhCmQVGWJ7/AJVXVnMZVR8u4EkjnntUi7ju3lRt4J7EdKaSvcnpYtxIFc9+4J6ew/KnPtD7dwZduS1MRQAAzbVcbwM/dx0/GmSAbjnO4YKkjg1b2J3ZOGYqzgYyOCRzmlKkJyfmHAUN/SiFdw2hhwOh7Cm3QkXGfvH8zStZXF1sNYO20FVRAPmbPOaEKoXUNuz0XJ5+tEUjyA+YW4PT0pSVilTLZU9scD8B1qPMq/Qe7Ow4AABwCB1+lVJkckjBC9s1eZ2U8kc85Hb29qZN5j3G5h94YyKclcUXYoRRkq2459qPLVgQRirsoEbYTLHo2ahYqX6YI7UkrIOZs4fx/wCEYfEWmMGTdcRKSgzjcf8AGvmbUtOm0+7ltrlCkkbYIIr7KlVjuKcHrivMPid4KTVIWv7NNlygy6AdfpTvfQadj54MZHakKkVsXFi8MrxyLh0OCPeq7W59Kz5ujK5jNwaTFXjb47VGYDTUkPmKtFTmI0wx0XTHc+onVmGep60tvAfMG4kHHI9KfEGYEbTz0FXUiUH5lyeRmhRU3crmtoJhVBZhjA/PNOEoIBGAO2KmdSyYc8dMtTFiVY0CjPPNW00SmmMVS4wcEAE5qSIY3Z5ycACkKumWAG0rjFOt0KgbSfmOSGGSCazV2x9CurbnDE9D0FO3skhYHpyT3qdVjVgipk555/lUr2wcJ0BZuF/rVcjaK5l1EjAZBwQSOo7UIgVACM8danlAB2KRgDt602EeZKOSQvpV2IT6iKA0Z3AkipSu4DBCjPWnNjcSuVAbqKbu2gjACg556E07WJvcYsbM5BAXI7jmojGVmDMSw6cDrj2q4n3QW4xzn0PpSpGmCYydwH60uW+wuYjUsUUBVwo69+vWmt3UfMQeRj9akOSygEAZ25xjFOmIDbW2k5IO0dKtCK0u5VG5FbAyD6g/yqBJPMDK6qR6kVPMyuCMrjjGOKghT74HQ8Dd0FRLctWsPQDPHO3kEL1qaMqFHzDOcYwfzqKKTbh+OOM571HLKqNyQOefWhaIOXmLO2NlViR+J6+9RbsDBGPQ56Uwynb+7k3YHIUZAHrVbz9xUnG0fQH8fWk5ByMuvIWQEgkA5GPWkDAngED1c9fxqFWzkKAB34xRtbbgEbT0APWmCRO5kWMeYpAzkE8/rTXw+QwyOxPFNGcZLHPQ4OQaCR8oJzznOOlAWFPzAoNwOMbsbunt6VEzbjtHPPI7CmzyqH2kkf7XJwffvTHfzAMn5gOD3I/rSGkEiYYYOTU0WGB5I/QfjUG4soBAwKlgYSPs6nHQdTQkNt2JFb+NCA3TB4pPMRgFbIGeMjpUMpAbAYcdfembmAIyCR3/AKikxJXFadkfg/KT3H55qzHKOByP1GKoSEBWbOSOue1QxTP55HGB2rPm5XZl8t0boZWGBgN708MGUglhjCkdc+lUYpCVGMA561PESwLYw+AeDWt7mdrF0K4UMTnjceece9WYo1SEncobP3c9AR/KqqlcLlvbjgmrWMozhRhVywA7dOlXYhssRKPLAZgvt6Gkba/8PIzggfeP8qp71WYYO4N2P8Qq7Cwki2ZKISSPX8/SldS0JasOt3BcHJGPbkVZJJGB1P8AKoIwCwIbkevBNTlmIGMFVH51STSJe4wxIvGWHfCnrUwJcgBzjPzDgVEgJySo4zyM05Jj8o6geoAqQZZeJSrDCqnXAIJqJsK3KkgjPAyaTzfLfAwpJ6M2d34U94XZW2jjrkdqq9xepSkYIcdCe1VpUMgHzEZ6Yq08aq4Bfhsj3IpkwVD8xxt7DvWb13NE7EIBCAMeR+tVrmEvgr+I9an3bwdvY96k+8vtSVnoDujx74jeE0AN7aRqFJ+ZVXkHueK8yks8EjHSvpy+t4p43gmUNHIMYIrx/wAX+Hn069dlUeUx+Vh3/ConDm2IloeePZnHSoHtCB0ro3t+elRPb57CstSeY5trX2qJ7Yg9K6R7YelQtbAjpRdoame9mIqQ5YhepzVxDySSACPSmOxmGW6KMClCsrFTzlvy/GupK2x0vXcaxcGPbzkk1PCCzbnGCBjGe9NkyoyOSBx7H1qKFmzwQYzxkmk2k9QSuiyRhRxkgcUiK2CW4BOc5pDLlVVgFJAJP1p0jeVHv55PFF1e4JNaEyhA2/knpmiVgpQk8L3FRxSbh2PP+cUSkYz0B6ZpuWmgra6ld5SzEL68ZHWra/INuSSeMCqMa7yqq2MtkA1cUAAZ6knBrOm29y5JbIkyxx8uee9MugyRBlyccFgOlK9wxk4G3A9ecU0Fm+VTuC/w9s+1W3fQhKxLE48rdjJGOegqWPfkknBxnpxURYBUKY5HTGPamSFjlTxgY7jn0prQVrkjkbVwAwx075oLGVMNxjkZPSoBKoGG+63PXkU12fGdu1W+6KdyuQGkLkbDuA5wOwoBVhkBs4yQTx+NRLuUhy/QkdO9SM52gAttHODUxuDQ2UqWICqO4AY1TlGdo3AMOuAankdskgMFxwCtV5GCoCDk+g4xQy4aDMAgq2MY57E02Jdkg29OwH/16iklKkEAkd+9SFmKgt83YUrJmjbJ9x38Flb09akQuYwUfIB6VRd9o5AHHSlgkHlyMZChHIHYmqFyaXNHLbstuUkZyelJJuKnAHHUEdPw7VUjlZl2klwOmacsmz1IzzighxsSseMseMdTUTbtqrn6D2prMM7l6Dt3qtK5BJVhkjIzwTSGotloyfKQeuPmz0qBZWVwVbDYxnpUjXBWIJKFeIHjI2unt9KilUPEskfXkEdx6Un5Fw7MmactwoXAGOnWiSRDEBn5/ft9KrpLkBVUAgZJA5JpSRgEHIIzRuS1YkKh13McdsVB5eyUszZQ8DPTNTKygfdz9e1JMBJxyADUSgmriTadi5D04+ZTjkc1cQgE7ZAVPIx2+tZkDsgAzgY71biY5G368jp61oiJIvxyLuZSPu8Ejv71ZEsjRkuQByAwHWqaMB8xA+apY34LY4I6nr/9aq1M2h0iBm3K+0gZUYwM+n1q5YzE4wQCAT8vG6s6UMTlGOQejHkDtVuBFyA3yqeQwH3T6VnHSQ3tqX4Wy+Ce56elWA2cLKM7uin+dVMfIp4JxgkdfyqWJw33mHTjHAroMWWZF8ztz6qajkYIoPCjtmnCbJTaWZl4+YZGPYU3yFZiQFz6n1qGuwLzJoT8vmEKpx9aFccA52/lSDiL3z0NRSStnBAP17UbINxkwUyloju9ailbfwwII49qTGGZxwv8R6/rTl/ebjnANZbssiVCjkDj0o3gHk9akbgKKguEyCyEg9aq1loG+5FcKG5PGKzdZsI7+yMbhS+MqWGa0c7l+br3qLYfL46g8Ur2YmtLHi+q6c9ndPG6beeBWcYeeBXp3jLSxcQfaVX5164rhXtzkiplHqjnlozIaEelRND7VrtB7VE0PtUcpPMevW6MVBK5YnoBUpACgsfmBwRTQ54A4wMZzTTJuBJOMcYzXRdHc027gfusxPPt1qKMKuMDK+/GabLM6sCv3MDA/wAafCrON7nbx8x64/CspO7sjRKyuxUG2UbPvNjA6g8UO4yOeSODjIzTYZAW2hQV4P0qYHcAMEnHp0pRXMgejGx/u3b5i2PyJpInb5ix9cAdvapE4zwOvWlblxhQMelO1tgvcjiQLufA3H9KkU7suePT60qRkoNmef1piBxOV4fByQB0/wATVLQNx75IBKjA7HqaYqujKCvyk4znqae2SW8xw3fPriq87gyELjZ7HPFJ7hFX0LSMqtuODg4PtTGZ5Bhd271Pan27l8nGNo4HX6Uhf5wXdQTkgD1z1/8A1VVtAtZlSVCJGJwG6sO9NMgzkuwJI46596Y00ssxZlVQDyvans2SS7LkdccZz6VNjVprcmk2iJmWQrjntgCoWuVbMbMcn+Hrk/WqYnkiDooBUkEcdDTY5G/ijDEnJBPX8afN2E6ehcaQbSXOAD91aqyyEcqB68DkVE0jMwU4BXtjpUTzfvBkEDvj+lFxKOo6G4IuVDHKHk5GakMitnaTt9MVTfrkZxUqFdg25DdyTST6Gkkh0pLKehx15qJVJI25z1wKlLFhhwcDn1pG27uWyfYU2rgpW0HJMy9AORjpkVYDM43YG4jsaq4DcAA56LnBP0qeM5wqr+D/AONNIUkmOE21SpXr3NQ3YUKACjYPDA/pU2YzblgGklBOU2n5B65qIoGVRvDEjOBjkUBBa3IWILLldgxnLH71DqyEoV+U8jPWmNtV/n3tHzgdCKcjFwFY7gMBTn9KRq1YmjuOgbaq5645FSuA25VYNjnIGP0quIyigke59qeF4ByMevp70K/UxklfQbvK8Y56fWpFfIHB65yajbaD0BPqBT2by2Qklvf0oQrXLWV+XDZyORjpU6uRgkjtmqMbHkjkZqxHnaeM0zNxsX4mLrjcAOgz3qZBwBmPJ9OPwrNWY5xgqD3NX4NnlpISdxbjHUfX2pp3JcbEcvmmNsAhlwQB6e1X7Z2kGNoXH3gvT60yAJ5ZHUg/dJx1609Ag+7zkY2+v1pKFnzXJcr6FwLIqgZXOc4fv7ZqSN2CgOhCsQVBOB9PpVWKRV2hxvB9/wDPNTPOzFSN5BJGScYrTRGbTLsb7g6bGZlJOMCpQSDkBY8AZAOefYVRjkO4jDMF6lWx/OpIrnBPKBsdGHA+nvVXJsWg3UEk89xj+VRvu38EMBxg9aWNkY5XIHYMc7qHbLsqqo9aUlcCCcttOBgelVlkO0jLVZmYDIyAD6c5qCQAZC96zlBvUuLFSTP3hTVcnIPI7Uzdszk01mK8jA9/WktAsJKOQ2cYqMSjYeCeccU4yhgapqzLNg52+1TJ2d0NK+5JdIssTKQGBGDXn2pWYgupExgZrvfMzIyk8deawvEEG8iUY47U9zCqtDkWg9qie3/CtUx0xowamxz3O7DZZeBk9TVSdW2hgwwTgGoVlIlyWKoAx+YdAKfbXCyghhtPYEdqHJS0Z6yi46kcsrY2g7gAAxPHNSxvulw7EE5yMdPrT2QTM2453fPnHpT7GARu0j43YIBPce9RytyKukhyxDYVQbSB3oikYE5bPGMHtUzNwwPPBzVMD5XOMDtzgnPAq5e69CFqncUXIjYqASB09c1PFPkcYzxu44FZ4UB+nP8AtevrV2BNueN2OvoDUQnJsuUUkWA/7xlzt4zk+lKsgIJHy4GSR1z6UwKVAbr7mguDggYP05Nb37mVuwkiJLtB4YnmozGhJCuQpOAOnFI5CspU9e9T25hUkSt8g79CfpSVmXsivKoUEKUXaDWa103mbkc7vU1duGD5AXA9B2HaqTRFCCVw3YVMrvY3ptdR0TH5m647HqfxqZBujDGMnHvmiFPnUsrHnH/6qHYIpCHHHOO1NaCk+xUnJDA4yD696rSSyBcRjnOOTwKtviQZ6ZPAzk4xVdsBTxyePmotcalZD3lLKFO0bR1A5P19ai2lueCB3piq4LEkbffinCUbQpByOhzinbuQ/IftG3BA9ff9KTO0DCkD1zThIUAXaGDDIP8AdqNyACc8+nrQ7AkyZFZgSg4HGc9KRomCqXOQehNRwM+0qApXqc8HFWERyQQxP06Y78UJdSrWZXKZ+6eSeM/41NDO6rtVm9CMciphbl14XGBn5Txj6GmCAr1QlfbrRZoaaehDcNJCd0L5yP4WyMEVDC5IAkjzt6N1GPpWj5Cuw28oeBng/jS26SQDaiqVY5AZMn8DWbi+a9ylJWsV1hJXds+Qn7wH8qeLYmMMEB45yK1ovLlQIlr5Jzln8xjn2x6E1ZhhCgEcOeMkZyK0jG+xhKq0Y8UA2lgjkqASS3PP86lWBTGSWAbptzyfcVsC3DO2OADk5/Kmy2wwF24BwSPQ+1XymLncwJrdpAq8hs4UkYqFYHOFIBI/Ot63h3GRdodcElc9PcVDLGFK4A3HoSMfjUtF+0exnxJjHHJGcVInXbkg/SrHl5ye+M+9Iq8gEY/CkFxgH/AqsW4YZXp61Gu0sc53DpjvVhBjlTz/ADoE3oTJuDrzjB4qR8K4MjEc9QKYpG0lCVxjHsakWQ+YAwLgc8EZqjJjl2PGwEjDv93+VJbytGzFty54OD2+lDAE4OwHGP7ue2KhlGSJUZww4bnqT60N21Ba6GgGhlHByF6ccipAyKQdhJHHJ5+uazYJvM+RsED1GDU2N+fKfAHUFsk0+a+pNrGmZRtXeDjH3n6/hTGmXcfLJA+lZpBQkLuDE8ljyPypyuVGNwJA78U+Zi5S28nOSfzqs8m9cZwahd/lwDg+tNyQpznPrUMpKxLv4A6+9LuyOKrmVV/GjfkDtmkmNjmOCeKjMY3dc4OaSQnaQetRh/l5zSaQrj2I3ZBzVDVAJIXHHSpnlwRzyaqXEgPDZIIPfFNGc1oYZXFMK1Ow5NNIpHGazAuRgEMe/pTtrebuwN4G48fhU8CNuZlJ2g4LGmXcczEFQwA+961i4aXPbvrYYLhvMKjIzxz3rUiy+MH5qyItxOGzjPT1q/FuZwrMQR3Pb1qqTfUU4k7kvHgkBTwTio2iAi2qcHIye59BTzwMEc9gazb6dwCFJH+Ga0qNRV2TGLbsizKgWPg/OOCe/wCFWLdVCqehIy2PWs/TTv3AnJyDx1xWruUKSeo4A9BU0kmuYJ3Wg2XDIVJ5/hHpULqp4BIAP51M+MZP1K0x9wUyfd9MdqprqJELIThVBKjufX0pZUaPAYDd7fyp0U+Yk5C4BHA9fX3oYZyWDHrgdeaFZ7FXZA7fKCRliSOO1RSFn++cY4z/AEqTaVLYyO30/GoNgBJ6D370mWgCSgbo8gED5s1FK3bvnOW4BpZ2ZNpJOMZwBjNVZ7gScBcDHb1qjRJsXfkFuQue/akkJ8veUIjP8R71XeRmXuQep96quWjVRJ35GP5imtCuS5e89ApGBgnJbvUJAwWUH39vxqKGdImcupbj5R703zQyndvLE5Bzx70N6C5LMes4jfK/hUnmNIy85BOfxqsoaRuFJGccCrCIRjAOR6Vkmy9C/HNLZ3EcpUeah3AMNwB/wq007XLedIAZMc4ArOhiZj82T6Vp20aqvC/n2rRNmMklr1LMe0oNw46Kf6VPAgBYEN+B79qVEQKDyR/FSKwC5AILHg+op3MbXLEUABU8sM8571L5X7rkYbJJ9qVHIjQBuo2gHjFTnCAo2Mf549qoh3KexRKjKSCDz6j3FWoY2KqxG585xmk8vzGBK5I+bjgnirSFV65xjgCosKTIgpDHuoBz3/OnGMFFOMkD5scH6in4DEbDnAxg96QIMk7s85GR+X41aZBTkURNkfeHUDuDTJkLL98suN3virYjdptygEtknHaop4gp+Qlcg7R/OkUZiZjkYtggn17+tSNgk5GSRzU0iZPKgEevHPeopFI+lK1hvUcEj2q428n7hpkgIChFYn6VKpxGyn8KhdvKz7HvQ9hLclix8pkJTJwT2FOYsFz1wPTtVQTqd3mBip65/Q0kcioF4IGcjJz+lCYOL6lvzwOpyG4I7fWoWbJGHXHuOR+Peq0s/wA3yqAep96Z5pDZH45NDZKVi0CVxuBAPcGpPOwfl3Aeo61QeXIDZJHfmo/OBztPTr7UINzTebaAd2Uz0BqBrgecG3EAj8z9aoGbj/Cmkkn72BSk2NRRrGUEcYHFQfa8Sf7PQ1WSXapHUVCr73O0nGeBUTk+g4pdTVVs/Q+tDHAx6VWWXKYHb1NBl456etXYlskkc+tR7sjrk1Xlm55yT61G8uF46/ypiHGYMzYGSODUE7ZHPXFMG1GZupbk1EZMk7TkY60o+ZnUejITnPNN/ClJ5JpM0jjOlDjG7A54APT6/SmiTzGI3Y7g02QDYc446CqrSlSVTaRwR65pSny7nsxjfYtKoJ5AXb3qeHCqFB4HSq0bHyw7Dlj+WOtTZC5GOOnBqo9xS7CzhxECnXv34rNvo5SylMcHnHrWixP8I7YokRSgLjC9Sce9RUhzKw4y5RlhEsMfzLhurEH8qseWS67uCP1pgkVeM9OTxUq5fktgYzkVUUrWRMm73FK4HIwO+ajkbeW3Dg9RUihjj5SR7/rUbuFbCgc9KsSIUGyU44boOKcxydqngdqkYIpIJ3A9yOlQLgOcA4+tRtoVuDbiFI7c5qu+XB7D1qV5OTkEeh9ailPy9cg+op7lRKNxhQx3Nv7VntIV6ZwPWrs+MEn/APXWZcPjkgHPvSZ109glbMRkZgC38IPJqrLOSEEjcdB7VXuZTt2lsAdKpeZ8wzk0uY3jTNqOWBUXfyo7E9TSwt5zNJjMYztGOKx4w0hJJ4FaVruaLYGAwfu55P0pJsznFLqadk8exlkbBAyMjIPtVuBRu4xgjjFZ9smWHXpWrbqPl6dMVaOWdlqWIkEbZU4z0xVtAuwsCeOPrUMS/MuDz9OlTscDjGT37UN2Mb3ZN22kYHY4606PACg4IX0qFHBUcZwO/f2qNpuqnuevekaRg3oaULEnYwxuGQe9PJyjdyVwSOhNUY5XbCgYyM4HX61PExZG2ZCsc/TjrVA4WLluuEVZCRwTg9W9BUzYIEmBtYZBqtpzGe1kDrnvz2/r1q1b5iiwMuucEf3T3/CnbQxlo2SBspsORghjgdqSI7wWOc7jx61DvwwDdV4JB7U9gGjygDA4HJ6/55qbkNEisA+5cjOFJ/GoWiLgJG/zISyn27061Cq7En1B3U4kliDlQCOg5A681SZLVmV7nbIWYgB/4sdsYqmW+XPfpmtG5XbISx6jcPQVnytiTGMA449PxpMcdRu9VBDcuOMdseuaglYc9c+gqSeMGXaDs9WPT8apyvtUEk+nB4pN2HbsI5yMBfxphkI4B47e1RPKd4XJYkZ4OOajeQKQHbtnFJSRQ9nwOpqJ5AMHPsQDUbycHnj6VA8uR2xnNDAtGUZprSc8dT3qp5uCcHjGKjabjGee1O5LRaMuOp4PYUGYjr1zjHeqXm4xzzR52RgDOTQBf84Djr+NKko8zkneetURMDjPSnqwzngH1pNCv3NPzhtx/KmvL3zVB5jkccmmGbkZNO5Ni4ZMtknp2qMy+3vVUyZzjvUbS5buB/KgCzJLt3dxUUTEqx7Hj8KrTSDPHHOB3q0oIUAnOKDnqvSwuaSiikc50MoKgrxuOBgVSVSkikE4BPNTSuBMNuBxjJ5NNcrjPU9/THpWc/ePcimiyh+QAHag6DvTWTdIWzhgPzqBGJ3sgyu35QeDVmLdJGS3J600+bQm1tSSFvMjKnOSDjilxnClgc8DPbFVy7B9q4Ge4q3uTkE/KO9WpJky02GRIMHI2ipz+7U44/GmfMx6gnr9aXgx9R1NNK2xLdxHkIQA8Z4FQ5yQc/KP85qK8O7YuWIH8NJbKWBPp3JqOa8rFJJK5INzSkknaBwO5qTA/iOO5zUTuRkISMjmmM/0Hue1WrBZsbdyl2YttJbkn09qqidkV1H3W4OR1FFwxBByMZxUbkFefTGcUuuhskrDJ9pBwOOvNZNyAGOeDWg27+H6daoXAJPPb9aHqaQdjMlUM+Bk54qtIojkKuPmFXLjaUGCRntVNo98e7PzjgD2pG6kEZB+7jK89ea6Pw/ZxXCSNJs8wNj5+ijGcmuZijI643DB69a0YmdBtBIDjBGeCKI92RVXMrJmwiBGB5KZIDjocHtV6PCtjj61iR3GNqdh6HitGGXfGfUfrVJp7GMoNbmrBJ82Ce+Kk3MoBHPeqEZyRzke1WVII56UGTVtRyM7DOQp5xUbufMGe3cd6kcKMgA/U1UdiPwqNkdNJ3NKG4w6P1IGACauTsXCSRkvGxC+3TOK5+OUq6k554FaFoShJIJQ5yueAaISvuE4W1RrQb0kDxE4C8Z7jrirzSrMN0RVSfmI5yCKz4QR5ZJGCMjPQVb3KADISfp0PY/StVscU3dj0QuNxyCT19PwqeNkVdhGVbkAdDVTcxk2E4HOO4qzAf3LfMAevzH0/wDr0lboZSHNlXZslCcg7f6fgajd3Dl1yM+nQ0rP3bG49SentTFlYoR5YOR1GTimxCM+R5YXDDlQegqmzZcEAN7VKZGHzYGeuD0/Cq8zmdgSUQnPGOKTY9ircsWz97aDjnt71SYOFKkAjrk1bdyzHccknqapTN1xncDxgVnIpMYYsHOceuKgn2nB9Pyqdm+VRjGOvNVZZOOemc/WmopIObW5E8hYGqjMxf2p8rjGSapySnnnGKTKuStNjioTKM5JqEvxg00sOBnjvTWpOxYL9cA4pu9gQQetQGTGec0jSDPHPvVCLYkOfYetSLJ8oyc1QBOAc4qUPgEAfjQJlsykDNRmXvk1WMw3YHPpzSGTH09KQFjzmBI6ZprT4Iwcn3qq06gnDHPvVd5d7bFBLEgAD1oJNW0DTTFjnaOce9aBNQWcXkQhf4u5HrU1BxTlzMKDQaT60iLHQhVc5HOKbNGCuML+HenRnC4PGeTn9Kb/ABlQfcqKppWPZTdxtuFyCwyF+6PU1ZRiRgDnpiocqrAgZGeppkc+9yFBz160laOgP3tSO5k2kqeAMkH3pkTs2AflQdQe9WCqsM5Bk5+XHT3pfK3lSTgYwQPSsXTbd0VzK1iQOSikcBuQDSudiZI742miU+UMsBkDvVIyscjJ+pq5T5dCUrl1toY8/U5ppnEe5SNo4OccY9KYzhlXjnPSqcuQxzyxOc0py5VdBGN9y6+JY8tk88/4VDMhGDzgjPFJC6mIc/N/KkzuI3ZrRWauPZkIzu3E5A9fSmFc9WwMVY2qWGche4pkqHPBAx3xTsVzXKM77TjueMdaz7rJPB6dauyMUdgu3J6nHNVZo8oecGp3NI6FFpNoORjPAxVPfkFcAbepFX5IiTtVfxqq6LgnnI6j1o1LTRVACTt5edh7nqatM21MY6VB5e35s4BqRcEYB4z0NCWhd0TRkh0HXuTWpA2OCBzWZbJ82GO1R3x+lXEcgsTx0xSS5Ry10NdHCnHBI/WrcLgDO3Izzisa3clj39z0q47kLtBAPqKq5zSjrYugh+CSD2qCYlVzxhu/eq0MpD5OSp64q0WJUqSCueOKjm5kUvcYQqzBdx4z6Vo2yjg5wAegqg4MS8Ec/wAJ7+9T28mBjPPvTTS0FOTaNmNo9hByWzxkdakjlUK0cisynkcdDWerbiSfvHue1TNJyoyR6c1pc5micL5cuAylemcc/WpjIpAweec56flVTf8AKD8oH60K5AJ+X3z3qVoSyy8xIIVuAMAdvpTY5tqEAsB0645qF5dpwCPTC8Z9qhaY5BXAIovrcGrk7upP3zz3PY/SqrvnuehOTzULSDvyTUMshKlVPP8AKmKwSy44A5quWzn5unFQySkEjr7mqVzcsmDjIzUOSSuVa+hdlmwR+dULiYdsE1A024bs8+lVbiY9uTQpXQcos0pAyc49arNITz3xxUDzcHPIPBqJJCMHtQNlmSXAwce9NRy+M5A9KgLZ4IyOvNTI2E9TTs7kuyRIMsePpinBcHvjpmoywHOOR1xSGXIPOc9qonUmbIA28j60hfB9j1qHzcdT16VG8o/E9cHpQBIXG7kYqJpQMZ646VA9xlQDjP61WklJYjsT+tS2Gpba4BIC4z6etaWi2rE/aJP4uVH9aztIsDeN5kmRGOQcdfauqVQqgAYApLXU5607e6haKOlJn2pnKLSfyooJoA3VnUhWXJ454703zE5OcZHP+FRqwA2KR0pw4BwRuApczPash+WaNv8Aa9KhgTaeCdvcetToMKejEDioI1YTsS/40pbpsa6k8kbKu1Dz7HtUqHYgHYD86ht5AZCG+bnr61OeFI7eh71Ss1dES7MhmkDnaScZ+pqIqHQ5XCgYJFLtYOOMAdW7mppVZo9qD5m45rNLmu2Ve2hVmnSKJcnA3daJ/N8ohBuYqOKesOdpKj6VOwATjkHrVQg5LUG0jKtfMEyg5OMgn0qcri4Zj3PAqxIUjyQOvX3ptuQxHBYjk8dKlRt7tynK+pPtyuSeepFRS7dp3ffz69KsLl5BEB87Hj61TkVWVsnaQcYPUeua6SIlKdgpO7Gfzqq5yRn7uasTYZcAYOf8mqcnytg9T09qg6ErojkIQ/INw6896zrl9xzjac9+pq1PI8b7sZQ5HNUbiYSyhsdDkik30KjG2okasSOeB61OzIBs2YYHk55zVWSQGVWOCp/Wp8qWwGyDzuxz+NJNBbqTwsQ4J6Bgamdw8jsAQucj2qrGwLYBPtitFLcNZmYMCQ+1h3FG6E5KLuwtW5w3B6/WrbMu3OecVSj+QA9BVjO4ZWktrEN63JI8qwYng1eVwvpnPU96pJjeCanVgCCBn60RViZyuSyAsPlPGc/Sn26bO+ajVvwHpSQoFyUz6kGly63J5tDQLZ4pyMCSpY/hVQSBuc0obIPPNU0Zl4PJGBs5JpizMpy2R9KrFxsAJzQjKBwRnB6mjlbYr9y8ZcjDDJ6cmq7SYBB61AJsAKT8tQSzckenSrJsTtKFHbj0qpJKMHBwe1Vp7jHANZ1xd4T73WpbKUWy7NP6nmqE9yOSDk1mXWorEC0kgA75Nc5f+JoVVkhzI3UEcCobuWonTT3gXp1HNZ0+oooO6RR261xV3rN1cdH2D+6vArOkndgd5yc5NTr3LUDvVvVYjD5yeSDUgu49nyujFhnAPQ+lecM7HgEgHtmnIzBh169qSnYp0bnpEdzzkngVKJvnxuribC/njXaW3qT0bpW5Z3okVV+6c1SmZyp2N1piWI4HOOKJJsAEED3qhHMpBZtxPcUjOTgLznjn1quYxaLj3GFOCfxFQNP0PTjGaiLbkOCTg8n1NXNM0+S9Xc2ViBxn1+lDZEmoq7KeHkdFUZLHhRW9pmjkDdcYYk/d7CrsekxRrEYsKUbJOM5rS6ULzOada60GogQbVAA+lLilz+VJmmYBRRSH+VMQp9qSj60maQGqCS5bad+fzqzsLqu87PYfyqLb5c0Y3FiRyMdKtxnOQDwRjPXFTTjvc9qUuxGYyEY5GcdPWqwVhjeTn096vKVDZblQMZpjAsGK8dqqcbkqViBWCJ8pHXj2qSFmY8impFsTAX5s0KwTaW75xSV1qNu+w8zKk4DdCeR2FTDlio+8OKzN5ExOMMexqeCVslj3GeeKmM76MJQ6lqMAOQScd/pTvL6HgHrjtUUTb8MPmPQCnbh3raL0M2RSxFxgfrSwRiJcg4PSpR0Oce9RSPgcj5fakoq9xpt6EM0hZSAQCOQT1rOaR/m3Hk9feprhhySQRVZX6EEDuAaHqdUI6DdvRiR7Z7UDyBu89iBtO088ntmpBPCyhXVmdsklep9hVOUM3OQWP8PpTb7FWvuVbhhxjjArLucBwyD61rvCMHcQT0x0qjcoOVfqvAFTZlX6FITqMqYwc8g9wasLcSGMRjATOcAd6qNw/wBw4HU+lTo6sq4UcelRZ33DTsWUO38e9WYnIwP4e4z1qnnamQR1xj0qWNiy4HGOck0yZO6LpfK46DvUsb7RkDg9KpI351IrFR6/0o8zJ2LcTtube2R7DpVhZBgcis5JARlQafHJ1PXFCJepprJg4xmlaTO6qSSgr71PG+eP51ROxYhcbcfrUu/HftjNUw+1cD1oM2BhjjHT3ppWJZadufXHvTHkAHBqqXHU598VVup8d+PrTBK+hZluNuecg1UnuiVHzcetZt3eqq5BGQe3esPVtZhs4w4LyNjlCMc+3t71DZqqZs32oJEjPIwCgcsTXIar4lkLFLMDA/jPf6D/ABrFvtRnvpd0r4HZR0UfSq4Ufn1rK5oohcXMs7l5WZmPPJzVYkn15q0E59qDCM9KlsqxWxkCjyyetW1iqVIsdaV2UtCksOe1TJEatiMd6VFGelSO9yOKLgcVet1KGiKP0FXIoc4ORVJdTKcu5PCwxzUysSUCA5PAHWp7LS57rhFwn98jj8K6TTdFgtmWRxvlBBBbsa01OGpVjEzrXQ5rpFM8nkxdcKOT6iunRVQbVAAHAApelFXY4JzcxeaSjNJmmQKaSikoAXsaKToDRz1oASlpKM0Aba/I2XcbcckVOJFA+UcHv0qkVJc7c46VNL8kQKtj1z0+lCZ7LQtxIV4U9zj/ABpbbe8YLsF71WWQbz5n3gKlLlZF4yoNRGWtxtaWHSSsvyLksTn2p4V3ALEA+uKivH2xg5IOcnHep4JCyqSMf0qt5WE9I3GeWC3bcOB3qtdqykcjAq8xARioBPqahA80KW7djRKCashRlbULQMi5ycVPvIbcOSBx7Ui4wSc7SMY9KieQHKqPmHX2FWlyqxLd3cSaba+AO1MZ2Kn0PNN2mU5Awc9Key/KM0k3crRFCRcNnt71FIQ742DHovFaMsG2NJCRljwvt6mqrqAW4IJ7D+VNI2jO5TikNs+5R849f89KjLkoSEXg5zjr7VYmQEAYwfSotjAEDAX0/pQa6PUruXZAuB61SuQ7PuwTx6VqOAR6/wBKpzA4JLcdKTJ5jIkyrkr0bhveoEcqTt49BV64VUXIGRnnFZE0pWQlelTLTUcdS4rljuPapo5AcZOB2xWWJiX+U9qXziBkgY9az5+xTjc1xPg57dqsGYFOOAeOtYaSruHOT6VaE6/KdpVPT1Her5kzOUDQibYuMjmp1fByOB/Osxp03/uyXXsTxj2qbzcMRuDAelNENGmjYGe9WEfGckVlrPjAPPf6043A7sRVKyM2maTyjnPJ61DJL8uc8Z9aoPcZ74zVeS5+U56elO4KJcmu9oHIIz17VlavqkdhhriaJiy5Cg7sj8KzNT1VlicWzRSOASdz4wPX3ribueW7bdMxYn86ylNI1hDU2L/xA75W2ULzyx5/KsiV5Jm3SsWJOcmoY4iOMVZVMCsuY2aIkBDdKsohPNOSPNWEjAAxR1JZGENO2eoqZUyKfsAFMVyAL6inhfbFSBc8CpBHjqRSE5EQj59vapY4Mj1NOMiR8dWq/p7KxBwM0JEOpbYn0zRp7o5A2J6tXVaf4ftIdplzK4GTu6Z+lGk8AVrxnAreMUctWTYgRYxhQAPaj+lKx596bTZ50ndi0lFJ1osSLSUUUgCikpaYCUUZ60g60ALSdaPpSZGKAN8KeT/F9KJASvUYNVWlKHAwzNx1qwB8uWyAeKq6bsew1bUaIgWxId27jmphEAuSBTVUAr3J9afJJwzn5jikopCbYSMrEBgMd+KVBgbVwB2qpbyEsxY5BGMelXFYqxZfToe1EZKWopJrQicMgJbtzgVUSVnlOeB2zVuaVQ21c475/Wo4oGYAk/KeQPWoldtJDi7LUfKxMLFc8dQKggYseeB3OashSflyAOnSmrAEJYDH8qtxd0xJq1hWwoyVxgdKQkldw6H+dNbcMlzkf0p0Lh4Ooxngd6d9RJEDkkgscYGBxUbqy7QxJYjoOoq0cMePvH9KhcsobbgEcfj61XqbR1I3g2uQ4Jbv60mwkBSox2NN3MSQHJZuu7rTgHdsJk/yFK6Kaa3KsiZyIz9aqvECQMc1pugVQuPx9ahdQUyO3UUrC5jJuUAXoDWNc242spQYfue1b80RGdnGe1QPCDksM+1BW2xx0qG3k2nLKOMjtTHkUgFWBPeugv7R2JIAwB6dBXN3dqYJGxyvtWM4uOxvBqW45ZNowKcspBzk4+tUi+Bx+NOD5BxnjrWW5bRoC4xwQSDVmK9YqEdvkHTgZFZCydFzSl8Y7Gmp2JcVI2/tG3BDowHJGaPtqAfNndnrmsQS7aikuDtOOMetVzk+zRsyXgCvuPTvnpWNq2sNOiwxpGoXO51zl/rVKRjITvLFj0qDyHGCy8Z60ud7IagluVHTcc4pyR5qwY+eR+FPjT2qbGhGkOQOKk8n8qswxZzmpBGMn27VSiZSepVWPkVLjGKsLH7UrRsB7UWIbIc8YHWmqwOd2cgce5qQRuDnsajZccd6PUzeo9GAx2B61BcyfNtj4FKzcHnpxUe3PApNkre4JyOprZ03gA+9ZcaY4Na+njBxjrRHcio7HY6SPkHvWqDhayNIOEArVAzXSjkm9Bx6c0lPKHvSEGluziG0GjHrRjmgBD0pMfSlOaQigA70gpe1IaAD60Gj8KT2oAKKKTHNAGs0e1gRnA/i96e7E45zgYFPYLnB5+lRyKAwK5+o71TXY9lSvuJaRSbmdmyD1XtVkyDaVIyuciow+0lOPfFMkkCq3TOOSaFaKE7tkhBj+4Bx1J7GnoCeOlVhI0pUo20Drx1NTlyFPqe4ojbcUrjnj3OPUfl9KVpBGoO7p0x2quXI7g9uO9Jhy4z06n/CpbtsK19y3HIHQEYx6U589Ac5qGIKiHH3j1NMLuImztJqr6akta6DHdfMG5iQOwoSQEbMjB71RcOGDMeCfxqyF4Xb2rGE22b8qSJXlKN8n3h09qgmld8bzyOmPWpGj+bPOfbvQISOW5P8q1d3oVFpakKqdpaQknoPerCKYlKt8rHk+p9qkEQBDEfKOfrTLhj5eQwyeRTSsJvnI5dxJMhGR71E3OQp496YNzsc9B1qVQHQYyD3zRe5Uo2KzICjZ/M1BIPkGRjtir8iAD5eR9aqSRYYEnmmEdSDyd8YXjnuax7ywRmYMvbriug25IJGPeobvbLgKvTv60eo46PQ4O+04BztXFZU6yRZBBIr0aa0jlVQRz3OKyLnS0kDll+VR64rKdK+qNVV7nGC4xkED6mnfaRtxtGR71bvNPAY7Rms6W1dHHcdxXM7rRmvKnsPFymMjrQ0iMBjHSoPKyx7D0pAh5CincVmWYfLDbjliB096JpC4CAFQOcdagVWB+YHmpUB5p9Cba3G7CevNTQxj+EfWnRx4AyCRU8MeBkVSBsWOMZ4IFP8r5snpViGIEjJ6+1WGjVc8A59K0SMXLUjlEZjURqBj26U0W5ztDA55q1FFtIJUgfTrT2T52OKqxi3bRGbLDj6HvVSWPFa8yEHGM1TkQc554qJIL6GOy5J9ackfcCrSxc8VMsQweKz5biuV0jJOTWlZoQRiooo8OMjIrQtk5qkiJs3tMOFFbdopeQVhWHAArpNJXMma3OOo/dLbQcdKia29BWqUFNMfHSlc5THa29KiMLDtWyYueRUbQ+1AjGMZHam7a12gz2qFrbI6UxmZijFXntvSoWgIosIrGkPWpjER2qPacc0gG+9JTiKQ+1AzShB3tl93anMhZgxbH0pyBVPyj3PvSkcZIBNVbSx7Deo1IgJQ+Se1Oli3IFzgDnPvSROCRhgSf0qZW64P40WVhOTuEUSxrgHp1pJlGwnjB4z708AkE/rTJvmjIGAeg9zTasrIm7vcrQgDIJzn9KtIRwOv+elV4ozGwJ5I6fX1qRRiUtxnGBntWcbpalS1JGAR2IG0HtSRqVywPJqUYY4ycA07aex4rSxHMQ+WGIO1TjpxUixqvUjnmpOx4xTGcryP5UWSGrsXC8Y/PvTtqFQAPbB/nUazMpJ+U8elLGzY3NnHQUXL5Rzx8DGDn3qvIgztBHPUinySbeVzu9TUAcgFuR9KHY0jFhsEedwx2oYgsAFAHcinKDgtIdx69aRzuUkgbR270DI9oywGMD3pqw4OcD8aapy3cCpSDtDc7TxmgGrFebl9oHWoHQl8DjHWpWbEg9alCbgT6Hmle5V7FN1xgCq01vvDBuPatGRATkcfWq0ijPt3phuYFzZIxJU+1ZNzZfOdyggDtXWvBvyQPlqrLaLu3AVLinuUp8pxc9kVJyCOMjiq5tyOeQTXYXNszkFsZA447Vny2qAkYz71m6SWxtGpdHPJEVOcZPvUoiDKMrg9BitUWYKnjvTvs21jkcY4FJRsNyRmrbBRySTVhYVGAgJ4rSht1x+8UjPoKlFrydtWkYSn0KUcB4GKnEA3ZxxV4REAZUfWnxoOQRnPeqsYORTVTkgj8TTxFjjGcVa8r0xT9mB0pmcmZssY29MtWbPEWbH3c963pVAPas+6iG/BIx7VEkK+hmR29SiEDntVtIec1FcHDgKDmk9EJO+wJFg/dqzFHghugqS2jzGCw5qykfYihLqKTLNmAMV0mlEBvwrnbZcfSt2yIUgjrVo5auxuBxTgwNUxKO5pwkFByWLZwRSYBquJKfvPajQWo8oDTTGKA9O3iiw7kbRZqJoQatbgaQgGkFyi8I9Kha3B7VplRTCmaBmS9tUTW5HStgxUxovbmmBVjPmxllz7U2MsFYyHJPAA7U2MkJjnaBjFThQxz/D6+tC13PYbsOjXDDcoAzUwIUk9D/KogDjJwDQ3zbieQOM+tVsQ9QklOAqqTzxzQM8ZGKZCNjOQQD29qc7HaCeh4oQ9tEPYEgdyfX0pIwd+ck+3qKajE5z0PFSLlSBkUmrhsKzFWGTyfTtU4bcCWIOeajKqx47d6dyo6YzQridmAb5iGxj2ol4IAxgetIXxnv296jnJZcDrR0GlqKo3em3pUrKdnHQdKgQ+XIBkkDnNLI7ZPPGaSkmXrcid8tyeB/OnyQGMKxKk9xnpSPAQBISAW6CoGb5mAXr6VSRsnfYeGy3A+QcZpkrANx244pvJYDAHHQUpXjK0MeiYySUO4Krt9akzuAz+VRrHkkmpVHPY0lcmTXQhkXbxg89BUigLGP73pT3Ge340js6dBzTSsTzX0IZHG7kZ9aiCeYG7kdKWTLEnueSaRVx8wJz39qV9S9kMK87Vzik8sNnH0qbG0HoM9/WmbQH4wBTJlqU5YPUc1Te15J52961tpZyAKrzAgFQSKYRdjIeAeYABxThb5GMk56iryxngdqkaIn7nBFSVKRQECjbgEGpki7/AMqnSL5uR1qZQBkAUGEmVjCNvTIpPJGeKuCPIJNQsCScjFFiE7kPlhegppXP0qwwLUm3HJwBQDM6ePBO6s+RG31szICp9PWs4pmTHpUNXYOWg1Iyyjg08W6MRkDNWY4/QZNTrEMAkc1djNMhjhwOBUnlEVZWM4HHFPdCeg6UrWGQRIQBWlEdqg1TAx1qcN+5xTRz1diws2O9SrN71l7yKcJTSOU1RN71Is1ZImqRZ6ANYS08Se/FZSze9PWf3oA0w/HXFOD1nrN708TUIVi+HpRIKpiX3p4k96YWLe4UcGqwcZ60of34pAUxyOBxUkb9sYPaoI5VZQR+tPimEgYKD1xkjrTuj12PeRVUljjHc0vmA7QMnIyBTgBtOelVp3YDCcZHpSk7aglfQesgMhGOKkZtuGHOPWq6J91m+93NTuAQQOp6UK7Wo3YbbFyGLHJPPSp1JJI7Dqahgi8v5yxLHjmps547URvYG9dCUNngnApTkDg5qrvZZDGFyp746VIpJGBn/CmmFhWcqcDqO+KFy64A+brTsZ59qdGCo46nv6CjUbkrEap3Y8n9KmWMBNxPPYUm1mOOMUpztAx9DSjFITlcikb5juDf8Bqu5IbIHXmrR3EADp3qNhghSOvrVFxlYgXIbIPJ7Cpwp4xQqhSAKkOM5XI+vahBKVyMgjIxTOA2KlYFcnvUffmmTcQ9MdzURZVPzDIp0mSABUBUkkHH0ouXHzGL8xPHBNPBUKSTgntSA7Rj2puTn5VznjBpF7g+19u3P09KYB2PXvTpFKjGcHvimKCWOO3Uk0h3ViTgjB6etL5alCOtDHZjdzu9KfgFeOPSqRlJkBjIbK8Edx2p2BtPI3enrUy45wRkVC/QnPFK1idWROMYOMA8UxQeik4NSlS/9KfEpUmgTdkKqgJg8moWUnJFTnAGKDjHHWgxuVgvPSmNyeRVhh8w4pkoA+tJlqRSm6MKpImXyPWrcwPNRRL296kJImiUZxVlUDdeopETb9TxViOIkhu1WjOwKowCBTShznHFW9mMYpkuFGTxTY0ypInBIqJ5NkWD0qZ3UrkVmalMY4+MVJlVWgnn8nmnrNmsRbnNTLc+9ZvyOaxsiUYHNOD1ki4HrUy3HvQDRph+OtOEhrOSepVmz3p3YrF5ZT61IJ/es8S5p4cZoTCxoLPUqz+9ZofpzS+YaadxWNQTD1qQTe9ZIlNPE3vTEWQ21wAMY7f41PESGwTkUzA5P86bIj4AUhe+aVranr3uWiTzuP4UoOT0PFQo3AGee59aa0uJdgJ2+op8wrMtcY4HA6UHKJuUcmo3lxtyccdKQPntVXFZ7k5bA55P8qUcnHcVAc8BRg1OjdiMDqDSuFhQAT1wBS7wgPPB7UNjPbntTZEDpzgnpSemweo8y4wQCwp7EqD3NR2yFRlsHHQf1p5bcecZ9aFd7hfXQFycD86lZsYOM/1pM/dPbNPJXOOtUK92NHfOKQr2x1pMcbs857UFizZbk9M0wI5VwCM/lTBlVGck1Kx5NMmkRcfN8x7YpFXFLDHsaiOMcnHtTsgConOTwMUXBDXY4pjdfen9TTG4BoKuV5nwuD09qjWXIyOAOlSOuc5OKi+QMBt/KkzeLVhckY3E88044C5HftUZwGO0g0zfluT0p+o9yzEMnJPTmnlvmyRkZ6VDb5Yk9BUxYbsEZ9fai5hN2Y0uTJgDHuKcEOcnkU9Sqg46UwsVTJPGaCOZjhtVhjGPSkyC3PBqEsDyeRRGMgkNkdaBNaEm395z0FHVuBxQh4Jz0pCxziggXIJ5NRPgkjvTyqnnOD6UzHryKGCRTlTLHFJDHzkDirflg4J4xQi4yam2o276DlAwMVbiXgGqnQ8VMJ1QDdVXsPkZb6r2qlqKnyG29cVaDAjI6YqnLJlWB7UNoSjZ3M2Jm8j5utZmqfvMCrt7cBWwtQFPNXNRsjOu9LmI0RHY03DCtdrf2qJ7Y1BymbvYVItwRU7we1RNBjtzQA5Lk1MtzzmqTQntTSrCnewWNRLjjrUq3HvWKHYU9ZyM5NAjcWfpUgn9+axFuTjrUqXPPWgLG0JRThIDjFZC3I7GpVn96BWOrg5XPQnrTjgdev1qNcKNo6Uq/OTjPHatPI9Ia7BOf50qncAV/OiaIN1OT1pVTYNq8ios7lXViNxkDJJ5qeCRcZU5IpCgcHdxUeDGwVRwadrO4XurFoEbuvNTLk55z3x61AiLnP8AF3NTA7ehqlqSLuweOfpSLJ85QDJ9acu0D39qYuAxKjBPeiwE54yD0xSIMOOM56Ypitjr1FPDYA4+namTsOdX6g80KuM5NO3AdDx71GxOPTiiw02POOeTihycD2qMsQh9e1IGO7vigB24d+npUToGbJyR6ikcgPx07CmGU+tA1foPPI57Uxj3oLdeajDdMfnQApbHPSo2bnnGaHZV4PX0qJ2bIGBg0XGh5xnPNQsMk8fSpM4+tRufM4HGKTKTaIwu0H35NCqDn5Tu7VMoyvqKTyQOcnNBXtBYsBeBzUpI4JGKYiqBg9RSgnBx0NNaGTd2NaXG4LTHZnyBxjqKbIjBsg5BpY0POTSZeiVwwCpx0NKuFHPenFcL0qRVwBuGQaEiHLQagHRfxpzKCox1HWgcHpSnABI700RcifLHHFNiL7SGxmn7h0xg00tz0NDKQpxil2/L1zUZOKMEqdppD5epIQMqDxT5IkBC5B71VnciPg80yF+Mk802+htbS5oxuAhA7Vj31xhnxxUv2ghHLHHPFYmp3W04z1qW7kW1EQtPcBAOc1rpGAAB2qtpNu0cPmSDDvz+FX6m9zz68+aVkQNGO9RtDn6VapCKDG5SaAE9Khe3rS200rRZhcynt/bioGt8H+lbLRj8aY0QPUUvUdzEa39qheDBPFbjwe1RPb9aYXMNoSOlMKMOlbLwe1Qtb0nqO5lgsDyKcsrDqKuNb+1QtARmkM6+FXLZLVeRvl2jiq6EY6ZFPHI74rSK5T0ZakqnPXH1oxlgM8VCvTj6Cn7j0BqhWJsgf0FIB7nJNRjOOv41IjHJznjpQBIi8daeCoPIz70i44601iOQPrQJEpcH5QAATnPekZgo45qMEYx2NBAx1HPrQMl3cjuKfuBzjGcd6gycDHbrTs4XjGTQIkzjpTScr61FuNBfmgZKpOcjPFI7YxzTdwIGOopGHJ5piFOc+3rUcijO4dTTmbCjPWoS+5eOlINRC45XPWl34XHGP5VCAuc5/wDr045J4wM00NiYG4n1pTTWYBcdx1pi5K7j0paCBgygkHNLGAqhj+IpQ3JUj8aXrwMUWKbJF55UHFKTznFRhvXI+lO8wMMHjPegzbGtkk8YFIxYDHGKXGVAJNAyvTkUDuDZK/Ke1Im4gEnBFSMQRn14oIPTI+tAuYaScZ/OmAOG4+6aeq7FKg/nS5KruxnNG4rjdrbuTgfzpkrsvGOaez546VC8gC89TQUhGcE5B+YUm4jkVXdgHyM8VG9wM4z+NJGiXYslgSeacH2g85qg9yBkHFQPdleO1MpRb0NJpM4K4x701pAq545rHa8Pr0prXe7qeaVy3FpFq+vAiMewrJ05TfaiCwyinNRXc3nSbRnH863tFs/stsCw/ePyf8Kl6HNXqcsbI0B0wOKWk9KKSPNAmiigcfWmAEelIKXNJQAcU3ApxoGKNgGkU0qKk6U3tS3AiKA9qjaIGrNIRTsFym8INRPBWhtzTCo6Uhpl1i2PlH1qWPhQM0cMOn0p2MCrtrc9O445AwKQjg4FJv8Al9x3pI33p6UMBIg29mbp2FWQd2O1QbiOBgetSbsHHXvmhKyBkobjk8+lMckkAfjTWOBkdTTcgcGgETDI79KAfU8VEvIOP/10rOSPQ1QEzN0xSF8r6Ec1BJLgDNRJOrMAM4qW0FiZpwD+lKHyB7VCEjIz6Ux5CpAQdTzSTa3H6FpnIHH5+lCyljzwKr7+dpB561ISo49KtEseSSD6037o470wtxwe9NkbjBzmgBr53cdPWkaTYOTx60FsjmmOxHFLYY4ksv0p24DpniqvnbTjv71Kr5UZ4FJMTRKWJyPxOKdvUZAqEuBnbUShjLnPHT607iSuWmYBcg1A5O5CpOO9OGTkHp6U5RtUnpS3C9iXzMKM9O1O3jAIHWoVbPWpFYDqPm9KohjmYDoOtM3Mc4PHpSF1HOaY553Rt+FKwXJUkA64FI8u44zzUDMC2e9RTMFw2aLlJE0jkcEj86qzyrgjOKhnlUruBPp1qjJJ6npTNIxLDznGM1VllwM5qCSYDrz2AqqZWLEH0pM12JXuSDntVeW6JPNROScgnAqNueuFXv70tS+ZIlM7E9+KmhV5WxziorbyyflBPoKueYsanDZb2o5TKdR7It2Nmsl0rEZVP1NbnT6VmaS+UrTzUvc82umpai0UmaKDEKKKKAA0maDRQAUUdqM80AJ70E0GigApO2aPUUUAHpzSYoNIeaBF4HH0NOJJFRbscDGKMn1NWeoOkcAUwSDgAZ+lI+H4PSiKLaSTx6VDvcrS2pOvK89cZpUPrTO2Bmhm2rj9aoncWWQLxyeOlIj5HSq7kSMeTmpRhRzSTdytkSq3OM0M2c+tRhSD1596X3BqhDZefl6elRCJsfjyalVCGJ9eaXPPPOKjku7sfMOUcdaYy4f72c0O/GR9cUxGJUlxyaryEmyTOOpzT94KcdarsR0U0pcAdMGmJ6k+8Acc4qGRyB0qEyHkg9aC+e54obuKwRyl26CpM/Kc1CpHOB2o3ELx1NJDeoGPLE7uOoFSksTkDAqEPgA0iygZAOaLWE2yyOh46ioz6D6ZpiSAtwc4HTNPBByDxTFew4MFXnJPel3HjnHce9NDAJxj8abnt39KBNko2k5zyaaZGLEHqP1phZQp55qATfN8wOPWgNyw0m4YYYPrSFwBgNVeWcYIPX1qnLc7fvHNMaVzR84AgsRVG4uM5wc+lZ09yS7YOVFV3n754oNFCxaMpySTyKgeU+vWqxm55PH86C24b2Ix0C96Cm7DyGzk9O1NfCjk4z0FRtccY44qFpRuJY0tAuyTlvZfWkURlgDk1HJdYXhR061RkuBnAbn2pXSKSctjSlmRBhOvoKdDufBY8DtVC1QyNk1qwJwAaL3NlS5dzW0nIrZFY2m5D1sDpjvSe55mM0mLQaQUGkcYtFJRQAdPpS96SjtQAUUUnbigQfhQaMe1JQAUH9KKMUDCkPSlFIaBExbbgEgk00SkHBGM96Cqk7m7dKU9Qcc9qep6qaHc4461IpOec1Gp70pY49BTFcniZNxLk9OAB1qvIWJ+TijdzgYFV23s+0McetTJ20HFallV44PPenL0AHSo/vDvinFsDkVSE2SEcdaCwA+lRk55FNGM8/lTEPD7gfSl6cHNAAHQcYpN3NAXE4J69KQsMnocCmNIFYnuKiSUPnAx60BvqP3Nu64GKCwY80xmGAB1pjN0INAmxzEbsHpTA53EjoKRiMg54x0pucofrSsCY4Pgn1NIHyevWo9y4JPJoGMc9BTDQezAk47+lNCBWJYn6UznK47c09SMnP60WuF7DYXy7bVxVrfnAxzVZSAMjp/KkedVOWOfp3oSsDdy0HwPm4FMaUkEfrVGS8DLlTkDg4qrJqC425OBTBRbNGScRj5jzVWe9X+HOazZr0Y5INUJb3J4HelsaqHc1J7487mqpLcmTgmqHm7jkmo5JiOP8ik2V6F0SgHnpTWkHU1jz6rbQttkkyw6he1UrnXox/qgW/ShS7C1Z0ZkTgYFRGeNc8kn2rlW1qUgny1z25qnJeXFw37xzj0HApcxUYHWyXUX8TqPbNVZdSgjHDbz6CuaAJPJJqzDHz0rOU7bG0aSZqG9luOB8q+lT2sRLZNVbWLkA1s2sOADUK8nqdEYqK0LllHgVpKuBVa2QgCruPlrpSIlqW9PP7zpWwOgrG0//Xe9bFTLc8fGfEhTR1xSUHpSOMOvFFAoosAtIaSjNAg9qX6dKSg0ALn1pOaTvQefpQAZoopCaBi+9J+VH60UAIjnaN2dx7VKOSciowMHPQ1Mg4po9NsACOT6U0yKTgmns3YdPWomAJG6h3EmOVcHOc0uPzpjsV4UZNPXJAPQ96EMUZONvbrTiTjpUcbNk545pGJZwP4aYiQU/vmoz+dLnKkHj0pksVm9e9MbdkDGM0nXgmmu2CKABsDO85I71FnapwOOlNkYlsDmoScALk+tADi4AYH1ozkHOM1CXJz7UjuAFB+9QJjy/JI7U/ORnOMVAD0zyAcmjeSxOcAGnYVybHPPQ0h2k/7I/Womm6AnCio5LlCpJIyO1OwK5ayF5zxUUlxs9OBxmsifUsNwT9Kzp78ux+Yn2pNpGipt7m3JegEjI/Gqc9+PXkelYk96q/ecLWdcaqq5EYLe9Q5o2jTN+S+Ocg4qpLeMxOeBXOy6jM5+UAD6VVmnml4d2x6VLmjVU30OjkuVH35F/OqkuoQoDukGfQc1g7WJ5JNAiyanmK9kzQuNYbpbr/wJqzZbm4lJLyuc+9PEHtUiW5IzijnKVIpbCRnvQIzitAWxPani2/OlzFKmUEjOKkERzxV9LbnpxVlbX2qbspQsUYISeoq9DbkYqxBb4IFasNqNoOKajcrYqW1vjHFa8EXyikhhAPSrca7T7VrFWBsfFgAVMcE4NMROc09jgCrRmy5p65lyOlao7Vn6YnBY1oZ4qHqzxcVK8wpc0lH1oOUKDzR0pO1AC5pKDQaACjNFGaAuFHrRSA0DDp9aTNGaT8qGhC54ozz7UlIcZpgSrjByKcOFNNjbcOCDTyu7oaZ6TYg3bv5ClYDg9xSEkdOopCemOtAbjuM9MmgZ9aQEYx3zS5AGKBCjpzSEkA8VGxI78elBOeF/GgB6t270xnJJHpUfQn1oLfKT0piJHJJBHpUEj7VJByaCwA681E7gDJPSgQMxJAU9arSSYc5/WmtNyWyABWdd3iIrPI4VD6mkNF7zsA1C1wA27tWHcazEmATnPQAVm3WunedkZI7ZNFy1TbOtmvAoCqQc8nmqj3o3EZ471ybaxOcBFCknk1XluriWQ5c4J7Uuc0VE6mfUsRks2PTJrOk1VSGw+Se9Ybxu/LFjUsNq2Bx1qeds1jSSRYl1BsHCkn1NVHuJpSSSQPQVc+yE4HNXoNO+UcHmizexoopLUwvLZsk5NRpCxbFdLNZFFA2AZotNPyxYrk9hS9m2XFq1zCNlIo6HFAsmxk8e1dS1pJGvMZA9TV77H/oR86MbiODiqVG4e0scUlkWOOKf9jKnBrpbfTy25idoHtRJZY5PPvihUnYvnV7HPfZT6ZqWO246c1sfZhj6UggGaOQu5mC246U9bb1Fagh9qcIh3pOI7maLfngVIIOnFaIjHTvTxGCPSjlQXM+O2+YVoQQ+1Lsx04q7CgEWRVRRE2ReX0qbYBHzT1Xg5pJCNpFXYi4xWHFOJ3dhUAPzGrNpH5kgGeOppMirJRjc1rNdsIqx7U1QAAB0pe5rM8Gbcm2LRx0pO9HfimQL2oFJRzQMUGjqRSUc0AFFHekzQIWkNA60hoGFIaKO1ABSUUfWgCVEC5OOKkGR349KjDEnB6U8kDFUegxScCm9TxwKRicYB4pMgD1oEOO3IxQQBTCc9aaTtzQA5yM4qJ5NpxTJSTk1S3FpcsSAO/rSbGlcuFix5PSo5JAc88DtULzAAjP41VnuAi5H60xWuW2k2554qpcXCKmWbA9azry+wgOTz6VlXUktyVBzt7Cp5ilAvX+pkKVj5rBlM10373JA6L2rWS0Lct1xircFgODijVmiSic09nLK2SDSrpzk8jmuyisQCDipWsQTwMVSpj9qcaumnPSrMWmn0rpvsWGJ21NHbhV5ABqlSL9oc1HppPQdOtXo7AH+HjFbaQAAj1qRIRgDvVciWwe0Zk22m7gWIq0LdI9pA5FaMYwuBRMvyYABNNWQczb1MwWv2iTJH1q6LdFUBVwPWpokCIPXvTnQlPTPSqSHcrLa+Z+8c5UHgVckUGEjGTt79qiKsseC2KTcSwAB4qrg02V/KWKHHVyelF1FiFVHzcc+1T/KG3EZNSGLzdodwpPX2FGhe25iyRAdKYsIboK03tle42IfkHc+lVXQCUhM7RWbiaxlcriPaMcZppXd2qdxz6UwL1OazZomN2E4xTiMDrTupAp5THFKw27EO0cVYQ/IFzikYBU6UxTlvemtCHqWFx0pjqRnjmnRGpJWIXpiqMnKxSYYBzWtpMRWLe3VulZtvEbm42fwg5JroEUKoUdqzk+hw4ytf3UOopuaX3pHnBRQD0ooAXtSUn40ZoAX6UmKKKBC/wA6TOaKKACk9KXNNoGL096Q0Ug9aAA9aKMUfhQFiUHOOBTiwA6VWOSQc49qkLfWqO9j3JboTTTznHKjrSBsLRuHIoEGQoJFRMfxpXbB9ugFRH5e9K4BKx2nHHqaqyNx1wadIxJ54qo7Fn9BQNIZNIM4/KqFwzs+0HjNXmjyS7de1RCAsT6GpaLRnNbmSTjkD0q9BaDjIq/b2e0ZNX44AB0FOKG5FK2tAp5GfarkdsDyBVmOMDoMGpNnPNWRcrpAc4xTmjK4zVke9G0fjTuCKvljGf50x4wTwKubARUbxk9KrmLRWEYx70uMZqQ8deajYMx4PFHMOxEM5PpTnYAHjmldAqnIOarEkt3oNEizkFevNIz8BSc1AZOwyMUm/wCYZOaLlFliMAYFDECPCD5j1qIvyDwBQZsdKaYIdENgJIyaeNykk8HvTFfJBY8Uk0mTgDApqRVxrnKttGAaqspQmrWcgYNQTqRnnii5cXbQqu2elCrhSaCp6kcU8KdnPFQaXI0OZBgflUp5brUIXDdaswikEmI6fu6aicdKkdjnHrQXVVGMe9FjNzshqsY8nGKrTTs7BVPJ6027uVjVmdgqjkkmsS21A3d0fL4jzwPX3pqLexyV66prXc7LTEWOMBfxPrWh1rP07/Vrir/6Vk9zzJNt3Yv40Hmko+lAhaQ0Z96M96AF7UlJ9aDQAtHtR2pM0CFP60A0gPFFAwNBopDQIXnFJRnikPvQAppKKDjFAxivxx0p5bAGDzUXHAxj3oJA6GqO9khfcOMU0vhelR7hzgYprEdyaBCtnOSaYxyT6etNcnHXPtTeoIz+FIYnBY56VGU+fOAf6VIijPpTwhzmgLkPklj/AEqzHCvpmnInIqzEmO1ADY4x3qYAelSIoFO4HpTENC8dqUYNNI9egpcgDHegY4gZzSNSAj6GmuQV60AmOpCcU0HI4NGcjFCY7jWHGagZuTipmIHFQMfm70FKQx8nrUbbT9aezUw46mnctTInQDmo2PYdamfpUJ+lO5aY13OOTTVdffNOZARk8GmMOBTuMVpCCDS+aPxqFwcDmmA/WkUiyJiORSGQueTVbd1zSiT07U7lE5PPNIzqo+8CfSq7uTzmogx9c0rjTLAfLU8yFOhzVTzMAkGozLmk2DlcsNMcnkVGZGboM0yNC55OBUl46Wli7jGcVHNd2RjUqpLQ5LxFePJL5Qb5FPQdzT/D3Lisa8l82die5rb8OjLLXdblhY8WpJzlzM9B0/8A1Yq/VKw+4KufpXC9yhc0ck8UgNL070aAFFJ70e5pAKKKaOtLTsIP50Z5ozRn1oAO9BpO9AoAKD0pKAetAC5o7UmcUGgYoxTTQMUhxQBAW56015OOOTRRVM7xis2Mng0FscHmiikg6iZwcnNAO7p1oooAXaSasIMAYoooESpgEZwKsLg+n4UUUDWw4t6UjEjvRRQgRHuJbB6U8GiihAITgZPWo2bI5NFFPcQm4dO1KGAoooAZI5xwOajLHbiiigfQiJzUUhOe9FFArkZJIPP51Gz9jx9KKKCkyMyjkHNN8z0PWiipuaRkxPMXuaDIp7DFFFHMy07kbODnFMXrwKKKq+hpewP9ajLqoJY0UUmyW7Iqy3A528mkgLSEls/SiisHJt2M3JmjAgArC8VXpVPJT8aKK6MPFc5zV21FnHk5auo8NryuRRRXbN6M4H0O/s+Ix9KtmiiuBmjEozRRQTcKM8UUUMYZzR60UUrAFBooouACkzRRT2APakoop2CwfyooooATrSE0UUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules and mild scale are present on the perinasal skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission of Edizioni Minerva Medica from G Ital Dermatol Venereol 2010; 145:433. Copyright &copy; 2010. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23666=[""].join("\n");
var outline_f23_7_23666=null;
var title_f23_7_23667="Abnormal neuronal firing in epilepsy";
var content_f23_7_23667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 614px\">",
"   <div class=\"ttl\">",
"    Abnormal neuronal firing in epilepsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stafstrom, CE. An introduction to seizures and epilepsy: cellular mechanisms underlying classification and treatment. In: Epilepsy and the Ketogenic Diet, Stafstrom, CE, Rho, JM (Eds), Humana Press, Totowa, New Jersey 2004. p.18. Copyright &copy;2004 Springer-Verlag.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23667=[""].join("\n");
var outline_f23_7_23667=null;
var title_f23_7_23668="Phenylephrine (ophthalmic): Drug information";
var content_f23_7_23668=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenylephrine (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/50/37668?source=see_link\">",
"    see \"Phenylephrine (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/13/40147?source=see_link\">",
"    see \"Phenylephrine (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9504770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AK-Dilate&trade;;",
"     </li>",
"     <li>",
"      Altafrin;",
"     </li>",
"     <li>",
"      Mydfrin&reg;;",
"     </li>",
"     <li>",
"      Neofrin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9504797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dionephrine&reg;;",
"     </li>",
"     <li>",
"      Mydfrin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9509121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-Adrenergic Agonist;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Mydriatic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9504926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ocular procedures:",
"     </b>",
"     Ophthalmic: Instill 1 drop of 2.5% or 10% solution; may repeat in 10-60 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic irritation (OTC formulation):",
"     </b>",
"     Ophthalmic: Instill 1-2 drops 0.12% solution into affected eye up to 4 times/day; do not use for &gt;72 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9504925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/13/40147?source=see_link\">",
"      see \"Phenylephrine (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Ocular procedures:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants &lt;1 year: Instill 1 drop of 2.5% 15-30 minutes before procedures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;1 year: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9504927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic preparations for pupil dilation: Instill 1 drop of 2.5% solution; may repeat in 1 hour if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Other indications: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9505019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 2.5% (2 mL, 3 mL, 5 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AK-Dilate&trade;: 2.5% (2 mL, 15 mL); 10% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altafrin: 2.5% (15 mL); 10% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mydfrin&reg;: 2.5% (3 mL, 5 mL) [contains benzalkonium chloride, sodium bisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neofrin: 2.5% (15 mL); 10% (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9504799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9504800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used as a mydriatic in ophthalmic procedures and treatment of wide-angle glaucoma; OTC use as symptomatic relief of redness of the eye due to irritation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9504769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Mydfrin&reg; may be confused with Midrin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9504837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. Systemic effects are rare at normal dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia (rare), hypertension (rare), myocardial infarction (rare), subarachnoid hemorrhage (rare), syncope (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Burning, irritation, vision changes, rebound miosis, floaters (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9504805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenylephrine or any component of the formulation; hypertension; ventricular tachycardia; narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9504806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Although rare, have been observed in elderly patients with underlying cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rebound miosis: Has occurred in elderly people 1 day after treatment with phenylephrine. Miosis may be resistant to redilation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; OTC: Notify healthcare provider in case of vision changes, continued redness, or if symptoms worsen or do not improve within 3 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Some products contain sulfites which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9504840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9504801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9504802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; therefore, the manufacturer classifies phenylephrine ophthalmic as pregnancy category C. When administered intravenously, phenylephrine crosses the placenta (refer to the Phenylephrine (Systemic) monograph for details). The amount of phenylephrine available systemically following ophthalmic application is generally less in comparison to oral or I.V. doses.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9504804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11391265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if phenylephrine is excreted into breast milk. The manufacturer recommends that caution be exercised when administering phenylephrine to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9505028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Altafrin Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (15 mL): $8.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (5 mL): $8.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Mydfrin Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (3 mL): $24.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Neofrin Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (15 mL): $16.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (5 mL): $17.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Phenylephrine HCl Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5% (5 mL): $27.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (5 mL): $6.24",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      AK-Dilate (PE);",
"     </li>",
"     <li>",
"      Albalon Relief (AU, NZ);",
"     </li>",
"     <li>",
"      Davinefrina (PT);",
"     </li>",
"     <li>",
"      Drosyn (IN);",
"     </li>",
"     <li>",
"      Efrin-10 (IL);",
"     </li>",
"     <li>",
"      Ethifrin (PK);",
"     </li>",
"     <li>",
"      Fenilefrina (BR);",
"     </li>",
"     <li>",
"      Irifrin (RU);",
"     </li>",
"     <li>",
"      Isonefrine (PK);",
"     </li>",
"     <li>",
"      Isopto Frin (AU);",
"     </li>",
"     <li>",
"      Metaoxedrin (DK, NO);",
"     </li>",
"     <li>",
"      Midfrin (KP);",
"     </li>",
"     <li>",
"      Midriafen (CO);",
"     </li>",
"     <li>",
"      Mydfrin (CN, HK, MY, PH, PY, SG, UY);",
"     </li>",
"     <li>",
"      Neo-Synephrin-POS (DE);",
"     </li>",
"     <li>",
"      Neosinicin (TW);",
"     </li>",
"     <li>",
"      Neosynephrine Faure (FR);",
"     </li>",
"     <li>",
"      Oftan-Metaoxedrin (FI);",
"     </li>",
"     <li>",
"      OQ-Dilat (CO);",
"     </li>",
"     <li>",
"      Prefrin (AR, AU, NZ, ZA);",
"     </li>",
"     <li>",
"      Visadron (AT, BE, DE, NL, PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9504881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent, direct-acting alpha-adrenergic agonist with virtually no beta-adrenergic activity; produces local vasoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9504903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Mydriasis: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Mydriasis: 2.5% solution: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Minimal systemic absorption (Kumar, 1986)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: &le;20 minutes (Kumar, 1986)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kumar V, Schoenwald RD, Barcellos WA, et al, &ldquo;Aqueous vs Viscous Phenylephrine. I. Systemic Absorption and Cardiovascular Effects,&rdquo;",
"      <i>",
"       Arch Ophthalm",
"      </i>",
"      , 1986,  104(8):1189-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/7/23668/abstract-text/3741249/pubmed\" id=\"3741249\" target=\"_blank\">",
"        3741249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9899 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23668=[""].join("\n");
var outline_f23_7_23668=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504770\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504797\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9509121\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504926\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504925\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504927\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505019\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504799\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504800\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504769\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504837\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504805\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504806\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299869\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504840\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504801\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504802\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504804\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11391265\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505028\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962000\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504881\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9504903\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9899\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9899|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/7/19572?source=related_link\">",
"      Phenylephrine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/52/21316?source=related_link\">",
"      Phenylephrine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/10/17572?source=related_link\">",
"      Phenylephrine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/50/37668?source=related_link\">",
"      Phenylephrine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/13/40147?source=related_link\">",
"      Phenylephrine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/47/6903?source=related_link\">",
"      Phenylephrine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/59/33717?source=related_link\">",
"      Phenylephrine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/23/13686?source=related_link\">",
"      Phenylephrine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/53/30547?source=related_link\">",
"      Phenylephrine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?19/36/20036?source=related_link\">",
"      Phenylephrine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/16/5379?source=related_link\">",
"      Phenylephrine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_7_23669="Electrocardiogram in pericarditis and pericardial effusion";
var content_f23_7_23669=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Electrocardiogram in pericarditis and pericardial effusion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/7/23669/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23669/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/7/23669/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23669/contributors\">",
"     Martin M LeWinter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/7/23669/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23669/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/7/23669/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both pericarditis and pericardial effusion can produce characteristic changes in the electrocardiogram (ECG). These changes also need to be differentiated from other disorders such as myocardial infarction or the early repolarization variant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ELECTROCARDIOGRAM IN PERICARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericarditis can be caused by a number of factors including viral or bacterial infection, metastatic tumors, collagen vascular diseases, myocardial infarction, cardiac surgery, and uremia (",
"    <a class=\"graphic graphic_table graphicRef67851 \" href=\"UTD.htm?7/0/7181\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ECG pattern of acute pericarditis resembles in some ways that seen with acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23669/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ST segment elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early phase of acute pericarditis is usually characterized by",
"    <strong>",
"     ST segment elevations",
"    </strong>",
"    due to alterations in ventricular repolarization (",
"    <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"UTD.htm?42/53/43866\">",
"     waveform 1",
"    </a>",
"    ). This current of injury pattern results from concomitant inflammation of the epicardium. This explains why the ECG often shows no signs of pericarditis in uremic patients who have a fibrinous pericarditis that may not affect the epicardium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6533?source=see_link\">",
"     \"Pericarditis in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     PR segment deviation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pericarditis also may affect repolarization of the atria, which starts during the PR segment (from the end of the P wave to beginning of the QRS) (",
"    <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"UTD.htm?42/53/43866\">",
"     waveform 1",
"    </a>",
"    ). Acute pericardial inflammation often causes an atrial current of injury, reflected by elevation of the PR segment in lead aVR and depression of the PR segment in other limb leads and in the left chest leads V5 and V6. Thus, in acute pericarditis, the PR and ST segments typically change in opposite directions. In aVR, for example, the PR segment is elevated (often by only 1 mm or so) while the ST segment is usually slightly depressed. Other leads may also show PR depression and ST elevation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23669/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     T wave inversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ST segment elevations seen with acute pericarditis are sometimes followed (after a variable time) by T wave inversions. The T wave inversions may resolve completely with time with normalization of the ECG. In some patients, however, the T wave inversions persist for a prolonged period (especially chronic pericarditis syndromes).",
"   </p>",
"   <p>",
"    This sequence of ST elevation followed by T wave inversion is the same as that described with myocardial infarction (",
"    <a class=\"graphic graphic_waveform graphicRef81914 \" href=\"UTD.htm?42/18/43306\">",
"     waveform 2",
"    </a>",
"    ). With pericarditis, however, the evolution of repolarization abnormalities often takes place more slowly and more asynchronously than with acute infarction.",
"   </p>",
"   <p>",
"    The distribution of these changes is also different in the two disorders. Leads facing an infarcted area tend to show the same stage of ST-T evolution; in comparison, the myocardial injury is more diffuse in pericarditis and different areas of myocardium reflect different stages in the pattern of repolarization abnormalities. As a result, varying degrees of T wave inversion or ST segment elevation can be present concurrently in different leads in pericarditis. Patients with concomitant myocarditis (perimyocarditis) may show ST-T changes resembling those with pericarditis alone or with acute ischemia.",
"   </p>",
"   <p>",
"    The temporal evolution of ECG changes with acute pericarditis is highly variable from one patient to another [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23669/abstract/4\">",
"     4",
"    </a>",
"    ]. In some cases, the ECG may fail to show ST-T changes (or the abnormalities may have resolved by the time the patient presents). In other cases of acute pericarditis, only PR segment deviations may appear, or the PR changes may precede the ST elevations. ST elevations may return to baseline without further evolution within a few days or so in some patients, without further evolution. In others, evolving T wave inversions in multiple leads may persist for weeks to months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective Holter study showed that sustained arrhythmias are uncommon in acute pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23669/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, the presence of atrial or ventricular arrhythmias is suggestive of concomitant myocarditis or an unrelated cardiac disease. Other findings suggestive of myocardial involvement include bundle branch block or other intraventricular conduction delay or Q waves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;ST elevation can occur in a number of disorders and contexts other than pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23669/abstract/6\">",
"     6",
"    </a>",
"    ]. These include acute ST elevation myocardial infarction (STEMI), takotsubo (stress) cardiomyopathy (apical left ventricular ballooning syndrome), Brugada patterns, and the early repolarization normal variant (",
"    <a class=\"graphic graphic_table graphicRef81757 \" href=\"UTD.htm?38/35/39483\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Distinction from STEMI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiographic changes in acute pericarditis differ from those in acute ST elevation myocardial infarction (STEMI) in the following ways [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23669/abstract/7\">",
"     7",
"    </a>",
"    ]. These distinctions refer to pericarditis that does not occur during or after an acute MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24055?source=see_link\">",
"     \"Pericardial complications of myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ST segment in acute pericarditis is elevated at the J point, is rarely elevated above 5 mm, and usually retains its normal concavity (",
"      <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"UTD.htm?42/53/43866\">",
"       waveform 1",
"      </a>",
"      ). In other cases, the ST segment rises obliquely in a straight line. Although similar patterns can occur with STEMI, the typical STEMI finding is convex (dome-shaped) ST elevation, a pattern not characteristic of acute pericarditis, that may be more than 5 mm in height (",
"      <a class=\"graphic graphic_waveform graphicRef81914 \" href=\"UTD.htm?42/18/43306\">",
"       waveform 2",
"      </a>",
"      ). The basis for these morphologic differences is not known, but is probably related to the greater injury current associated with infarction.",
"     </li>",
"     <li>",
"      The distribution is different. ST segment elevations in STEMI are characteristically limited to either the",
"      <span class=\"nowrap\">",
"       anterior/lateral",
"      </span>",
"      leads (I, aVL, V1 to V6) or the inferior (II, III, aVF) leads because of the localized area of the infarct (",
"      <a class=\"graphic graphic_waveform graphicRef81914 \" href=\"UTD.htm?42/18/43306\">",
"       waveform 2",
"      </a>",
"      ). The pericardium envelops the heart, and the ST-T changes are therefore more generalized, being present in most of the chest leads (eg V2 to V6) as well as leads I, aVL, II, and aVF (",
"      <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"UTD.htm?42/53/43866\">",
"       waveform 1",
"      </a>",
"      ). ST segment elevation in the precordial leads is most commonly seen in V5 and V6, and in decreasing frequency from V4 to V1 in precordial leads. In the limb leads, it is often more evident in leads I and II than in leads III, aVF, and aVL.",
"     </li>",
"     <li>",
"      Acute STEMI is often associated with regional reciprocal ST segment changes, which are not seen with pericarditis except in aVR and V1.",
"     </li>",
"     <li>",
"      ST segment elevation and T wave inversions do not generally occur simultaneously in pericarditis, while this is common in acute STEMI. Furthermore, the evolution of repolarization abnormalities often takes place more slowly and more asynchronously in pericarditis than in STEMI (",
"      <a class=\"graphic graphic_waveform graphicRef62059 \" href=\"UTD.htm?42/35/43578\">",
"       waveform 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The distribution of ST and T changes is also different in the two disorders. Leads facing an infarcted area tend to show the same stage of ST-T evolution; in comparison, the myocardial injury is more diffuse in pericarditis and different areas of myocardium reflect different stages in the pattern of repolarization abnormalities. As a result, varying degrees of T wave inversion or ST segment elevation can be present concurrently in different leads in pericarditis. Patients with concomitant myocarditis may show ST-T changes resembling those with pericarditis alone or with acute ischemia.",
"     </li>",
"     <li>",
"      PR elevation in aVR with PR depressions in other leads due to a concomitant atrial current of injury are often seen in acute pericarditis. In comparison, PR segment abnormalities are not common in acute STEMI.",
"     </li>",
"     <li>",
"      Q waves, which often occur in STEMI, are generally not seen in pericarditis. The abnormal Q waves in MI reflect the loss of positive depolarization voltages because of the death of heart muscle. Pericarditis, on the other hand, generally causes only superficial inflammation, not frank myocardial necrosis. Abnormal Q waves are not seen unless there is concomitant myocarditis.",
"     </li>",
"     <li>",
"      Hyperacute T waves, which can be seen in STEMI, are not typical in pericarditis, although fusion of the ST segment and T wave into a single monophasic curve is rarely seen.",
"     </li>",
"     <li>",
"      Definite prolongation of the QT interval with regional T wave inversion (in the absence of drug effects or relevant metabolic disorders) favors the diagnosis of ischemia over pericarditis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Distinction from early repolarization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal early repolarization variant is characterized by ST elevation of the J point, which represents the junction between the end of the QRS complex (termination of depolarization) and the beginning of the ST segment (onset of ventricular repolarization). As a result, there is elevation of the ST segment itself, which maintains its normal configuration (",
"    <a class=\"graphic graphic_waveform graphicRef79999 \" href=\"UTD.htm?27/15/27892\">",
"     waveform 4",
"    </a>",
"    ). ST elevation is most often present in the mid to lateral chest leads (V3-V6), although many leads can be involved.",
"   </p>",
"   <p>",
"    The following features can be used to distinguish the electrocardiographic changes in acute pericarditis from those in early repolarization:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ST elevations occur in both the limb and precordial leads in most cases of acute pericarditis (47 of 48 in one study), whereas about one-half of subjects with early repolarization have no ST deviations in the limb leads [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23669/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two other findings that strongly favor pericarditis are PR deviation and evolution of the ST and T changes, which are not seen in early repolarization.",
"     </li>",
"     <li>",
"      In a prospective study, the most reliable distinguishing feature was the ratio of ST elevation to T wave amplitude in lead V6 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23669/abstract/9\">",
"       9",
"      </a>",
"      ]. If the ratio exceeded 0.24, acute pericarditis was present (positive and negative predictive values were both 100 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ELECTROCARDIOGRAM IN PERICARDIAL EFFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardial effusion is usually the result of pericarditis. However, it can occur in the absence of generalized pericarditis in a number of disorders such as myxedema, rupture of the heart, or aortic dissection. The major hemodynamic significance of pericardial effusion is the danger of cardiac tamponade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common ECG sign of pericardial effusion is",
"    <strong>",
"     low voltage",
"    </strong>",
"    of the QRS complexes (",
"    <a class=\"graphic graphic_table graphicRef80629 \" href=\"UTD.htm?32/46/33515\">",
"     table 3",
"    </a>",
"    ). This finding is probably due to short-circuiting of cardiac potentials caused by the fluid surrounding the heart as well as inflammatory mechanisms affecting the pericardium and myocardium. Low voltage is said to be present when the total amplitude of the QRS complexes in each of the six limb leads is 5 mm (0.5 mV) or less. Low voltage in the limb leads may or may not be accompanied by low voltage in the chest leads (defined as a total QRS amplitude of 10 mm or less in V1 to V6).",
"   </p>",
"   <p>",
"    One study suggested that low QRS voltage in this setting is actually a specific manifestation of pericardial tamponade, rather than merely of pericardial effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23669/abstract/10\">",
"     10",
"    </a>",
"    ]. Among 43 patients with a pericardial effusion, tamponade was present in 23. Low QRS voltage was found in 14 of these 23 patients (61 percent), but in none with effusion without tamponade. After treatment of tamponade by either pericardiocentesis or antiinflammatory medication, low voltage resolved within one week.",
"   </p>",
"   <p>",
"    The combination of low voltage and sinus tachycardia should always raise concern about pericardial effusion with tamponade. Other causes of this combination include chronic obstructive pulmonary disease, pleural effusion, cardiomyopathy, and after open heart surgery.",
"   </p>",
"   <p>",
"    Another pattern that can occur with pericardial effusion and tamponade is total",
"    <strong>",
"     electrical alternans",
"    </strong>",
"    usually with sinus tachycardia (",
"    <a class=\"graphic graphic_waveform graphicRef72525 \" href=\"UTD.htm?42/27/43450\">",
"     waveform 5",
"    </a>",
"    ). This abnormality is characterized by a cyclic beat-to-beat shift in the QRS axis (and more subtly in other waveforms) in the limb and precordial leads in association with mechanical swinging of the heart to-and-fro, usually in a large pericardial effusion. The pattern is usually most apparent in one or more of the precordial leads.",
"   </p>",
"   <p>",
"    Electrical alternans with sinus tachycardia is a highly specific sign of pericardial effusion, usually with cardiac tamponade, but is only modestly sensitive. As a result, its absence does not exclude cardiac tamponade. QRS alternans with other tachycardias (eg, paroxysmal supraventricular tachycardias or ventricular tachycardia) is a nonspecific finding resulting from alternation in conduction on a beat-to-beat basis, not from mechanical movement of the heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=see_link\">",
"       \"Patient information: Pericarditis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12861630\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both pericarditis and pericardial effusion may produce changes in the electrocardiogram that can be mistaken for other diagnoses. The following summarizes key points made in this topic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute pericarditis often produces a distinctive ECG appearance marked initially by diffuse ST elevations (eg, in leads I, II, III, aVL, aVF and V2-V6) with PR segment depression in those leads and primary PR segment elevation in lead aVR (discordant ST-PR segment sign). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'ST segment elevation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'PR segment deviation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In acute pericarditis, leads showing ST elevation may develop T wave inversions, simulating evolving ischemia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'T wave inversion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major differential diagnosis of these ST elevations includes acute ischemic syndromes, left ventricular dyskinetic segments, and benign early repolarization variants. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low voltage may be seen in patients with pericardial effusion. Pericardial effusion with tamponade physiology is usually associated with sinus tachycardia, and sometimes with electrical alternans (usually best seen in the midprecordial leads). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Electrocardiogram in pericardial effusion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Goldberger AL, Goldberger ZD, Shvilkin A. Goldberger's Clinical Electrocardiography: A Simplified Approach, 8th ed, Elsevier/Saunders, Philadelphia 2013.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23669/abstract/2\">",
"      Surawicz B, Lasseter KC. Electrocardiogram in pericarditis. Am J Cardiol 1970; 26:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23669/abstract/3\">",
"      Baljepally R, Spodick DH. PR-segment deviation as the initial electrocardiographic response in acute pericarditis. Am J Cardiol 1998; 81:1505.",
"     </a>",
"    </li>",
"    <li>",
"     Spodick, DH. The Pericardium: A Comprehensive Textbook, Marcel Dekker, New York 1997. p.46-64.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23669/abstract/5\">",
"      Spodick DH. Arrhythmias during acute pericarditis. A prospective study of 100 consecutive cases. JAMA 1976; 235:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23669/abstract/6\">",
"      Wang K, Asinger RW, Marriott HJ. ST-segment elevation in conditions other than acute myocardial infarction. N Engl J Med 2003; 349:2128.",
"     </a>",
"    </li>",
"    <li>",
"     Surawicz, B, Knilans, T. Chou's Electrocardiography in Clinical Practice: Adults and Pediatrics, 5th ed, WB Saunders, Philadelphia 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23669/abstract/8\">",
"      Spodick DH. Differential characteristics of the electrocardiogram in early repolarization and acute pericarditis. N Engl J Med 1976; 295:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23669/abstract/9\">",
"      Ginzton LE, Laks MM. The differential diagnosis of acute pericarditis from the normal variant: new electrocardiographic criteria. Circulation 1982; 65:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23669/abstract/10\">",
"      Bruch C, Schmermund A, Dagres N, et al. Changes in QRS voltage in cardiac tamponade and pericardial effusion: reversibility after pericardiocentesis and after anti-inflammatory drug treatment. J Am Coll Cardiol 2001; 38:219.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2105 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23669=[""].join("\n");
var outline_f23_7_23669=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12861630\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ELECTROCARDIOGRAM IN PERICARDITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ST segment elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PR segment deviation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      T wave inversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Distinction from STEMI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Distinction from early repolarization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ELECTROCARDIOGRAM IN PERICARDIAL EFFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12861630\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2105\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2105|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/0/7181\" title=\"table 1\">",
"      Causes of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/35/39483\" title=\"table 2\">",
"      Causes of ST segment elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/46/33515\" title=\"table 3\">",
"      Causes of low QRS voltage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2105|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/53/43866\" title=\"waveform 1\">",
"      ECG in pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/18/43306\" title=\"waveform 2\">",
"      ECG in evolving anterior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/35/43578\" title=\"waveform 3\">",
"      ECG late evolution of anterior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?27/15/27892\" title=\"waveform 4\">",
"      ECG early repolarization tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/27/43450\" title=\"waveform 5\">",
"      ECG in electrical alternans",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/53/12115?source=related_link\">",
"      Patient information: Pericarditis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24055?source=related_link\">",
"      Pericardial complications of myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6533?source=related_link\">",
"      Pericarditis in renal failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_7_23670="Hyperimmunoglobulin-D syndrome: Management";
var content_f23_7_23670=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyperimmunoglobulin-D syndrome: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/7/23670/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23670/contributors\">",
"     Yoram C Padeh, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23670/contributors\">",
"     Arye Rubinstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/7/23670/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23670/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/7/23670/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23670/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/7/23670/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hyperimmunoglobulin-D syndrome (HIDS) is a genetically inherited periodic fever syndrome associated with sustained high fevers, lymphadenopathy, abdominal pain, arthritis, and skin rashes. Interval periods range from four to eight weeks on average during which patients remain completely asymptomatic (MIM #260920). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3768?source=see_link\">",
"     \"Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although mutations in the mevalonate kinase (MVK) gene have been identified in a substantial proportion of patients with HIDS, other patients with a similar phenotype do not have identifiable MVK gene mutations. The pathophysiology of the disease is incompletely understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9720?source=see_link\">",
"     \"Hyperimmunoglobulin-D syndrome: Pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients with HIDS have a normal lifespan and rarely suffer any serious complications of the disease, with the possible rare exception being the occurrence of amyloidosis. Potentially curative therapy in the form of allogeneic bone marrow transplant (BMT) has been performed for the more severe disorder mevalonic aciduria, although the risks of allogeneic BMT outweigh any potential benefit for patients with HIDS given the typically benign clinical course [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3768?source=see_link\">",
"     \"Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Alleviate symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of a curative treatment or intervention that prevents the febrile episodes, symptomatic treatment is generally the main focus of management. Various pharmacologic approaches have been used and their effectiveness has been suggested based on small series (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Pharmacologic approaches'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Avoid unnecessary surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the diagnosis of HIDS, patients who present with fever and severe abdominal pain, may undergo laparotomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    appendectomy. Once the diagnosis of HIDS is established, a much higher threshold for exploratory surgery is appropriate. If the timing and nature of the symptoms are compatible with a recurrent episode a high threshold is appropriate. If, however, abdominal pain occurs at a shorter than usual interval or there are symptoms that are unusual for a particular patient, clinical judgement may favor laparotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATIENT EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful management of children with HIDS requires cooperation and involvement of the parents. Parents and professionals weigh the risks and benefits of the interventions versus the disquiet that is required to simply observe a child who is having a febrile episode. Adults also need to be informed about the benign prognosis and the tradeoff between potential adverse effects of the drugs that are discussed below and the limited evidence of effectiveness of currently available pharmacologic interventions.",
"   </p>",
"   <p>",
"    Parent should be encouraged to be aware of the general timing of episodes and of the child's symptoms in order to assist clinicians in deciding when watchful waiting is appropriate versus additional diagnostic testing or even laparotomy, as discussed above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Avoid unnecessary surgery'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;No universally reliable means of arresting or mitigating the symptoms of a febrile episode have yet been identified. Several pharmacologic agents have been used to treat febrile episodes and associated symptoms, with varying results. Drugs and drug classes for which some data have been published include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs)",
"     </li>",
"     <li>",
"      Oral glucocorticoids",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"     </li>",
"     <li>",
"      Intravenous immunoglobulin (IVIG)",
"     </li>",
"     <li>",
"      HMG-CoA reductase inhibitors (statins)",
"     </li>",
"     <li>",
"      Tumor necrosis factor alpha (TNF-alpha) inhibitors",
"     </li>",
"     <li>",
"      Recombinant human interleukin 1 receptor antagonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With a low risk of long-term sequelae, as noted earlier, treatment options with the lowest risk of serious side effects are considered first.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     NSAIDs for fever and pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of nonsteroidal antiinflammatory drugs (NSAIDs) may alleviate the height and duration of fevers in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/2\">",
"     2",
"    </a>",
"    ]. It may also mitigate associated symptoms in individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preemptive use of medication during prodromal symptoms, when these are reliably present before the febrile episode, has had disparate results. It has reduced the severity of the fever and associated symptoms in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/4\">",
"     4",
"    </a>",
"    ], but not in others [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No randomized controlled trials have been done to determine the effectiveness of NSAIDs or to evaluate different doses. Treatment should be tailored to individual patients. If parents or patients opt for symptomatic management during febrile episodes, we suggest use of an NSAID rather than an oral glucocorticoid as the initial agent. Any NSAID can be used, generally one that the parents and clinician are comfortable using and in doses appropriate for the child's age.",
"   </p>",
"   <p>",
"    If there is a partial response to the initial dose, a higher dose, up to the manufacturer's recommended maximum, can be used and the effect observed. NSAIDs are used for the duration characteristic of a particular child&rsquo;s pattern, typically for four to seven days. There is no role for NSAIDs between episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Oral glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual reports demonstrate good responses to oral glucocorticoids, usually given for one to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/2,3,5\">",
"     2,3,5",
"    </a>",
"    ]. Patients responded with normalized temperatures and markedly decreased symptoms. Dosing varies from a single pulse dose at the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/3\">",
"     3",
"    </a>",
"    ] to 30 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    daily for three days followed by a one week taper [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/5\">",
"     5",
"    </a>",
"    ], to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    prednisone initial dose with a two week taper which also alleviated arthritic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/2\">",
"     2",
"    </a>",
"    ]. Again, no randomized controlled trials are available. This treatment option should be considered if the response to NSAIDs is weak or nonexistent. For those who do not respond to an NSAID, and are willing to accept the potential adverse effect of a short course of glucocorticoids, we suggest prednisone or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, orally) for four to seven days, depending upon the typical duration of attacks in a patient. This dose is appropriate for both children and adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a therapeutic trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    may have a role in excluding familial Mediterranean fever, clinical experiences with colchicine in HIDS suggest a minimal effect, if any. Colchicine slightly increased duration of symptom-free intervals and had little or no effect on symptoms during febrile episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/2,3,5,6\">",
"     2,3,5,6",
"    </a>",
"    ]. In the absence of even anecdotal documentation to support efficacy, and given the significant side effect profile, we suggest not using colchicine for patients with HIDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in this disease. Two patients in one family were treated with cyclosporine; one remained attack-free for six years, while her brother had no benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Intravenous IG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are similarly sparse on the use of intravenous immunoglobulin (IVIG). Among five patients treated with IVIG, one had a diminished number and severity of episodes while the other four showed no response [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/2\">",
"     2",
"    </a>",
"    ]. We are unaware of any other reports of successful use. In view of the expense and risk of adverse effects for IVIG, we recommend it not be used in HIDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mevalonate kinase (MK) is one enzymatic step downstream of the HMG-CoA reductase enzyme in the cholesterol synthetic pathway. Thus, use of an HMG-CoA reductase enzyme inhibitor (statin) seemed a logical choice for treatment of HIDS episodes. However, clinical experience has provided mixed results. The following are illustrative [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two cases of mevalonic aciduria (due to near or complete absence of MK enzyme activity and resulting in a more severe phenotype than HIDS), treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      resulted in worse crises [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A one-year study randomly assigned six adult patients with HIDS to statin therapy with a crossover design [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/8\">",
"       8",
"      </a>",
"      ]. There was no statistically significant difference in febrile days or severity between the statin and placebo periods. No deleterious effects were noted. This study lacked statistical power to exclude a small difference.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results, and an evolving understanding of the pathogenesis of disease symptoms, suggest that statins are likely not to be of benefit and may instead increase the risk of exacerbating symptoms. Thus, we suggest not using statins to treat patients with HIDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Anticytokine therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated acute-phase reactants and serum levels of inflammatory cytokines including TNF-alpha suggest that a systemic inflammatory process causes the symptoms during febrile attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/9\">",
"     9",
"    </a>",
"    ]. Small therapeutic trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    have been reported and these are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    may reduce cytokine release, but has no demonstrated efficacy for HIDS. This was illustrated in a study of six adults with HIDS who were randomly assigned to thalidomide or placebo and followed for 36 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/10\">",
"     10",
"    </a>",
"    ]. No significant difference in the severity of symptoms and only a mild decrease in acute-phase reactant levels were noted in those treated with thalidomide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/10\">",
"     10",
"    </a>",
"    ]. No side effects were noted. In view of the frequent side effects of thalidomide, particularly somnolence and neuropathy, and the lack of supporting evidence of efficacy we recommend not using thalidomide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    , a TNF alpha receptor-immunoglobulin fusion protein, has been administered to some patients with HIDS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A three-year-old boy with HIDS and a genetic mutation found in tumor necrosis factor receptor-1 gene that is known to cause another periodic fever disorder, the tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS), initially responded well to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , but developed tachyphylaxis and had no further response to the drug [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two girls with HIDS were separately treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      and were noted to have a decrease in duration and severity of febrile episodes. Dosing was adjusted in one patient who developed recurrent upper respiratory infections. When treatment was stopped for five weeks in the same patient, she subsequently experienced a \"full-blown attack\" [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two of three adult female patients with HIDS showed no response to pulse treatment with two doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      in the beginning hours of a febrile attack [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/13\">",
"       13",
"      </a>",
"      ]. The third patient had reproducible attacks in response to vaccinations. Using this opportunity, the patient was given etanercept subsequent to one vaccination, which was followed by a febrile episode [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 10-year-old Caucasian girl who partially responded to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      demonstrated prolonged duration of febrile episodes upon treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 20-month-old boy with HIDS who was homozygous for the T322S mutation as well as heterozygous for the E148Q FMF mutation was treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      <span class=\"nowrap\">",
"       0.8mg/kg",
"      </span>",
"      per week. He had significant improvement of his febrile attacks, but remained with hepatomegaly [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A six-year-old Turkish girl with HIDS who was homozygous for the R277C mutation as well as heterozygous for the E148Q FMF mutation was treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      <span class=\"nowrap\">",
"       0.8mg/kg",
"      </span>",
"      per week. She had almost complete resolution of her febrile episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Except in rare syndrome-overlap situations, such as",
"    <span class=\"nowrap\">",
"     HIDS/TRAPS",
"    </span>",
"    in the case reported above [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/11\">",
"     11",
"    </a>",
"    ], there is no evidence thus far to support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    in the treatment of HIDS. However, there may be a role for etanercept in the treatment of HIDS patients with homozygous mutations who also carry the E148Q FMF mutation, based upon case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], although further investigation is necessary before any recommendations can be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Anakinra",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin-1 receptor antagonist (IL-1 ra), the physiologic inhibitor of IL-1, may be elevated during HIDS attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/9\">",
"     9",
"    </a>",
"    ]. Febrile episodes in HIDS as well as other periodic fever syndromes may be caused by elevated IL-1 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9720?source=see_link\">",
"     \"Hyperimmunoglobulin-D syndrome: Pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study reports using the synthetic IL-1 receptor antagonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      in a patient with vaccine-induced attacks in three doses subsequent to a vaccine administration as described above [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/13\">",
"       13",
"      </a>",
"      ]. Her body temperature normalized and symptoms disappeared seventeen hours after the first dose.",
"     </li>",
"     <li>",
"      A seven-year-old girl with an established diagnosis of HIDS refractory to NSAIDs, glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      by subcutaneous injection) for 18 months [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/18\">",
"       18",
"      </a>",
"      ]. The frequency and severity of fever attacks were reported to be \"totally\" reduced.",
"     </li>",
"     <li>",
"      A 10-year-old Caucasian girl who partially responded to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      demonstrated prolonged duration of febrile episodes upon treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 19-year-old male with HIDS, compound heterozygous for L264F and I268T, who developed an IgD-related pauci-immune crescentic glomerulonephritis at the age of eight, requiring a renal transplant, was treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      <span class=\"nowrap\">",
"       2mg/kg",
"      </span>",
"      per day. He had resolution of his febrile episodes, and tolerated dose reduction of the immunosuppressive agent. The number of times he was hospitalized per month decreased to zero from an average of 1.16 hospitalizations per month the year prior [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23670/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No recommendation can be made on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    in HIDS at this time, because there are only a few reported cases of successful treatment, a report of increased febrile episode duration, and no controlled studies. Further study of this agent in HIDS is anticipated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperimmunoglobulin-D syndrome (HIDS) is a genetically inherited periodic fever syndrome associated with sustained high fevers, lymphadenopathy, abdominal pain, arthritis, and skin rashes. Interval periods range from four to eight weeks on average during which patients remain completely asymptomatic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3768?source=see_link\">",
"       \"Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The goals of management are to avoid unnecessary surgical intervention, alleviate symptoms, and minimize the risk of adverse effects of treatment. Side effects of pharmacologic agents and their cost must be weighed against the knowledge that HIDS usually does not cause premature death or serious permanent complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Goals of management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with HIDS, decisions regarding the choice of therapy should involve the patient, when feasible, and his or her",
"      <span class=\"nowrap\">",
"       parents/caregivers.",
"      </span>",
"      After appropriate education, they, in conjunction with the treating clinician, must weigh the risks and benefits to determine their choice of therapy.",
"     </li>",
"     <li>",
"      For parents or patients who opt for symptomatic management during febrile episodes, we suggest use of an NSAID rather than an oral glucocorticoid as the initial agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For those who do not respond to an NSAID, we suggest a short course of an oral glucocorticoid (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A typical dose is 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for the predicted duration of an attack. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'NSAIDs for fever and pain'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Oral glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      to treat or prevent febrile episodes in patient with an established diagnosis of HIDS (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A therapeutic trial of colchicine may be indicated to help exclude familial Mediterranean fever. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Colchicine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT using statins (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Statins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Thalidomide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the patient with HIDS alone, we suggest NOT using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For the very rare patient with both HIDS and TRAPS, use of etanercept may be useful. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Etanercept'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28551?source=see_link&amp;anchor=H22#H22\">",
"       \"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)\", section on 'Anti-TNF therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinical experience with other agents (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , IVIG, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      ) is either not encouraging or too limited to warrant making suggestions or recommendations about their use in HIDS.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/1\">",
"      Neven B, Valayannopoulos V, Quartier P, et al. Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med 2007; 356:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/2\">",
"      Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 1994; 73:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/3\">",
"      Picco P, Gattorno M, Di Rocco M, Buoncompagni A. Non-steroidal anti-inflammatory drugs in the treatment of hyper-IgD syndrome. Ann Rheum Dis 2001; 60:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/4\">",
"      Armbrust S, Drenth JP, Schr&ouml;der C, et al. Tendonitis in variant hyperimmunoglobulinaemia D and periodic fever syndrome--a rare disease with a new symptom. Eur J Pediatr 2005; 164:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/5\">",
"      de Dios Garc&iacute;a-D&iacute;az J, Alvarez-Blanco MJ. Glucocorticoids but not NSAID abort attacks in hyper-IgD and periodic fever syndrome. J Rheumatol 2001; 28:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/6\">",
"      Ostuni P, Vertolli U, Marson P. Atypical hypergammaglobulinaemia D syndrome with amyloidosis: an overlap with familial Mediterranean fever? Clin Rheumatol 1996; 15:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/7\">",
"      Hoffmann GF, Charpentier C, Mayatepek E, et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 1993; 91:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/8\">",
"      Simon A, Drewe E, van der Meer JW, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004; 75:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/9\">",
"      Drenth JP, van Deuren M, van der Ven-Jongekrijg J, et al. Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood 1995; 85:3586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/10\">",
"      Drenth JP, Vonk AG, Simon A, et al. Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial. J Pharmacol Exp Ther 2001; 298:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/11\">",
"      Arkwright PD, McDermott MF, Houten SM, et al. Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 2002; 130:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/12\">",
"      Takada K, Aksentijevich I, Mahadevan V, et al. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003; 48:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/13\">",
"      Bodar EJ, van der Hilst JC, Drenth JP, et al. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 2005; 63:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/14\">",
"      Shendi HM, Walsh D, Edgar JD. Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome. Rheumatol Int 2012; 32:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/15\">",
"      Topalo��lu R, Ayaz NA, Waterham HR, et al. Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up. Clin Rheumatol 2008; 27:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/16\">",
"      Demirkaya E, Caglar MK, Waterham HR, et al. A patient with hyper-IgD syndrome responding to anti-TNF treatment. Clin Rheumatol 2007; 26:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/17\">",
"      Normand S, Massonnet B, Delwail A, et al. Specific increase in caspase-1 activity and secretion of IL-1 family cytokines: a putative link between mevalonate kinase deficiency and inflammation. Eur Cytokine Netw 2009; 20:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/18\">",
"      Rigante D, Ansuini V, Bertoni B, et al. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int 2006; 27:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23670/abstract/19\">",
"      Cailliez M, Garaix F, Rousset-Rouvi&egrave;re C, et al. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J Inherit Metab Dis 2006; 29:763.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5955 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23670=[""].join("\n");
var outline_f23_7_23670=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Alleviate symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Avoid unnecessary surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATIENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHARMACOLOGIC APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NSAIDs for fever and pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Oral glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Intravenous IG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anticytokine therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Etanercept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Anakinra",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3768?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9720?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28551?source=related_link\">",
"      Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_7_23671="Stages neurodegeneration PD";
var content_f23_7_23671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F69456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F69456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stages in the development of Parkinson disease-related pathology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 547px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parkinson disease presymptomatic and symptomatic phases.",
"    <strong>",
"     (Panel A)",
"    </strong>",
"    The presymptomatic phase is marked by the appearance of Lewy neurites/bodies in the brains of asymptomatic persons. In the symptomatic phase, the individual neuropathological threshold is exceeded (black arrow). The increasing slope and intensity of the colored areas below the diagonal indicate the growing severity of the pathology in vulnerable brain regions (panel B). The severity of the pathology is indicated by darker degrees of shading in the colored arrow left.",
"    <strong>",
"     (Panel B)",
"    </strong>",
"    Diagram showing the ascending pathological process (white arrows). The shading intensity of the colored areas corresponds to that in panel A.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Braak H, Ghebremedhi E, R&uuml;b U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318:121; with kind permission from Springer Science&nbsp;+ Business Media B.V.&nbsp;Copyright &copy; 2004.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23671=[""].join("\n");
var outline_f23_7_23671=null;
var title_f23_7_23672="Viral findings VZV vasc";
var content_f23_7_23672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathological and virological findings in the arteries of patients who died from VZV vasculopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 479px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) A cerebral artery with multinucleated giant cells (arrow). (B) Multiple herpesvirions within a cerebral artery. (C) VZV DNA in the posterior cerebral artery (lane 3) and basilar artery (lane 5). (D) VZV antigen (red) in the media of a cerebral artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Panels A and B courtesy of Donald H Gilden, MD; Panels C and D reproduced with permission from: Gilden DH, Kleinschmidt-DeMasters BK, Wellish M, et al. Varicella zoster virus, a cause of waxing and waning vasculitis: The New England Journal of Medicine case 5-1995 revisited. Neurology 1996; 47:1441. Copyright &copy; 1996 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23672=[""].join("\n");
var outline_f23_7_23672=null;
var title_f23_7_23673="Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)";
var content_f23_7_23673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pediatric acute kidney injury: Indications, timing, and choice of modality for renal replacement therapy (RRT)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/7/23673/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23673/contributors\">",
"     Patrick D Brophy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23673/contributors\">",
"     Jennifer G Jetton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/7/23673/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23673/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/7/23673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23673/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/7/23673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4746388\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury (AKI) is characterized by the acute failure of the kidneys to maintain adequate electrolyte, acid-base, and fluid homeostasis along with a reduction in glomerular filtration rate (GFR) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Clinically, AKI is manifested by increases in nitrogenous waste products (BUN) and serum creatinine, and, in some cases, a concomitant reduction in urine output (less than 0.5 to 1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour) that is often refractory to diuretic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=see_link\">",
"     \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AKI is increasingly recognized as an important and independent risk factor of morbidity and mortality in critically ill children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. With at least 30 different definitions of AKI reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/8\">",
"     8",
"    </a>",
"    ], generalizations across studies and comparisons of different data sets are challenging. As a result, the lack of evidence-based guidelines regarding the management of the pediatric patient with AKI has led to uncertainty and controversy regarding the appropriate timing for the initiation of renal replacement therapy (RRT), as well as the most appropriate RRT modality.",
"   </p>",
"   <p>",
"    The indications, timing, and modalities for renal replacement therapy (RRT) for children with AKI will be reviewed here. RRT in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link&amp;anchor=H3#H3\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4746395\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR AND TIMING OF RRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective reviews of large databases of critically ill children demonstrate that children tend to develop organ failure, including acute kidney injury (AKI), early in their hospital course, and children with AKI have a greater mortality risk and longer length of stay than those without AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Renal replacement therapy (RRT) may prevent and correct the adverse and potentially life-threatening complications of AKI including symptomatic uremia, metabolic and electrolyte imbalance, and severe fluid overload, thereby reducing the mortality and length of stay of children with AKI.",
"   </p>",
"   <p>",
"    Indicators for the provision of RRT in pediatric AKI have been traditionally extrapolated from the following parameters used for dialysis initiation for end-stage renal disease (ESRD) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic and electrolyte imbalance not amenable to medical therapy (eg, severe hyperkalemia or metabolic acidosis)",
"     </li>",
"     <li>",
"      Symptomatic uremia (eg, bleeding, pericarditis, and encephalopathy)",
"     </li>",
"     <li>",
"      Severe fluid overload leading to hypertension, pulmonary edema and respiratory failure, or heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these indicators are usually late findings of severe kidney dysfunction, and data from adult patients with AKI suggest that earlier initiation of RRT prior to the appearance of these life-threatening complications is associated with better outcome. Similar data in critically ill children are not available. Thus, based on the adult literature, most pediatric intensivists and nephrologists advocate for earlier implementation of RRT to avoid these late manifestations of AKI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link&amp;anchor=H3#H3\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the optimal timing and clinical criteria remain unknown, most experts initiate RRT when there is evidence of significant reduction in glomerular filtration rate (GFR), fluid overload, and metabolic imbalance. While there are insufficient data to support evidence-based guidelines that include quantifiable values for uremia and metabolic disturbances, there are sufficient data to provide guidelines for fluid overload. Specifically, fluid overload greater than 20 percent has been associated with increased mortality when controlled for severity of illness in both single center and multicenter pediatric analyses, and these indices are being used to direct the care of the pediatric patient with AKI at many (but not all) centers.",
"   </p>",
"   <p>",
"    The decision to begin RRT is based primarily on the judgement of clinicians in evaluating the level of impairment including the effect of patient factors",
"    <span class=\"nowrap\">",
"     (age/size,",
"    </span>",
"    illness acuity, and co-morbidities), organizational resources including availability of necessary equipment, and trained and experienced staff.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4746409\">",
"    <span class=\"h2\">",
"     Severity of AKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of AKI is generally based on the degree of GFR reduction, which is clinically measured by blood urea nitrogen (BUN) and serum creatinine.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BUN &ndash; The degree of uremia, quantified by BUN concentration, is usually used to measure the severity of AKI and as an indicator for the initiation of RRT [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/12\">",
"       12",
"      </a>",
"      ]. Data from adult studies demonstrated improved outcome when RRT was initiated when the BUN reached 90 to 100",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      as compared with waiting until the BUN exceeded 150",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      In addition, a retrospective study in adults with AKI reported a higher survival rate in patients initiated on RRT (continuous venous hemofiltration) at a BUN less than 60",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      compared with those who received RRT at a higher BUN concentration (30 versus 20 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link&amp;anchor=H2#H2\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\", section on 'Indications for and timing of initiation of dialysis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      However, using BUN as an indicator for RRT is limited by a number of nonrenal factors that affect BUN measurements, including gastrointestinal bleeding, steroid use, diuretic use, catabolism, and nutritional intake. Nevertheless, in our practice, we consider the use of RRT when the BUN reaches a level between 80 to 100",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Serum creatinine &ndash; Significant increases in serum creatinine (SCr) occur late in the course of AKI and thus, it is an imperfect marker to determine the appropriate timing of RRT [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/8,14\">",
"       8,14",
"      </a>",
"      ]. It is affected by muscle mass that varies according to the size, nutritional status, and underlying medical comorbidities of the child. Although data are insufficient, early initiation of RRT before a significant change in SCr appears to improve outcome of children with AKI.",
"     </li>",
"     <li>",
"      Novel biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18) show promise in both their diagnostic and prognostic utility in the setting of AKI, and may allow for early intervention prior to the onset of SCr rise, severe metabolic derangements, and fluid overload [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/15-17\">",
"       15-17",
"      </a>",
"      ]. However, future studies are needed to establish whether any of these markers will provide beneficial guidance in determining the optimal time for RRT initiation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4746416\">",
"    <span class=\"h2\">",
"     Fluid overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have shown that fluid overload is an independent predictor of mortality in children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/18-22\">",
"     18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 157 children with multiorgan dysfunction syndrome (MODS) from the Pediatric Continuous Renal Replacement Therapy (ppCRRT) registry, multivariate analysis, which controlled for severity of illness including the use of mechanical ventilation and ionotropic agents, showed that the degree of fluid overload was lower in survivors versus nonsurvivors [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subsequent study from the ppCRRT registry of 297 children who received continuous RRT, the mortality rate increased as the degree of fluid overload increased [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/22\">",
"       22",
"      </a>",
"      ]. Mortality rates for patients who developed overload greater than 20 percent, between 10 and 20 percent, and less than 10 percent were 66, 43, and 29 percent, respectively. After adjusting for severity of illness and intergroup differences, there was a 3 percent increase in mortality for each 1 percent increase in severity of fluid overload.",
"     </li>",
"     <li>",
"      At-risk patient populations, such as those who have undergone stem cell transplantation, have a poorer survival outcome with a greater than 10 percent fluid overload [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that early initiation of RRT in patients with MODS is beneficial as it prevents or corrects significant fluid overload, which is associated with increased mortality.",
"   </p>",
"   <p>",
"    The 2007 update of the 2002 American College of Critical Care Medicine Clinical Guidelines for Hemodynamic Support of Neonates and Children with Septic Shock includes the suggestion that RRT be considered following early goal-directed fluid resuscitation in patients at risk for worsening fluid overload [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/24\">",
"     24",
"    </a>",
"    ]. In these guidelines, once hemodynamic stability is achieved, the patient&rsquo;s fluid status is evaluated by determining the percent fluid overload (FO) using the following equation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Percent FO at RRT initiation = [fluid in (Liters) &ndash; fluid out",
"    <span class=\"nowrap\">",
"     (Liters)]/admission",
"    </span>",
"    weight (kg) X 100",
"   </p>",
"   <p>",
"    In addition, RRT may be used to maintain the fluid status of critically ill children who remain oliguric, especially those who are hemodynamically unstable, while administering intravenous fluids including parenteral nutrition and medications, and",
"    <span class=\"nowrap\">",
"     /or",
"    </span>",
"    blood products. In this setting, RRT is not used to remove fluid but to prevent further fluid overload, which may lead to worsening respiratory status and cardiac function. Once the patient has achieved a satisfactory level of hemodynamic stability, the process of fluid removal can commence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21365186\">",
"    <span class=\"h2\">",
"     Renal angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because there is no reliable marker to determine the severity and prognosis of AKI, the use of collection of clinical risk factors and signs of renal disease has been proposed as a method to identify patients most at risk for developing AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/25\">",
"     25",
"    </a>",
"    ]. Analogous to assessing the risk of a myocardial infarction in a patient presenting with chest pain, the threshold for &ldquo;renal angina&rdquo; would be based on the presence of established AKI risk factors (eg, mechanical ventilation, history of cardiopulmonary bypass, bone marrow transplantation) and evidence of renal disease (fluid overload and changes in serum creatinine) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/26\">",
"     26",
"    </a>",
"    ]. The proposed renal angina criteria stratify patients into moderate-risk, high-risk, and very-high-risk patients according to their underlying clinical condition. For each level of preexisting risk factors, there is a threshold of evidence of injury that a patient must meet to be considered to have renal angina [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We feel that this AKI scoring system, while still early in development and not yet fully validated and refined, has great potential utility for informing the appropriate timing of initiation of renal replacement therapy. Patients in the very-high-risk category are likely at greatest risk for &ldquo;late manifestations&rdquo; of AKI (metabolic imbalance, symptomatic uremia, severe fluid overload), and therefore would benefit the most from earlier RRT initiation. The addition of novel biomarker confirmation will further enhance our ability to determine which patients would most benefit from initiation of RRT and at what point in the clinical course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H719049\">",
"    <span class=\"h2\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the critically ill child with AKI in the pediatric intensive care unit (PICU), our practice is to initiate renal replacement therapy if the patient has the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      15 percent or greater fluid overload",
"     </li>",
"     <li>",
"      Oliguria not responsive to diuretics",
"     </li>",
"     <li>",
"      Escalating ventilatory requirements, especially if related to volume status (prior to intubation is preferred when possible)",
"     </li>",
"     <li>",
"      Need for adequate nutrition, especially when nutrition is compromised by fluid restriction or electrolyte abnormalities",
"     </li>",
"     <li>",
"      Need for provision of large volumes of medications or blood products in a patient already &gt;10 percent fluid overloaded",
"     </li>",
"     <li>",
"      BUN between 80 and 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Life-threatening metabolic derangements (eg, hyperkalemia) that are refractory to medical management",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4746438\">",
"    <span class=\"h1\">",
"     MODALITY CHOICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The renal replacement therapeutic interventions are based on the exchange (movement) of solute and water between two solutions (eg, blood and dialysate) across a membrane based on the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffusion consists of a solute exchange between two solutions (eg, blood and peritoneal fluid or dialysis fluid) separated by a semipermeable membrane. The factors governing the rate of solute exchange are the solute concentration gradient, solute size and charge, the permeability of the membrane for the solute, and the effective surface area of the membrane.",
"     </li>",
"     <li>",
"      Filtration consists of movement of water and permeable solutes across the membrane primarily driven by either differences in hydrostatic pressure (eg, hemodialysis and hemofiltration) or osmotic pressure (eg, hemodialysis and peritoneal dialysis). Convection refers to the phenomenon of solute movement (also referred to as solute drag) with filtration across the membrane independent of concentration gradient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following modalities are currently available for the provision of renal replacement therapy (RRT) in the pediatric patient with acute kidney injury (AKI) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/1,27,28\">",
"     1,27,28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peritoneal dialysis (PD): both convective and diffusion-based solute clearance",
"     </li>",
"     <li>",
"      Intermittent hemodialysis (HD): both convective and diffusion-based solute clearance",
"     </li>",
"     <li>",
"      Continuous renal replacement therapies (CRRT) including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Continuous venovenous hemodialysis (CVVHD): predominantly diffusion-based solute clearance",
"     </li>",
"     <li>",
"      Continuous venovenous hemofiltration (CVVH): predominantly convective-based solute clearance",
"     </li>",
"     <li>",
"      Continuous venovenous hemodiafiltration (CVVHDF): both convective and diffusion-based solute clearance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When considering the initiation of RRT, the patient and clinical situation should be assessed for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of the major goal of dialytic therapy: solute clearance",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fluid removal",
"     </li>",
"     <li>",
"      Identification of patient characteristics that may preclude one or more of the modalities. These include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Size of the patient: For example, at some centers, equipment and supplies may not be available for infants and small children for HD or CRRT",
"     </li>",
"     <li>",
"      Hemodynamic stability: HD may be difficult to perform in hemodynamically unstable patients",
"     </li>",
"     <li>",
"      Abdominal or diaphragmatic pathology may preclude the use of PD",
"     </li>",
"     <li>",
"      Lack of vascular access precludes the use of HD and CRRT",
"     </li>",
"     <li>",
"      The anticipated duration of RRT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Organizational resources and practices (equipment, appropriately trained staff including dialysis nurses, pediatric intensive care staff, surgeons, or interventional radiologists)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the modality choice, initiating RRT in a critically ill child requires collaboration among the pediatric nephrologists, intensivists, and other subspecialists. Early discussion and planning will facilitate the process and allow for more rapid intervention, thereby improving survival outcomes.",
"   </p>",
"   <p>",
"    The following sections will review each modality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4746452\">",
"    <span class=\"h2\">",
"     Peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many pediatric clinicians have a relatively greater experience and comfort level using peritoneal dialysis (PD) in pediatric patients compared with the other modalities. PD historically has provided effective therapy for the management of pediatric AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/29-37\">",
"     29-37",
"    </a>",
"    ] and continues to provide reasonably cost-effective, efficient therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    PD is widely available in developed and developing countries because it requires less technological expertise and resource allocation, and is more cost-effective than CRRT or HD. PD is critical in the treatment of sepsis-induced AKI in facilities where pediatric HD and CRRT are unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/38,40\">",
"     38,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PD provides gradual, continuous solute and water clearance through diffusion and ultrafiltration, although the ability to separate these components is somewhat limited with this modality. PD does not require vascular access and thus allows critically ill patients to be dialyzed with preservation of vasculature for future needs. Access for peritoneal dialysis can be quickly and safely obtained, even in hemodynamically unstable patients, thus allowing for the rapid institution of therapy. Typical access includes Tenckhoff catheters usually placed by pediatric surgeons, or acute PD or adapted PD catheters placed at the bedside percutaneously in patients unable to tolerate a surgical placement [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The components of the PD prescription include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dialysate composition &ndash; The composition of commercially available dialysate solutions vary depending upon their osmolality, and the osmotic agent (usually dextrose) and buffer used. The composition can be modified based on the patient&rsquo;s needs. Three different dextrose solutions are available commercially: 1.5, 2.5, and 4.25% solutions with respective osmolalities of 346, 396, and 485",
"      <span class=\"nowrap\">",
"       mOsm/L.",
"      </span>",
"      In patients with hepatic dysfunction, lactate as a buffer should be avoided. Commercially prepared bicarbonate-based solutions are not available in the United States because of incompatibility with calcium and magnesium. Customized bicarbonate solutions with electrolyte modification can be prepared by hospital pharmacies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/43,44\">",
"       43,44",
"      </a>",
"      ], although prescription errors pose a significant risk to patient safety [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/45\">",
"       45",
"      </a>",
"      ]. The dextrose used in PD dialysate can provide an extra source of carbohydrate nutrition and calories [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/44,46\">",
"       44,46",
"      </a>",
"      ]; on the other hand, it may also lead to hyperglycemia necessitating insulin correction [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/47\">",
"       47",
"      </a>",
"      ]. Supplementation with amino acids may be required due to increased clearance in the setting of AKI.",
"     </li>",
"     <li>",
"      Exchange volume &ndash; The initial exchange volume is low (10",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      in order to minimize abdominal pressure that may cause dialysate leakage around the catheter. The volume can be slowly increased to a maximum of 35 to 40",
"      <span class=\"nowrap\">",
"       mL/kg.",
"      </span>",
"      As volume increases, the number of exchanges per day often can be decreased.",
"     </li>",
"     <li>",
"      Number of exchanges per 24 hours and the time duration for the inflow, dwell, and outflow of dialysate for each exchange.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retrospective pediatric data show that PD can be performed successfully in the setting of multisystem organ failure including cardiovascular instability requiring vasopressor support [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/37,40\">",
"     37,40",
"    </a>",
"    ]. However, the ability to provide adequate dosing of dialysis in the AKI setting is problematic when using PD in the most critically ill patients. These patients, who may have severe fluid overload, lactic acidosis, and hypotension, require precise fluid balance with controlled ultrafiltration, yet may not have adequate blood flow (cardiac output) to the peritoneum to allow for efficient solute and fluid removal. Pressor agents may alter peritoneal blood flow in septic patients, further diminishing these processes. Thus, in patients with sepsis-induced AKI the beneficial aspects of slow solute clearance and ultrafiltration provided by PD also limit its effectiveness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172029046\">",
"    <span class=\"h3\">",
"     Contraindications and complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;PD is absolutely contraindicated in patients with diaphragmatic defects. It is generally not recommended in patients with ventriculoperitoneal shunts, prune belly syndrome, abdominal surgeries, and ventilation via the high-frequency oscillator because of the high risk of catheter leak due to abdominal movement.",
"   </p>",
"   <p>",
"    Patients with preload dependent cardiac physiology may become unstable with filling and draining [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/11,37\">",
"     11,37",
"    </a>",
"    ], necessitating the use of tidal PD prescriptions or an alternative modality. Patients with pulmonary compromise may worsen with increased abdominal dialysate volumes that may prevent full diaphragmatic excursion. Additional complications with PD include peritonitis, hernias, catheter malfunction, and hydrothorax due to dialysate leakage into the pleural space. Patients may have significant losses of immunoglobulins in the dialysate, making them more susceptible to infection. Peritonitis can enhance dialysate protein loss, compromise nutrition, and permanently damage the peritoneal membrane.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4746469\">",
"    <span class=\"h2\">",
"     Intermittent hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent hemodialysis (HD) provides more efficient solute clearance and ultrafiltration compared with other RRT modalities. In the hemodynamically stable patient, no other modality is better suited for rapid and accurate small solute reduction with or without ultrafiltration. Thus, this therapy is particularly important in the pediatric population for the treatment of acute and life-threatening electrolyte abnormalities (eg, hyperkalemia), ingestions (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    ), drug toxicity (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    ), tumor lysis syndrome, and hyperammonemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/27,48,49\">",
"     27,48,49",
"    </a>",
"    ]. Most secondary or tertiary care centers have the equipment and expertise to offer this therapy to the pediatric patient.",
"   </p>",
"   <p>",
"    Access is one of the most important components leading to the satisfactory provision of HD. A wide variety of temporary vascular catheters are available for the pediatric population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/50\">",
"     50",
"    </a>",
"    ]. The placement of acute catheters can be performed in most children at the bedside by pediatric nephrologists or intensivists. Placement of semipermanent tunneled catheters and acute catheters in very small infants is usually done in the operating room by surgeons or interventional radiologists. Placement of the catheter in the neck veins allows for less recirculation and avoids the potential high venous return pressures often associated with groin lines in patients with high intra-abdominal pressures. In neonates, the use of umbilical veins may be considered if no other options are available.",
"   </p>",
"   <p>",
"    Complications related to the placement of acute or permanent vascular catheters include blood vessel sclerosis or thrombosis, introduction of air emboli, or hemorrhage. Depending on location or degree of difficulty involved in placing these catheters, future vascular access needs may be compromised, an issue of great importance in patients who may progress from acute to chronic kidney injury and eventually end-stage renal disease (ESRD). In particular, subclavian veins should be avoided, in order to preserve these vessels for future use as arteriovenous fistulas in patients who may progress to end-stage renal disease. As with all central lines, vascular catheters are a potential source of infection.",
"   </p>",
"   <p>",
"    Most secondary or tertiary care centers have the equipment and expertise to provide intermittent HD. However, it may not be tenable in the smallest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sickest patients who present to the pediatric intensive care unit (PICU). These patients require experienced and trained pediatric dialysis personnel to deliver HD safely to patients with small blood volumes who cannot tolerate rapid fluid shifts. In these cases, the hemodynamic instability and labile nature of the patient&rsquo;s condition render PD or CRRT better RRT options.",
"   </p>",
"   <p>",
"    The components of the HD prescription include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood flow rate",
"     </li>",
"     <li>",
"      Dialysate flow rate",
"     </li>",
"     <li>",
"      Dialysate composition, which may be changed based on patient needs. Components that are commonly adjusted in patients with AKI are sodium and potassium concentration.",
"     </li>",
"     <li>",
"      Size of the dialyzer",
"     </li>",
"     <li>",
"      Volume of fluid removal during the dialysis treatment",
"     </li>",
"     <li>",
"      Length of dialysis treatment that is determined on the preset goal of either solute or fluid removal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Careful dosing, dialysate solution selection, and monitoring are required to prevent osmolar shifts that can cause cerebral edema with subsequent mental status changes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures (referred to as dialysis disequilibrium) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/51\">",
"     51",
"    </a>",
"    ]. Most oligo-anuric patients treated with HD require fluid restriction because many patients will not tolerate removal of large fluid volumes over the short treatment times typically used with HD. Daily intermittent HD is an option, but will not eliminate the need for at least some fluid restriction, which in turn, may limit the amount of nutritional support provided. Finally, hypotension in the critically ill patient will limit the capacity for ultrafiltration and ultimately the ability to provide adequate treatment with this modality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4746485\">",
"    <span class=\"h2\">",
"     Continuous renal replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous renal replacement therapy (CRRT) includes dialysis (diffusion-based solute removal)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    filtration (convection-based solute and water removal) treatments that operate in a continuous mode. Over the past 10 years, CRRT has supplanted PD as the primary modality choice for the treatment of the critically ill pediatric patient in many PICUs as CRRT has improved delivery of care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRRT mimics native renal function with its continual ultrafiltration and solute clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], and has several advantages over HD and PD in the management of patients with AKI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CRRT is more precise in delivering the goals of solute clearance and ultrafiltration than PD. Although PD provides continuous solute clearance and ultrafiltration, the rates of clearance are variable and dependent on the patient&rsquo;s clinical status. CRRT can control ultrafiltration separately from solute removal, which PD cannot, allowing for greater flexibility within the prescription.",
"     </li>",
"     <li>",
"      Because ultrafiltration is continuous and can be adjusted to meet the patient&rsquo;s needs with CRRT, there is usually no need for fluid restriction unlike that required in patients managed by HD. CRRT allows for administration of all necessary blood products, large volumes of medications, and adequate nutrition without compromising the volume status of the patient. However, supplemental protein (up to 3 to 4",
"      <span class=\"nowrap\">",
"       gm/kg/day)",
"      </span>",
"      may be required during CRRT because amino acid loss can be quite high with this therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CRRT provides superior uremia control compared with PD [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/39,55\">",
"       39,55",
"      </a>",
"      ] or HD [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/56,57\">",
"       56,57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dialysate or filter replacement fluid customization is possible, allowing for rapid alteration of electrolyte levels targeted to a desired range [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/58\">",
"     58",
"    </a>",
"    ]. However, because of potential pharmacy compounding errors when manually preparing custom solutions, caution needs to be exercised when performing these alterations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main disadvantages of CRRT are its complexity and expense, and risk of hemorrhage, which may be aggravated by coagulopathy in a critically ill patient [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/11\">",
"     11",
"    </a>",
"    ]. While it is an established therapy at many tertiary care hospitals in developed countries, CRRT requires significant technological expertise and resource allocation, such that it may be more costly than PD or HD. Specialized nursing education and pharmacy support are necessary for safe and proper provision of CRRT. Although new technology, US Food and Drug Administration approval of both commercially available dialysate and filter replacement solutions and readily available anticoagulation protocols have improved safety, though these new technologies have also increased costs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/28,59\">",
"     28,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other drawbacks include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Like HD, adequate vascular access is essential. An additional central line may also be required for the administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19446?source=see_link\">",
"       calcium chloride",
"      </a>",
"      as part of regional citrate anticoagulation protocols.",
"     </li>",
"     <li>",
"      Despite the availability of smaller circuits in some centers, the large extracorporeal volume required for CRRT (as well as HD), particularly in infants, may exceed 10 percent of the patient&rsquo;s blood volume. Even in pediatric tertiary centers, for patients who weigh less than 5 kg, the circuits must be primed with blood, which may expose these infants to transfusion risks and hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/60\">",
"       60",
"      </a>",
"      ]. These smaller circuits are also more likely to use",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      for anticoagulation, which increases the risk of bleeding. In neonates, there is often a need for a higher blood flow rate and daily effluent volume because of neonatal-specific conditions, such as hyperammonia, that require high effluent rates for optimal therapy. The lack of pediatric-specific (much less neonatal-specific) equipment in some centers is a barrier to providing the best application of CRRT to the smallest patients with AKI.",
"     </li>",
"     <li>",
"      Careful attention must be made to medications that a patient is receiving because CRRT may alter the clearance of these drugs, especially those that are of lower molecular weight, water soluble, and not highly protein bound.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Technologic advances have incorporated the different CRRT options into one commercially available platform. Ongoing research is trying to determine which modality is better suited for specific patient conditions. Convective therapies (continuous venovenous hemofiltration [CVVH] and continuous venovenous hemodiafiltration [CVVHDF]) provide superior middle molecule clearance compared with diffusive therapy (continuous venovenous hemodialysis [CVVHD]) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/61\">",
"     61",
"    </a>",
"    ]. These convective modalities are thought to be superior in clearing proinflammatory cytokines, and may be beneficial in the treatment of patients with sepsis-related AKI. However, there are only limited observational data in pediatric stem cell transplant recipients with AKI that suggest improved survival with convective CRRT therapies (CVVH, CVVHDF) compared with diffusive therapy (CVVHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4746501\">",
"    <span class=\"h2\">",
"     Comparisons of modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no randomized clinical trials comparing the three modalities (PD, HD, and CRRT) for treatment of children with AKI. In addition, there are only limited data from adult trials, which are summarized below and discussed in greater detail separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several trials have demonstrated no difference in survival between CRRT and HD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link&amp;anchor=H9#H9\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\", section on 'CRRT versus intermittent hemodialysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Data are more limited in comparing CRRT and PD. In the one published trial, which was performed in a developing country, survival was lower in the group assigned to PD compared with those who received continuous venovenous hemofiltration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link&amp;anchor=H10#H10\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\", section on 'Comparisons between other modalities of renal replacement therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational data in children with AKI include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 42 children following congenital heart disease repair, there was no difference in mortality between patients who were treated with PD (n = 21) and those who received CRRT (n = 21), with a mortality rate of 62 percent for both groups. However, CRRT was superior to PD in terms of fluid balance, solute clearance, and ability to provide adequate nutrition.",
"     </li>",
"     <li>",
"      In an unpublished retrospective study of 118 infants or children treated either with PD (n = 82) or CRRT (n = 36), there was no difference in mortality between the two groups, although CRRT provided better fluid control [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/39\">",
"       39",
"      </a>",
"      ]. Main CRRT complications were related to access and circuit clotting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is clear further studies are needed to determine the optimal approach to providing renal replacement therapy in children with AKI because these studies are limited by the small number of patients and confounding factors, such as severity of illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4746509\">",
"    <span class=\"h1\">",
"     DISCONTINUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors determining when or how renal replacement therapy (RRT) should be discontinued (or transitioned to another modality) are less well described than the factors determining initiation. Although step-down case reports exist for continuous renal replacement therapy after hemodialysis (HD) in patients with inborn errors of metabolism and toxic overdose, no approach has been defined for patients with acute kidney injury (AKI). Just as with initiation, RRT cessation or modality change is influenced by multiple factors such as urine output (including response to diuretic therapy), hemodynamic stability, respiratory, nutritional and volume status, and changes in underlying disease and overall prognosis. Other considerations may include ongoing resource use, staff availability, family wishes, and long-term patient needs. For example, if a patient with multiorgan failure has improved and is at the point of extubation, it may be reasonable to change the patient from a continuous therapy to intermittent HD to facilitate patient rehabilitation and transfer from the pediatric intensive care unit to the ward.",
"   </p>",
"   <p>",
"    Currently no guidelines or strategies have been published regarding transitioning patients off of RRT. Unlike mechanical ventilation weaning, which has been studied extensively, the approach to tapering and discontinuation of RRT is an area ripe for investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4746516\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective data demonstrate the overall survival rates range between 50 and 60 percent in children with acute kidney injury who received renal replacement therapy (RRT) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/5,6,62\">",
"     5,6,62",
"    </a>",
"    ]. Factors that increase mortality rates include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Underlying diseases that cause secondary renal failure including bone marrow failure, hepatic failure, and severe pulmonary disease. In addition, stem cell and solid organ transplantation (eg, lung and liver) are associated with poorer survival [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/6,23\">",
"       6,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypotension at the onset of RRT [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of inotropic agents anytime during the course of RRT [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Degree of fluid overload present on initiation of RRT [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23673/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4746523\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children, acute kidney injury (AKI) is an independent predictor of morbidity and mortality.",
"     </li>",
"     <li>",
"      Among children with serious and potentially life-threatening complications of AKI, we recommend the initiation of renal replacement therapy (RRT) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4746395\">",
"       'Indications for and timing of RRT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that RRT should be initiated prior to the development of significant signs and symptoms of renal failure due to AKI (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). While not yet fully validated, a risk stratification system based on the presence of clinical risk factors and signs of renal disease could be helpful in identifying patients most at risk of developing AKI and who would most benefit from early initiation of RRT. (See",
"      <a class=\"local\" href=\"#H4746395\">",
"       'Indications for and timing of RRT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In our practice, RRT is initiated in the following settings (see",
"      <a class=\"local\" href=\"#H719049\">",
"       'Our approach'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Although there are insufficient data to support evidence-based guidelines that include quantifiable values for uremia to direct the care of the pediatric patient, RRT is initiated in patients whose blood urea nitrogen (BUN) is between 80 and 100",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"     </li>",
"     <li>",
"      Patients who are greater than 15 percent fluid overload. (See",
"      <a class=\"local\" href=\"#H4746416\">",
"       'Fluid overload'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients requiring large volumes of parenteral fluid (eg, nutrition, medications,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blood products) for adequate care; and who are also oliguric, not responsive to diuretics, have escalating ventilatory requirements, or have life-threatening metabolic derangements that are refractory to medical management.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several RRT modalities, including peritoneal dialysis, intermittent hemodialysis, and continuous RRT, are available to manage pediatric patients with AKI. Data are insufficient to recommend one modality over another. Thus, the selection of modality of RRT is based on patient factors (size, underlying illness, ability to obtain access), the local expertise and experience, and available resources. (See",
"      <a class=\"local\" href=\"#H4746438\">",
"       'Modality choice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initiating RRT in a critically ill child requires collaboration among the nephrologists, intensivists, and other subspecialists caring for the child. Early discussion and planning will facilitate the process and allow for more rapid intervention, thereby improving survival outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Benfield MR, Bunchman TE. Management of acute renal failure. In: Pediatric Nephrology, 5th ed, Avner ED, Harmon WE, Niaudet P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.1253.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/2\">",
"      Andreoli SP. Acute renal failure in the newborn. Semin Perinatol 2004; 28:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/3\">",
"      Maxvold NJ, Bunchman TE. Renal failure and renal replacement therapy. Crit Care Clin 2003; 19:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/4\">",
"      Vachvanichsanong P, Dissaneewate P, Lim A, McNeil E. Childhood acute renal failure: 22-year experience in a university hospital in southern Thailand. Pediatrics 2006; 118:e786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/5\">",
"      Bunchman TE, McBryde KD, Mottes TE, et al. Pediatric acute renal failure: outcome by modality and disease. Pediatr Nephrol 2001; 16:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/6\">",
"      Symons JM, Chua AN, Somers MJ, et al. Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry. Clin J Am Soc Nephrol 2007; 2:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/7\">",
"      Price JF, Mott AR, Dickerson HA, et al. Worsening renal function in children hospitalized with decompensated heart failure: evidence for a pediatric cardiorenal syndrome? Pediatr Crit Care Med 2008; 9:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/8\">",
"      Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/9\">",
"      Proulx F, Gauthier M, Nadeau D, et al. Timing and predictors of death in pediatric patients with multiple organ system failure. Crit Care Med 1994; 22:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/10\">",
"      Schneider J, Khemani R, Grushkin C, Bart R. Serum creatinine as stratified in the RIFLE score for acute kidney injury is associated with mortality and length of stay for children in the pediatric intensive care unit. Crit Care Med 2010; 38:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/11\">",
"      Flynn JT. Choice of dialysis modality for management of pediatric acute renal failure. Pediatr Nephrol 2002; 17:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/12\">",
"      Palevsky PM. Dialysis modality and dosing strategy in acute renal failure. Semin Dial 2006; 19:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/13\">",
"      Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 2000; 356:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/14\">",
"      Devarajan P. Cellular and molecular derangements in acute tubular necrosis. Curr Opin Pediatr 2005; 17:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/15\">",
"      Zappitelli M, Washburn KK, Arikan AA, et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care 2007; 11:R84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/16\">",
"      Parikh CR, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 2006; 70:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/17\">",
"      Han WK, Bailly V, Abichandani R, et al. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/18\">",
"      Goldstein SL, Somers MJ, Baum MA, et al. Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int 2005; 67:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/19\">",
"      Goldstein SL, Currier H, Cosio CC, et al. Outcome in children receiving continuous venovenous hemofiltration. Pediatrics 2001; 107:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/20\">",
"      Foland JA, Fortenberry JD, Warshaw BL, et al. Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. Crit Care Med 2004; 32:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/21\">",
"      Gillespie RS, Seidel K, Symons JM. Effect of fluid overload and dose of replacement fluid on survival in hemofiltration. Pediatr Nephrol 2004; 19:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/22\">",
"      Sutherland SM, Zappitelli M, Alexander SR, et al. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis 2010; 55:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/23\">",
"      Flores FX, Brophy PD, Symons JM, et al. Continuous renal replacement therapy (CRRT) after stem cell transplantation. A report from the prospective pediatric CRRT Registry Group. Pediatr Nephrol 2008; 23:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/24\">",
"      Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 2009; 37:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/25\">",
"      Goldstein SL, Chawla LS. Renal angina. Clin J Am Soc Nephrol 2010; 5:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/26\">",
"      Basu RK, Chawla LS, Wheeler DS, Goldstein SL. Renal angina: an emerging paradigm to identify children at risk for acute kidney injury. Pediatr Nephrol 2012; 27:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/27\">",
"      Parakininkas D, Greenbaum LA. Comparison of solute clearance in three modes of continuous renal replacement therapy. Pediatr Crit Care Med 2004; 5:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/28\">",
"      Bunchman TE, Maxvold NJ, Brophy PD. Pediatric convective hemofiltration: Normocarb replacement fluid and citrate anticoagulation. Am J Kidney Dis 2003; 42:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/29\">",
"      Bunchman TE, Smoyer WE, Valentini RP, et al. Modality and mortality in pediatric renal replacement therapy (abstract). J Am Soc Nephrol 1994; 5:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/30\">",
"      Arora P, Kher V, Rai PK, et al. Prognosis of acute renal failure in children: a multivariate analysis. Pediatr Nephrol 1997; 11:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/31\">",
"      Kandoth PW, Agarwal GJ, Dharnidharka VR. Acute renal failure in children requiring dialysis therapy. Indian Pediatr 1994; 31:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/32\">",
"      Wong W, McCall E, Anderson B, et al. Acute renal failure in the paediatric intensive care unit. N Z Med J 1996; 109:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/33\">",
"      Blowey DL, McFarland K, Alon U, et al. Peritoneal dialysis in the neonatal period: outcome data. J Perinatol 1993; 13:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/34\">",
"      Gong WK, Tan TH, Foong PP, et al. Eighteen years experience in pediatric acute dialysis: analysis of predictors of outcome. Pediatr Nephrol 2001; 16:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/35\">",
"      Alarabi AA, Petersson T, Danielson BG, Wikstr&ouml;m B. Continuous peritoneal dialysis in children with acute renal failure. Adv Perit Dial 1994; 10:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/36\">",
"      Kohli HS, Arora P, Kher V, et al. Daily peritoneal dialysis using a surgically placed Tenckhoff catheter for acute renal failure in children. Ren Fail 1995; 17:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/37\">",
"      Flynn JT, Kershaw DB, Smoyer WE, et al. Peritoneal dialysis for management of pediatric acute renal failure. Perit Dial Int 2001; 21:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/38\">",
"      Anochie IC, Eke FU. Paediatric acute peritoneal dialysis in southern Nigeria. Postgrad Med J 2006; 82:228.",
"     </a>",
"    </li>",
"    <li>",
"     Bandeira MF, Gam A, Zagury A, et al. Renal Replacement Therapy (RRT) in Acute Renal Failure (ARF) in Critically Ill Children Under 10 kg. Poster/Abstract Annual Dialysis Conference Tampa, FL, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/40\">",
"      Phadke KD, Dinakar C. The challenges of treating children with renal failure in a developing country. Perit Dial Int 2001; 21 Suppl 3:S326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/41\">",
"      Auron A, Warady BA, Simon S, et al. Use of the multipurpose drainage catheter for the provision of acute peritoneal dialysis in infants and children. Am J Kidney Dis 2007; 49:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/42\">",
"      Bunchman TE. Acute peritoneal dialysis access in infant renal failure. Perit Dial Int 1996; 16 Suppl 1:S509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/43\">",
"      Nash MA, Russo JC. Neonatal lactic acidosis and renal failure: the role of peritoneal dialysis. J Pediatr 1977; 91:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/44\">",
"      Grodstein GP, Blumenkrantz MJ, Kopple JD, et al. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int 1981; 19:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/45\">",
"      Barletta JF, Barletta GM, Brophy PD, et al. Medication errors and patient complications with continuous renal replacement therapy. Pediatr Nephrol 2006; 21:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/46\">",
"      Podel J, Hodelin-Wetzel R, Saha DC, Burns G. Glucose absorption in acute peritoneal dialysis. J Ren Nutr 2000; 10:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/47\">",
"      Reznik VM, Griswold WR, Peterson BM, et al. Peritoneal dialysis for acute renal failure in children. Pediatr Nephrol 1991; 5:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/48\">",
"      McBryde KD, Kershaw DB, Bunchman TE, et al. Renal replacement therapy in the treatment of confirmed or suspected inborn errors of metabolism. J Pediatr 2006; 148:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/49\">",
"      Brophy PD, Flynn JT, Kershaw DB, et al. Pediatric overdose: effective treatment with high-efficiency hemodialysis (abstract). J Am Soc Neprhol 1999; 10:137A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/50\">",
"      Bunchman TE, Gardner JJ, Kershaw DB, Maxvoid JN. Vascular access for hemodialysis or CVVH(D) in infants and children. Dial Transplant 1994; 23:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/51\">",
"      Arieff AI. Dialysis disequilibrium syndrome: current concepts on pathogenesis and prevention. Kidney Int 1994; 45:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/52\">",
"      Bunchman TE, Donckerwolcke RA. Continuous arterial-venous diahemofiltration and continuous veno-venous diahemofiltration in infants and children. Pediatr Nephrol 1994; 8:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/53\">",
"      Forni LG, Hilton PJ. Continuous hemofiltration in the treatment of acute renal failure. N Engl J Med 1997; 336:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/54\">",
"      Maxvold NJ, Smoyer WE, Custer JR, Bunchman TE. Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. Crit Care Med 2000; 28:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/55\">",
"      Fleming F, Bohn D, Edwards H, et al. Renal replacement therapy after repair of congenital heart disease in children. A comparison of hemofiltration and peritoneal dialysis. J Thorac Cardiovasc Surg 1995; 109:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/56\">",
"      Clark WR, Mueller BA, Alaka KJ, Macias WL. A comparison of metabolic control by continuous and intermittent therapies in acute renal failure. J Am Soc Nephrol 1994; 4:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/57\">",
"      Swartz RD, Bustami RT, Daley JM, et al. Estimating the impact of renal replacement therapy choice on outcome in severe acute renal failure. Clin Nephrol 2005; 63:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/58\">",
"      McBryde KD, Bunchman TE, Kudelka TL, et al. Hyperosmolar solutions in continuous renal replacement therapy for hyperosmolar acute renal failure: a preliminary report. Pediatr Crit Care Med 2005; 6:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/59\">",
"      Brophy PD, Somers MJ, Baum MA, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant 2005; 20:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/60\">",
"      Askenazi DJ, Goldstein SL, Koralkar R, et al. Continuous Renal Replacement Therapy for Children &le;10 kg: A Report from the Prospective Pediatric Continuous Renal Replacement Therapy Registry. J Pediatr 2013; 162:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/61\">",
"      Troyanov S, Cardinal J, Geadah D, et al. Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters. Nephrol Dial Transplant 2003; 18:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23673/abstract/62\">",
"      Hui-Stickle S, Brewer ED, Goldstein SL. Pediatric ARF epidemiology at a tertiary care center from 1999 to 2001. Am J Kidney Dis 2005; 45:96.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15895 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-2ED5F37753-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23673=[""].join("\n");
var outline_f23_7_23673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4746523\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4746388\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4746395\">",
"      INDICATIONS FOR AND TIMING OF RRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4746409\">",
"      Severity of AKI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4746416\">",
"      Fluid overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21365186\">",
"      Renal angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H719049\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4746438\">",
"      MODALITY CHOICE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4746452\">",
"      Peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172029046\">",
"      - Contraindications and complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4746469\">",
"      Intermittent hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4746485\">",
"      Continuous renal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4746501\">",
"      Comparisons of modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4746509\">",
"      DISCONTINUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4746516\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4746523\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=related_link\">",
"      Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_7_23674="Intrapartum fetal heart rate assessment";
var content_f23_7_23674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intrapartum fetal heart rate assessment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/7/23674/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23674/contributors\">",
"     Bruce K Young, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/7/23674/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23674/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/7/23674/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/7/23674/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/7/23674/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the fetus during labor is a challenging task. The rationale for monitoring the fetal heart rate (FHR) is that FHR patterns are indirect markers of the fetal cardiac and medullary responses to blood volume changes, acidemia, and hypoxemia, since the brain modulates heart rate. Virtually all obstetrical organizations advise monitoring the FHR during labor. This position is largely based upon the experience of experts and medicolegal precedent; no trials comparing electronic fetal monitoring versus no monitoring have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/1\">",
"     1",
"    </a>",
"    ]. A trial comparing auscultation with no monitoring found that auscultation was associated with an increased risk of operative delivery without any reduction in perinatal mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/2\">",
"     2",
"    </a>",
"    ]. Furthermore, no reliable auscultatory indicator of fetal distress has been determined, other than extreme changes in FHR [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, neither electronic fetal monitoring nor auscultation has been proven to reduce mortality, despite large clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intrapartum fetal monitoring will be discussed here. Fetal cardiac physiology, FHR patterns, and antepartum FHR monitoring (nonstress test, contraction stress test) are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=see_link\">",
"     \"Antepartum fetal heart rate assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS OF INTRAPARTUM FHR MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of FHR monitoring is to identify hypoxemic and acidotic fetuses in whom timely intervention will prevent death. A secondary goal is to avoid fetal neurologic injury, if possible. The two commonly used modalities for intrapartum FHR monitoring, continuous electronic FHR monitoring and intermittent auscultation, have been extensively reviewed; there is no high quality evidence that these techniques achieve either of these goals or that one performs better than the other in low risk pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. A 2006 systematic review of 12 randomized trials including &gt;37,000 women (both low and high risk) comparing these two techniques showed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intrapartum fetal death rate was approximately 0.5 per 1000 births with either approach",
"     </li>",
"     <li>",
"      Apgar scores and neonatal intensive care unit admission rates were similar for both modalities",
"     </li>",
"     <li>",
"      Use of electronic FHR monitoring instead of intermittent auscultation did not reduce the risk of hypoxic ischemic encephalopathy, long-term neurologic impairment, or cerebral palsy, although the frequency of neonatal seizures was reduced in the electronically monitored group (RR 0.50, 95% CI 0.31-0.80)",
"     </li>",
"     <li>",
"      Use of electronic FHR monitoring instead of intermittent auscultation did not result in a significant reduction in the overall risk of perinatal death (RR 0.85, 95% CI 0.59-1.23).",
"     </li>",
"     <li>",
"      Use of electronic FHR monitoring instead of intermittent auscultation increased the frequency of operative delivery (cesarean delivery RR 1.66, 95% CI 1.30-2.13; instrumental vaginal delivery RR 1.16, 95% CI 1.01-1.32)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A significant decrease in the perinatal death rate would be difficult to demonstrate since death is a rare outcome; even pooling results from multiple randomized trials lacked sufficient power to provide a definitive conclusion. Analysis of national data from birth and death certificates provides some insight about these relationships. A retrospective cohort study of birth and infant data from almost two million singleton births in the United States found that 89 percent of the labors utilized electronic FHR monitoring and these pregnancies had a significantly lower rate of early neonatal death than those without electronic FHR monitoring (0.8 versus 1.7 per 1000 births); the magnitude of the reduction in early death increased as gestational age decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/11\">",
"     11",
"    </a>",
"    ]. These data are limited by ascertainment bias inherent in observational data; unmonitored patients likely had different baseline risk for neonatal death than monitored patients. However, a 1995 meta-analysis of nine randomized trials observed a significant reduction in those perinatal deaths specifically attributed to fetal hypoxia in pregnancies electronically monitored compared with those followed by intermittent auscultation",
"    <span class=\"nowrap\">",
"     (7/9398",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     17/9163;",
"    </span>",
"    0.7 versus 1.8 per 1000) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of electronic FHR monitoring instead of intermittent auscultation has also not led to a reduction in the prevalence of cerebral palsy (RR 1.74, 95% CI 0.97-3.11) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/6\">",
"     6",
"    </a>",
"    ]. The absence of a reduction in cerebral palsy is not surprising since most cases of cerebral palsy are due to a remote antepartum event, rather than intrapartum asphyxia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/13\">",
"     13",
"    </a>",
"    ]. The lack of a strong correlation between use of intrapartum monitoring and neurologic outcome is likely related to the observation that most FHR abnormalities are not associated with fetal acidosis or hypoxemia and most fetal acidosis and hypoxemia does not result in neurologic disability. Indeed, 99.8 percent of nonreassuring FHR tracings are",
"    <strong>",
"     not",
"    </strong>",
"    associated with development of cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/13\">",
"     13",
"    </a>",
"    ]. Furthermore, a fetal neurologic disorder may be the cause (rather than the result) of FHR abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/14\">",
"     14",
"    </a>",
"    ]. Lastly, the degree of asphyxia that leads to long-term neurologic damage is close to that causing fetal death, thus most asphyxiated term fetuses either survive intact or die, rather than survive disabled [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The systematic reviews demonstrated that the major benefits of continuous electronic FHR monitoring were a reduction in perinatal mortality due to intrapartum hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/12\">",
"     12",
"    </a>",
"    ], a reduction in the frequency of neonatal seizures (RR 0.50, 95% CI 0.31-0.80) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/6\">",
"     6",
"    </a>",
"    ] and, in one trial, better prediction of fetal acidemia at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the seizures prevented by electronic FHR monitoring did not appear to be associated with long-term consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major disadvantage of continuous electronic FHR monitoring was that in all studies it led to higher operative delivery rates (cesarean delivery RR 1.66, 95% CI 1.30-2.13; instrumental vaginal delivery RR 1.16, 95% CI 1.01-1.32) often without an associated neonatal benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/6\">",
"     6",
"    </a>",
"    ]. In particular, compared to intermittent auscultation, continuous electronic FHR monitoring was associated with a two-fold increase in risk of cesarean delivery performed because of a nonreassuring FHR (RR 2.37, 95% CI 1.88-3.00).",
"   </p>",
"   <p>",
"    The increased risk of operative delivery persisted in subgroup analysis of low and high risk pregnancies; however, data were more limited. In any case, any monitoring, even by auscultation, results in more operative deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Preventive Services Task Force and the Canadian Task Force on Preventive Health Care have made the following statements [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine electronic FHR monitoring for low-risk women in labor is not recommended",
"     </li>",
"     <li>",
"      There is insufficient evidence to recommend for or against intrapartum electronic FHR monitoring for high-risk pregnant women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Royal College of Obstetricians and Gynaecologists recommends [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continuous electronic FHR monitoring for high risk women",
"     </li>",
"     <li>",
"      Intermittent auscultation for low risk women",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists stated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk pregnancies (eg, preeclampsia, suspected growth restriction, type 1 diabetes mellitus) should be monitored continuously during labor.",
"     </li>",
"     <li>",
"      Either electronic FHR monitoring or intermittent auscultation is acceptable in uncomplicated patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nevertheless, some type of FHR monitoring during labor has become routine for all women in the United States and will not be abandoned because patients and clinicians are reassured by normal results and believe there is some value in detecting nonreassuring patterns. There is a willingness to accept the increase in cesarean and operative vaginal births estimated to be 12 cesareans and 25 operative deliveries per 1000 births with electronic fetal monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EQUIPMENT AND TECHNIQUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Doppler ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FHR is determined noninvasively using a Doppler ultrasound device belted to the maternal abdomen throughout labor. The device is typically connected to an electronic monitor, which continuously plots the FHR on a paper strip, while a pressure transducer simultaneously monitors the frequency, timing, and duration of uterine contractions (this process is called continuous cardiotocography or continuous electronic FHR monitoring). In uncomplicated patients, it is common practice for the FHR tracing to be reviewed at least every 30 minutes in the first stage of labor and every 15 minutes in the second stage, and the interpretation should be documented [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, the electronic fetal monitor is applied intermittently rather than continuously (called intermittent cardiotocography or intermittent electronic FHR monitoring), to allow the parturient more mobility. Wireless monitors are available which enable FHR monitoring while the women is ambulating. Because of the inherent variation in the Doppler ultrasound signal, auto correlation processing by computer is used. This results in a highly processed record which smooths out the signal variation and produces a processed sound, which is not the actual fetal heart beat.",
"   </p>",
"   <p>",
"    Intermittent auscultation is an alternative to continuous electronic FHR monitoring. Using a Doppler device, the FHR is determined over one to two minutes at intervals of 5 to 30 minutes, depending upon the stage of labor. Ideally, the FHR is checked both during and immediately after a contraction and the lowest rate is manually recorded. There are no data on which to base a recommendation for the frequency of intermittent auscultation, but a 1979 National Institutes of Health consensus conference recommended every 15 minutes in the active phase of the first stage and every 5 minutes in the second stage, an impractical standard for most Obstetrical Services [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/19\">",
"     19",
"    </a>",
"    ]. In contrast to continuous cardiotocography, intermittent auscultation does not provide any information about FHR variability, the shape of FHR decelerations, or uterine contractions. Auscultation of the FHR using a fetal stethoscope is also possible, but more cumbersome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=see_link&amp;anchor=H9#H9\">",
"     \"Antepartum fetal heart rate assessment\", section on 'Antepartum FHR monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=see_link&amp;anchor=H7#H7\">",
"     \"Antepartum fetal heart rate assessment\", section on 'Equipment for FHR monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is more baseline variability inherent with the external or Doppler technique compared with internal fetal monitoring (see below). Since a computer calculates the FHR by averaging several consecutive beat-to-beat frequencies to minimize artifact (called \"autocorrelation\"), the FHR pattern produced closely resembles that derived from a fetal electrocardiogram (ECG), but there is more baseline variability inherent with the Doppler technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fetal electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Internal measurement of FHR is an invasive procedure; thus, its use is restricted to the intrapartum period. A bipolar spiral electrode is inserted transcervically to penetrate the fetal scalp and a second reference electrode is placed upon the maternal thigh to eliminate electrical interference. The internal electrode detects the fetal electrocardiogram (ECG) and calculates the FHR based upon the interval between R waves (",
"    <a class=\"graphic graphic_waveform graphicRef65200 \" href=\"UTD.htm?21/10/21673\">",
"     waveform 1",
"    </a>",
"    ). This signal is very clear and provides accurate measurement of beat-to-beat variability. Artifact is kept to a minimum, and there is little need for autocorrelation.",
"   </p>",
"   <p>",
"    External monitoring is usually as reliable as internal monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/20\">",
"     20",
"    </a>",
"    ] and is the preferred approach since it is noninvasive. Internal monitoring should be used, however, when the externally derived tracing is difficult to interpret because of poor technical quality. This occurs in various situations, such as when the fetus or mother is frequently changing position and sometimes in multiple fetus gestations.",
"   </p>",
"   <p>",
"    With both internal and external methods, the credence correlation circuitry of the monitor represents signals interpreted as artifactual with a pen lift, which results in non-recording areas. The accompanying sound should be regarded as an unreliable signal, since it is generated by the same electronic mechanisms. Nevertheless, certain arrhythmias may present in this way, and confirmation by sonography may be helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=see_link\">",
"     \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Artificial intelligence computer programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal ECG has been the gold standard for signal acquisition during intrapartum FHR monitoring. Computer analysis of these signals is the standard methodology for recording the signal, analysis of variability, and more recently, interpretation of fetal status. Application of \"artificial intelligence\" computer programs to fetal ECG signal processing has led to clinical devices for overcoming the limitations of FHR pattern interpretation by an human observer, expert or not. This has been made possible by technical improvements in signal acquisition and processing, and by algorithms for pattern interpretation based on standardization of visual pattern analysis and correlation with fetal scalp blood and umbilical artery pH determinations, with improving success as the models have improved [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'STAN fetal heart monitor (ST analysis)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION OF THE FETAL HEART RATE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Standards for interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of FHR tracings is subjective and not very reproducible. Studies have consistently shown that there is large inter- and intraobserver variability in interpretation of electronic FHR monitoring tracings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. For this reason, the National Institutes of Child Health and Human Development convened a workshop to try to reach consensus, for research purposes, on definitions of FHR patterns (",
"    <a class=\"graphic graphic_table graphicRef65859 \" href=\"UTD.htm?3/5/3165\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/29\">",
"     29",
"    </a>",
"    ]. This approach to evaluation has been endorsed by the American College of Obstetricians and Gynecologists [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/5\">",
"     5",
"    </a>",
"    ]. Inter- and intraobserver agreement, however, remain a problem because of disagreement about absent versus minimal variability in the most concerning tracings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, these definitions do not apply to computer generated FHR interpretations, and European standards differ from those in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Reassuring patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FHR pattern recorded by an electronic FHR monitor is typically interpreted as reassuring or nonreassuring. The presence of a reassuring pattern indicates that there is minimal likelihood of acidemia",
"    <strong>",
"     at that point in time",
"    </strong>",
"    ; it is not predictive of future status, as tracing patterns can change. A reassuring fetal heart rate pattern (category I) has all of the following components (",
"    <a class=\"graphic graphic_waveform graphicRef86064 \" href=\"UTD.htm?20/10/20647\">",
"     waveform 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A baseline fetal heart rate of 110 to 160 bpm",
"     </li>",
"     <li>",
"      Absence of late or variable FHR decelerations",
"     </li>",
"     <li>",
"      Moderate FHR variability (6 to 25 bpm)",
"     </li>",
"     <li>",
"      Age appropriate FHR accelerations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early decelerations may or may not be present. FHR accelerations are an important finding because their presence, especially in the presence of moderate variability, almost always indicates that the fetus is not acidotic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. However, less than moderate variability (",
"    <a class=\"graphic graphic_waveform graphicRef86063 \" href=\"UTD.htm?28/37/29272\">",
"     waveform 3",
"    </a>",
"    ) does not reliably mean the fetus is acidotic. In the absence of accelerations despite scalp stimulation, fetal acidemia is present in about 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Slight deviations from the normal baseline and some periodic changes (ie, changes associated with contractions) are innocuous in the continuum of the FHR pattern. As an example, early decelerations (",
"    <a class=\"graphic graphic_table graphicRef65859 \" href=\"UTD.htm?3/5/3165\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef50036 \" href=\"UTD.htm?6/62/7144\">",
"     waveform 4",
"    </a>",
"    ) are believed to be vagally mediated and due to fetal head compression. They are generally not associated with fetal acidosis or poor neonatal outcome. A baseline FHR of 100 to 110 follows the same physiology; if it persists for more than an hour, cephalopelvic disproportion may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many cardiac arrhythmias also pose no immediate threat to the fetus, irrespective of a FHR pattern that deviates from what is considered reassuring. In fact, the majority of fetal arrhythmias are benign and spontaneously convert to normal sinus rhythm by 24 hours after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/36\">",
"     36",
"    </a>",
"    ]. Persistent tachyarrhythmias may cause fetal hydrops if present for many hours to days. Persistent bradyarrhythmias are often associated with fetal heart disease (eg, cardiac conduction defects due to anatomic derangements or autoantibody (SSA, anti-Ro) induced-cardiomyopathy related to lupus), but seldom result in hypoxemia or acidosis in fetal life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=see_link\">",
"     \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonreassuring patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonreassuring tracings (category III) are associated with abnormal fetal acid-base status at the time of observation. Prompt evaluation of these patients is indicated and expeditious intervention (provision of supplemental oxygen therapy, change in position, treatment of hypotension, discontinuation of any uterotonic drugs) may be necessary because fetal or neonatal death or damage may occur if the pattern does not resolve and persists for an hour or more. Fetal oxygen deprivation can lead to significant fetal acidosis (umbilical artery pH &lt;7.0, base deficit &ge;12",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    which is the precursor of intrapartum hypoxic neurologic injury. The goal of intervention is to improve fetal oxygenation by improving uteroplacental perfusion.",
"   </p>",
"   <p>",
"    Nonreassuring patterns include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Absent or minimal variability with decelerations or bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absent variability (",
"    <a class=\"graphic graphic_table graphicRef65859 \" href=\"UTD.htm?3/5/3165\">",
"     table 1",
"    </a>",
"    ) is concerning. The absence of FHR variability is thought to be a result of cerebral hypoxemia and acidosis, and signifies failure of fetal compensatory mechanisms to maintain adequate oxygenation of the brain. Thus, absence of variability is often accompanied by abnormalities in FHR baseline or periodic late decelerations when the fetus is distressed. Nonhypoxia-related causes of diminished variability include anencephaly and other central nervous system defects, use of some centrally acting drugs (eg, opiates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    ), sepsis, defective cardiac conduction (eg, complete heart block), and quiet fetal sleep.",
"   </p>",
"   <p>",
"    Absent variability with any of the following FHR changes is predictive of abnormal fetal acid-base status [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/31\">",
"     31",
"    </a>",
"    ]. For any of these patterns, the likelihood of fetal acidemia increases as the frequency, depth, and duration of the decelerations increase [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059913\">",
"    <span class=\"h4\">",
"     Recurrent late decelerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late decelerations (",
"    <a class=\"graphic graphic_table graphicRef65859 \" href=\"UTD.htm?3/5/3165\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef67464 \" href=\"UTD.htm?23/19/23861\">",
"     waveform 5",
"    </a>",
"    ) are caused by the reflex central nervous system response to hypoxia and acidemia, as well as direct myocardial depression and humoral factors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/38\">",
"     38",
"    </a>",
"    ]. They can be associated with a falling fetal pH and perinatal morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/39\">",
"     39",
"    </a>",
"    ]. Recurrent late decelerations (ie, occurring with &ge;50 percent of contractions in a 20-minute segment) with absent variability are especially predictive of current or impending fetal acidosis due to progressively falling pH [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35702?source=see_link\">",
"     \"Umbilical cord blood acid-base analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059921\">",
"    <span class=\"h4\">",
"     Recurrent variable decelerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variable decelerations (",
"    <a class=\"graphic graphic_table graphicRef65859 \" href=\"UTD.htm?3/5/3165\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef86060 \" href=\"UTD.htm?17/46/18152\">",
"     waveform 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef86062 \" href=\"UTD.htm?16/33/16920\">",
"     waveform 7",
"    </a>",
"    ) occur when the umbilical cord is compressed, such as in the setting of low amniotic fluid volume or a nuchal cord. The thin walled umbilical vein is more sensitive to compression than the umbilical artery. This results in variable effects on fetal preload and afterload, which lead to changes in FHR mediated by baroreceptors, and chemoreceptors when there is sufficient hypoxemia. Intermittent variable decelerations are frequently observed in labor tracings and are not usually associated with adverse consequences, presumably because transient cord compression is well tolerated by the fetus. In sheep studies, fetal metabolic acidosis or mixed metabolic and respiratory acidosis developed with increasing duration, depth, and frequency of variable decelerations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    There are many atypical variations, particularly with this type of deceleration, which is inherently variable (",
"    <a class=\"graphic graphic_waveform graphicRef86066 \" href=\"UTD.htm?3/35/3639\">",
"     waveform 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef86061 \" href=\"UTD.htm?33/43/34487\">",
"     waveform 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/42\">",
"     42",
"    </a>",
"    ]. Nevertheless, the data do not support attaching clinical significance to atypical features: variable decelerations with lambda or W pattern (biphasic deceleration), slow return to baseline, loss of primary or secondary acceleration (shoulders), persistent secondary acceleration (overshoot), or reduction in post-deceleration baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. The current NICHHD classification does not include atypical variable decelerations as a category of FHR pattern. However, it does consider variable decelerations with absent baseline variability as predictive of an abnormal pH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1059929\">",
"    <span class=\"h4\">",
"     Bradycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradycardia with absent variability appears as a smooth FHR below 110 bpm. It is ominous when it occurs for a prolonged period of time (ie, at least 10 minutes) in the absence of hypothermia, complete heart block, or use of certain drugs (eg, beta-adrenergic blockers, paracervical block). When the FHR falls below 100, tissue perfusion may not be adequate; this degree of bradycardia is nonreassuring even when variability is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Sinusoidal heart rate pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sinusoidal heart rate is defined as a pattern of regular variability resembling a sine wave, with a fixed periodicity of three to five cycles per minute, an amplitude of 5 to 40 bpm, and lasting for at least 10 minutes (",
"    <a class=\"graphic graphic_waveform graphicRef61189 \" href=\"UTD.htm?12/38/12902\">",
"     waveform 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/31\">",
"     31",
"    </a>",
"    ]. Decelerations and accelerations in response to movement are absent. The mechanism for the sinusoidal pattern is believed to be a response to moderate fetal hypoxemia, often secondary to fetal anemia. Beat to beat changes are often small, but in the same direction, creating the wave pattern.",
"   </p>",
"   <p>",
"    This pattern was initially thought to be preterminal in all cases, but is no longer considered preterminal or due to acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. A sinusoidal-like pattern has been associated with physiological changes in fetal peripheral arterial resistance, fetal sucking movements, and maternal narcotic administration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a sinusoidal pattern is observed, we try to determine the reason for the pattern, while continuing to monitor the fetal heart rate. Fetal anemia can be due to bleeding or a chronic process; causes include fetomaternal hemorrhage, iatrogenic fetal bleeding, fetal bleeding secondary to vasa previa or placental abruption, alloimmunization, and parvovirus infection. Sonographic evaluation may suggest one of these etiologies. Severe fetal anemia can be diagnosed via Doppler assessment of the fetal middle cerebral artery peak systolic velocity and fetal bleeding can be determined by a rosette test (qualitative) or a Kleihauer-Betke test (quantitative) or flow cytometry (semi-quantitative) on maternal venous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vaginal blood (if vaginal bleeding is present). However, rapid results from these tests are seldom available on the labor floor. We do not consider sinusoidal patterns to be predictive of fetal acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal scalp stimulation or fetal blood sampling may provide some reassurance that the fetus is not acidotic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/45\">",
"     45",
"    </a>",
"    ]. In the absence of evidence of acidosis or other concerns, fetuses with a sinusoidal FHR pattern do not need to be delivered immediately. The sinusoidal pattern sometimes resolves; however, if acidosis or a worsening FHR pattern develops, we suggest urgent delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Indeterminate patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;FHR patterns that are category II are not reassuring and are considered indeterminate. The fetus may not be acidotic; however, continuation or worsening of the clinical situation may result in fetal acidosis. Therefore, continued surveillance and evaluation of these patients is indicated. Intervention (provision of supplemental oxygen, change in position, treatment of hypotension, discontinuation of any uterotonic drugs) may be needed if additional assessment suggests a progressively worse situation.",
"   </p>",
"   <p>",
"    Some examples of indeterminate patterns include tachycardia, minimal or marked variability, absent variability without recurrent decelerations, absence of accelerations without absent variability, recurrent late or variable decelerations without absent variability, and prolonged decelerations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pre-existing fetal neurological injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether there are FHR patterns that may indicate fetal brain damage before labor is controversial. Since the first report of fetal intracranial hemorrhage 25 years ago suggesting that cerebral palsy could be due to antepartum events [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/50\">",
"     50",
"    </a>",
"    ], a consensus has developed that 50 to 90 percent of neurologically impaired infants are suffering from a problem present before the onset of labor. Specific abnormal FHR patterns associated with neurological injury have been described and can be observed from the initiation of monitoring. The most common FHR abnormality is a persistent nonreactive heart rate and a persistent fixed baseline with minimal or absent variability [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/14,51,52\">",
"     14,51,52",
"    </a>",
"    ]. However, these patterns are not uniform and not always present. As an example, a study of 300 neurologically impaired term singletons in whom 54 percent had a probable injury before labor reported one-half had a normal FHR pattern until birth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of infants with congenital brain lesions suggest that damage to the medulla oblongata and mid brain may be responsible for the loss of FHR variability [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonreassuring and indeterminate tracings can be due to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal arrhythmias (",
"      <a class=\"graphic graphic_waveform graphicRef67962 \" href=\"UTD.htm?39/56/40836\">",
"       waveform 11",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=see_link\">",
"       \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Technical factors including a faulty leg plate, electrode, or monitor; setting the recording rate at 1",
"      <span class=\"nowrap\">",
"       cm/min",
"      </span>",
"      instead of the standard 3",
"      <span class=\"nowrap\">",
"       cm/min;",
"      </span>",
"      and the fact that very slow FH rates may be doubled and very fast rates (&gt;240 bpm) may be halved by the machine.",
"     </li>",
"     <li>",
"      The fetal and maternal heart beats are typically distinguished by the faster rate of the fetus (110 to 160 versus &lt;100 bpm). However, they can beat at a similar rate. The fetal heart rate may be the same or slower than the maternal rate if there is a fetal heart rate deceleration or prolonged bradycardia or in the presence of maternal tachycardia due to fever or stress.",
"      <br/>",
"      <br/>",
"      A maternal pulse rate approximating the FHR displayed on the monitor should prompt a reevaluation of the fetal tracing and the use of another method to distinguish between maternal and fetal patterns. It is important to confirm that the external fetal monitor is actually recording the FHR and not the maternal heart rate transmitted from a maternal vessel, such as the aorta or uterine artery. An internal fetal electrode is not definitive, as a fetus that is recently dead can conduct the maternal cardiac signals though its body to the electrode [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/55\">",
"       55",
"      </a>",
"      ]. The simplest way to confirm that the FHR is being recorded is to confirm that the sound is not synchronous with the maternal pulse. Alternatively, the rate on the fetal monitor can be compared with that on a maternal pulse oximeter. If uncertainty remains, ultrasound examination of the fetal heart can be performed.",
"     </li>",
"     <li>",
"      Effects of medications. For example, opioids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      can decrease variability,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9543?source=see_link\">",
"       butorphanol",
"      </a>",
"      can cause a sinusoidal pattern, and beta-blockers can increase FHR [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LABOR ADMISSION TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"labor admission test\" refers to an electronic FHR monitoring tracing performed for 20 to 30 minutes upon admission to the labor and delivery unit. It is widely used for initial assessment of the fetus. The goal is to identify fetuses who may be at increased risk of having nonreassuring FHR patterns during labor and thus might benefit from continuous FHR monitoring rather than intermittent auscultation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials involving over 12,000 low risk patients compared use of the labor admission test to intermittent auscultation for initial assessment of the parturient [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. In each trial women admitted to a labor unit were randomly assigned to receive usual care (Doppler FHR auscultation) or a labor admission test. Women with reassuring results were followed by intermittent auscultation during labor and those with nonreassuring results were followed by continuous electronic FHR monitoring. The rates of neonatal morbidity and operative intervention were similar in both groups; however, women who had a labor admission test were more likely to be continuously monitored and undergo fetal scalp blood sampling during the remainder of their labors. They also trended toward a higher rate of operative delivery (OR 1.15, 95% CI 1.00-1.32) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above trials did not assess the effect of normal and abnormal initial testing results on fetal outcomes. This issue was addressed in an observational study of 845 labor admission tests on high and low risk Norwegian women: 5.9 percent of these patients developed fetal distress in labor (defined as operative delivery indicated by interpretation of the FHR pattern or Apgar less than 7 at five minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/59\">",
"     59",
"    </a>",
"    ]. However, the rate of fetal distress (5 percent) was not significantly lower in those who had a normal test on admission.",
"   </p>",
"   <p>",
"    A systematic review of both randomized and quasi-randomized trials of the prognostic value of the labor admission test also concluded that there was no evidence that the labor admission test resulted in less neonatal morbidity in low risk women than intermittent auscultation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the above data, the labor admission test does not appear to reliably predict fetal ability to tolerate labor over time in low risk pregnancies and has not been associated with a reduction in any parameter of neonatal morbidity at birth. Its use offers no advantage over auscultation of the FHR and may lead to more obstetrical interventions. It has a theoretical value in detecting cases of immediate fetal jeopardy, but that benefit remains intuitive and unproven. There are insufficient data to draw any conclusions about its value in women with high risk pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF FETAL HEART RATE PATTERNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To be useful, FHR monitoring requires that the clinician correctly recognize nonreassuring and reassuring FHR patterns, communicate with the patient's other labor and delivery providers (eg, nursing, obstetrics, anesthesia, pediatrics) when the pattern is nonreassuring, and initiate appropriate and timely intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/25\">",
"     25",
"    </a>",
"    ]. No randomized trials have evaluated an operative versus a conservative approach to suspected fetal distress on intrapartum electronic fetal monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Three tier approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, the National Institutes of Child Health and Human Development creating a three tier FHR interpretation system (",
"    <a class=\"graphic graphic_table graphicRef57583 \" href=\"UTD.htm?11/43/11964\">",
"     table 2",
"    </a>",
"    ), in which category I represents a normal tracing (predictive of normal fetal acid-base balance at the time of observation), category II represents an indeterminate tracing, and category III represents an abnormal tracing (predictive of a significant incidence of abnormal fetal acid-base status at the time of observation) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    They recommended prompt evaluation of category III tracings; most patients with these tracings require expeditious intervention, such as provision of maternal oxygen, change in maternal position, treatment of maternal hypotension, and discontinuation of any uterotonic drugs being administered [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/31\">",
"     31",
"    </a>",
"    ]. The goal of these interventions is to improve fetal oxygenation by improving uteroplacental perfusion. Preparations for delivery are made while these interventions are initiated so that delivery can be performed promptly if the fetal heart rate pattern does not improve. While the fetal impact of the timing-of-decision to delivery interval is controversial, we try to make the decision to deliver within 15 to 20 minutes of the start of severe bradycardia (FHR below 100 bpm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/35\">",
"     35",
"    </a>",
"    ]) and deliver the infant within 20 to 30 minutes of the start of the bradycardia when there is no improvement despite therapeutic intervention.",
"   </p>",
"   <p>",
"    Category II tracings are not predictive of abnormal fetal acid-base status, but require continued surveillance, evaluation, initiation of appropriate corrective measures as indicated, and reevaluation. The guidelines do not offer specific recommendations for evaluation of these fetuses, but it seems reasonable to employ other diagnostic measures, such as sonography, scalp stimulation, and scalp blood sampling (see below).",
"   </p>",
"   <p>",
"    Category I tracings are normal, thus these fetuses are monitored either intermittently or continuously, depending on underlying risk factors.",
"   </p>",
"   <p>",
"    This approach to management of FHR tracings has been endorsed by the American College of Obstetricians and Gynecologists [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/5,62\">",
"     5,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of category I, II, and III tracing is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38311?source=see_link\">",
"     \"Management of intrapartum category I, II, and III fetal heart rate tracings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Further evaluation of nonreassuring patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient episodes of hypoxemia, such as during a contraction or temporary cord occlusion, are generally well-tolerated by the fetus. Repeated or prolonged episodes, especially if severe, may lead to fetal acidosis, sometimes with subsequent hypoxic-ischemic encephalopathy (defined as metabolic acidosis pH &lt;7, base deficit &ge;12",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    and Apgar score 0 to 3 for &gt;5 minutes, and evidence of neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/63\">",
"     63",
"    </a>",
"    ]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35702?source=see_link\">",
"     \"Umbilical cord blood acid-base analysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1253?source=see_link\">",
"     \"Fetal acid-base physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One goal of intrapartum fetal surveillance is to distinguish the fetus with a nonreassuring FHR tracing who is hypoxemic, but well compensated, from one who is acidotic and at risk for neurologic impairment or death. Further evaluation using ancillary tests are useful for this purpose. After adequate cervical dilation and rupture of the membranes, direct access to the fetus is readily available and permits measurement of its physiologic status.",
"   </p>",
"   <p>",
"    One group has attempted to formulate a framework for standardizing management of intrapartum FHR patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/64\">",
"     64",
"    </a>",
"    ]. They identified 134 FHR patterns (combinations of variability, rate, and various types of decelerations), and determined the risk of newborn acidemia associated with each pattern. A grid was created to relate the FHR patterns and risk of fetal acidemia (five gradations from none to severe). Obstetrical interventions were proposed based on the degree of risk. This algorithm has not been validated clinically.",
"   </p>",
"   <p>",
"    Since FHR patterns are at best only a screening tool, this approach is a valuable beginning to evaluation and management of FHR patterns in laboring patients. However, some important variables, such as rate of change of pH under different circumstances, acidosis despite a vigorous fetus, pre-existing fetal acidemia with a normal FHR pattern, response to specific therapies, and stage of labor, were not considered. Furthermore, the algorithm does not lend itself to use of clinical judgment in the setting of complex and rapidly changing conditions. The individual patient needs to participate in the decision as to whether an immediate cesarean or continued monitoring and evaluation is the best approach for her. The algorithm is also not useful when there is a 10 percent risk of a depressed infant, and possibly when the risk of neurological injury or stillbirth is increased, but less than 10 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     FHR response to stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal scalp stimulation maneuver is easy to perform, inexpensive, readily available, and not uncomfortable. The examiner stimulates the fetal vertex by prodding it with the examining finger or an instrument, such as an Allis clamp, during a vaginal examination [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/32\">",
"     32",
"    </a>",
"    ]. If a FHR acceleration is elicited (rise of &ge;15 bpm above baseline lasting for &ge;15 seconds), absence of acidosis (ie, fetal pH greater than 7.20) is likely. Vibroacoustic stimulation is a less invasive alternative technique. In general, when accelerations are induced by scalp stimulation, acidosis is present in less than 10 percent of fetuses, and when no accelerations occur, acidosis is present in about 50 percent of fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/32,65,66\">",
"     32,65,66",
"    </a>",
"    ]. One study, however, reported five fetuses with pH &lt;7.20 out of 70 fetal blood samples; three of these five fetuses had FHR accelerations and two did not [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=see_link&amp;anchor=H11#H11\">",
"     \"Antepartum fetal heart rate assessment\", section on 'Vibroacoustic stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Scalp stimulation should be performed when the FHR is at its baseline rate. Performance during a deceleration is not likely to terminate the deceleration, is not predictive of fetal acid-base status, and might exacerbate fetal compromise if parasympathetic tone increases in response to the stimulus.",
"   </p>",
"   <p>",
"    A meta-analysis that assessed performance of various stimulation tests (vibroacoustic stimulation, digital scalp stimulation, fetal scalp puncture, Allis clamp scalp stimulation) for the prediction of intrapartum fetal acidemia found them to be similarly effective and more useful for predicting the absence, rather than the presence, of acidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/65\">",
"     65",
"    </a>",
"    ]. Less traumatic techniques (vibroacoustic stimulation, digital scalp stimulation) are preferable to more traumatic techniques (fetal scalp puncture, Allis clamp scalp stimulation). For digital stimulation, the pooled likelihood ratio (LR) for acidosis with a negative test (ie, acceleration elicited) was 0.06, 95% CI 0.01-0.31. Failure to elicit an acceleration was not a definitive sign of acidosis. For digital stimulation, the pooled LR of acidosis with a positive test (ie, no acceleration) was 15, 95% CI 3-76.",
"   </p>",
"   <p>",
"    Continued monitoring and repeat testing is advised if the suspicious FHR pattern persists since test results reflect acute fetal status at the time of the test, and may worsen over time. Rarely, acidemia is present despite FHR accelerations and a prenatal insult associated with fetal neurological injury may not show FHR abnormalities in the intrapartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     STAN fetal heart monitor (ST analysis)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A technical system, the STAN S31 fetal heart monitor, monitors the fetal electrocardiogram (ECG) during labor. Use of this device is based on the principle that fetal hypoxemia can result in elevation or depression of the ST segment. The monitor's software automatically identifies and analyzes changes in the T wave and the ST segment of the fetal ECG, which is obtained via a spiral electrode attached to the fetal scalp. The analysis is displayed in the lower section of the monitor's screen as a series of data points",
"    <span class=\"nowrap\">",
"     ('T/QRS",
"    </span>",
"    crosses') and event markers. Studies have reported the STAN computerized interpretation of FHR monitoring system has sensitivity of 38 to 90 percent and specificity of 83 to 100 percent for detecting fetal acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major benefit of this technique appears to be a reduced need for fetal blood sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. A 2012 meta-analysis of five randomized trials involving a total of 15,352 pregnant women assessed the use of the fetal ECG as an adjunct to continuous electronic FHR monitoring during labor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/73\">",
"     73",
"    </a>",
"    ]. In comparison to continuous electronic fetal heart rate monitoring alone, the use of adjunctive ST waveform analysis was associated with significant reductions in fetal scalp sampling during labor (RR 0.59, 95% CI 0.44-0.79; number needed to treat 11) and operative vaginal delivery (RR 0.88, 95% CI 0.80-0.97; number needed to treat 64). There were no statistically significant differences in the number of babies with metabolic acidosis at birth",
"    <span class=\"nowrap\">",
"     (50/7689",
"    </span>",
"    [ST analysis group] versus",
"    <span class=\"nowrap\">",
"     73/7641",
"    </span>",
"    [usual care group], RR 0.72, 95% CI 0.43-1.19), cord artery pH &lt;7.05, or rate of cesarean delivery, Apgar score less than 7, NICU admission, neonatal encephalopathy, or perinatal death. A subsequent meta-analysis using individual participant data had similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/75\">",
"     75",
"    </a>",
"    ]. The finding of reduced need for scalp sampling could be important because it may allow a reduction in cesarean deliveries in countries (eg, United States) where scalp sampling is not used [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The STAN S31 fetal heart monitor has been approved by the United States Food and Drug Administration as an adjunct to assessment of nonreassuring FHR tracings in pregnancies over 36 weeks of gestation, in labor, with vertex presentation and ruptured fetal membranes. The device should not be used if there is a contraindication to placement of a fetal scalp electrode. It is also not indicated for monitoring initiated in the second stage of labor or for precipitous labor, since there may not be enough time to establish the baseline fetal ECG data required for automatic ST event signals. Transcutaneous Electrical Nerve Stimulation (TENS) for analgesia during labor is another contraindication because TENS may interfere with acquisition of the fetal ECG signal.",
"   </p>",
"   <p>",
"    Clinicians using this device should be trained and credentialed in its use and interpretation. This technique is promising, but at this time, there are inadequate clinical and cost data from a variety of hospital settings to allow a recommendation for routine use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Fetal scalp blood sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal blood sampling is typically performed using a kit. An amnioscope with a light source is used to expose the fetal scalp, which is cleansed of blood, mucous, and amniotic fluid. The scalp is smeared with silicone gel so that a droplet of blood forms when the scalp is punctured with a 2-mm blade. The blood is collected in long, heparinized capillary tubes. The test requires that the cervix be dilated at least 2 to 3 cm, can be difficult to perform, and can be uncomfortable for the parturient.",
"   </p>",
"   <p>",
"    Both pH and lactate measurements (see below) require the same laboratory facilities for microsample analysis. Quality control and laboratory standards must be in place to utilize these tests, and most obstetrical services in the United States cannot support them, even when shared with neonatology. Most hospitals have centralized laboratories for these tests and cannot function in a logistically efficient way for patients in labor. The degree of technical skill required, cost, need for continuous availability of standardized equipment and trained personnel, and parturient discomfort have precluded use of these tests in many labor and delivery units, despite their proven benefit in diagnosing fetal acidosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       pH",
"      </strong>",
"      &mdash; Capillary blood collected from the fetal scalp usually has a pH lower than umbilical venous blood, and correlates well with fetal arterial values. However, scalp edema can result in erroneous results. A scalp pH value of &lt;7.20 has traditionally been used to represent the critical value for identifying fetal acidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/77-79\">",
"       77-79",
"      </a>",
"      ]. However, a scalp pH below 7.15 is more representative of the 10th percentile and is closer to the threshold currently used in umbilical cord blood analysis to define fetal acidemia associated with neurological deficits [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/80\">",
"       80",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35702?source=see_link\">",
"       \"Umbilical cord blood acid-base analysis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The accuracy of intermittent fetal scalp pH assessment for predicting neonatal acidosis with subsequent neurologic sequelae has been questioned [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/80\">",
"       80",
"      </a>",
"      ]. It is no longer used in many institutions [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/81\">",
"       81",
"      </a>",
"      ], although its use can result in fewer cesarean deliveries performed for the indication of nonreassuring fetal status [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/77,82\">",
"       77,82",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The test has poor sensitivity and positive predictive value (PPV) for predicting umbilical arterial pH &lt;7.0 (sensitivity 35 percent, PPV 9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/80\">",
"       80",
"      </a>",
"      ]. The test also has poor sensitivity and PPV for identifying newborns with hypoxic-ischemic encephalopathy (sensitivity 50 percent, PPV 3 percent). However, logistics and skill in sampling, as well as laboratory capability, may affect results.",
"     </li>",
"     <li>",
"      <strong>",
"       Fetal lactate concentration",
"      </strong>",
"      &mdash; Fetal lactate concentration is determined by collecting a sample of capillary blood from the fetal scalp, similar to the method used for assessing scalp pH; however, much less fetal blood is needed (5 microL versus 35 microL) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/83\">",
"       83",
"      </a>",
"      ]. A large multicenter randomized trial compared the performance of pH measurement in fetal scalp blood with the performance of lactate measurement for predicting fetal acidemia and obstetrical and neonatal outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/84\">",
"       84",
"      </a>",
"      ]. There were no significant differences between the groups in any outcome, although sampling failure rates were lower in the lactate group (1 versus 10 percent for pH measurement). A smaller study reported similar results (1.3 versus 20.6 percent for pH measurement) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/85\">",
"       85",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Lactate has been proposed as the major determinant of fetal pH and it has been known for many years that lactate measurements are as valid as pH measurement, but, as discussed above, measurement of lactate levels was problematic [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/86-88\">",
"       86-88",
"      </a>",
"      ]. We do not measure fetal lactate concentrations routinely because of the practical difficulties of obtaining results, which are similar to the difficulties of getting results of fetal pH measurements (see above). Since rapid enzymatic assays for lactate are now available, it may become a more useful test in the evaluation of possible acidosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Fetal pulse oximetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from human and animal studies suggest that fetal arterial oxygen saturation (SaO",
"    <sub>",
"     2",
"    </sub>",
"    by blood gas co-oximetry) &gt;30 percent is usually associated with pH &gt;7.13 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/89\">",
"     89",
"    </a>",
"    ]. In humans, the mean fetal oxygen saturation (SpO",
"    <sub>",
"     2",
"    </sub>",
"    by fetal pulse oximetry) during the first and second stages of labor is 59&plusmn;10 percent and 53&plusmn;10 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/90\">",
"     90",
"    </a>",
"    ]. In the setting of a nonreassuring FHR pattern, fetal SpO",
"    <sub>",
"     2",
"    </sub>",
"    &lt;30 percent for greater than 10 minutes has been associated with an increased risk of fetal acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/91-93\">",
"     91-93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence that assessment of fetal oxygen saturation by fetal pulse oximetry (FPO) as an adjunct to electronic FHR monitoring improves neonatal outcome. Four randomized trials have compared the outcome of pregnancies in which FPO results were available for intrapartum clinical management to the outcome of controls in which this information was not available [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/94-97\">",
"     94-97",
"    </a>",
"    ]. All four trials found that use of FPO had no significant effect on the overall rate of cesarean delivery or on the rate of any maternal or infant outcome evaluated; the rates were similar in both groups. In two of the four trials (n = 1010, n = 601 subjects), the rate of cesarean delivery performed because of nonreassuring FHR tracings was lower when FPO was used, but the difference was more cesareans for other indications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/94,96\">",
"     94,96",
"    </a>",
"    ]. However, these findings were not supported by the largest trial (n = 5341 subjects) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/97\">",
"     97",
"    </a>",
"    ], which also found that low oxygen saturation was present almost as often in fetuses with reassuring FHR patterns as in fetuses with nonreassuring FHR patterns: 25 and 35 percent of fetuses, respectively.",
"   </p>",
"   <p>",
"    We do not recommend use of this device because there is insufficient evidence of any benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Management of nonreassuring FHR patterns",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determine the likely cause of the abnormality, if possible (eg, abruptio placenta, cord prolapse, maternal medication, rapid descent of fetal head).",
"     </li>",
"     <li>",
"      Attempt to correct the problem or initiate general measures to improve fetal oxygenation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/98-106\">",
"       98-106",
"      </a>",
"      ]. The approach for specific FHR patterns is summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef71679 \" href=\"UTD.htm?9/38/9838\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/107\">",
"       107",
"      </a>",
"      ] and discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38311?source=see_link\">",
"       \"Management of intrapartum category I, II, and III fetal heart rate tracings\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the nonreassuring pattern does not improve within a few minutes, perform ancillary tests to determine the fetal condition. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Further evaluation of nonreassuring patterns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determine whether operative intervention (cesarean or instrumental vaginal delivery) is needed, and the urgency of this intervention. Prepare for rapid intervention, if needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of accelerations almost always assures the absence of fetal acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. If such accelerations are not observed, they should be elicited by manual or vibroacoustic stimulation. If accelerations cannot be elicited, further evaluation by fetal scalp sampling for pH, lactate concentration, or fetal ECG is indicated to help clarify the fetal acid-base status. Combined results from two series showed that 37 of 87 fetuses (45 percent) in whom accelerations could not be elicited were acidotic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/32,108\">",
"     32,108",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'FHR response to stimulation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If accelerations cannot be elicited, then variability should be evaluated. Good FHR variability is strongly associated (98 percent) with an umbilical pH &gt;7.15 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/109\">",
"     109",
"    </a>",
"    ]. If variability is decreased in the setting of repetitive decelerations and absent accelerations, we suggest delivery. The combination of undetectable or minimal FHR variability and late or variable decelerations is the FHR pattern most predictive of acidemia, although only one in four to five fetuses with these findings will be acidotic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serial evaluation every 20 to 30 minutes is necessary if the FHR pattern remains nonreassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?23/7/23674/abstract/107\">",
"     107",
"    </a>",
"    ]. Expeditious delivery is indicated for persistent nonreassuring FHR patterns associated with acidosis or if the presence of acidosis cannot be excluded (ie, category III tracings (",
"    <a class=\"graphic graphic_table graphicRef57583 \" href=\"UTD.htm?11/43/11964\">",
"     table 2",
"    </a>",
"    )).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rationale for monitoring the FHR during labor is that the fetal response to blood volume changes, acidemia, and hypoxemia may be reflected indirectly by FHR patterns since the fetal medullary cardiorespiratory center modulates the fetal heart rate. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two commonly used modalities for intrapartum FHR monitoring are continuous electronic FHR monitoring and intermittent auscultation. In uncomplicated pregnancies, there is no evidence that one of these techniques is better than the other or that use of these techniques reduces the incidence of stillbirth, low Apgar scores, neonatal intensive care unit admission, neurological injury, or cerebral palsy. There is evidence that continuous electronic FHR monitoring leads to higher operative delivery rates than auscultation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effectiveness of intrapartum FHR monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Medicolegal precedent in the United States mandates some form of intrapartum FHR monitoring. For high-risk pregnant women, we suggest continuous rather than intermittent intrapartum FHR monitoring (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For low risk women, we suggest either intermittent or continuous electronic FHR monitoring (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Frequent intermittent auscultation is cumbersome and difficult for most nursing services to achieve. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effectiveness of intrapartum FHR monitoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three tier approach (",
"      <a class=\"graphic graphic_table graphicRef57583 \" href=\"UTD.htm?11/43/11964\">",
"       table 2",
"      </a>",
"      ) is a useful method for evaluation and management of FHR patterns. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Three tier approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transient episodes of hypoxemia, such as during a contraction or temporary cord compression, are generally well-tolerated by the fetus. Repeated or prolonged episodes, especially if severe, may lead to fetal acidosis. Further evaluation of a nonreassuring FHR tracing is indicated to distinguish the fetus who is not hypoxemic, or hypoxemic but well compensated, from one who is acidotic. We recommend assessing the FHR response to stimulation. In contrast to other modalities, this test is readily available, easy to perform, inexpensive, and comfortable for the patient. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Further evaluation of nonreassuring patterns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normal FHR variability is strongly associated (98 percent) with an umbilical pH &gt;7.15. The combination of undetectable or minimal FHR variability and late or variable decelerations with late recovery are the FHR patterns most predictive of acidemia, although only about 23 percent of fetuses with these findings will be acidotic. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Management of nonreassuring FHR patterns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If possible, determine the cause of the nonreassuring FHR and initiate potentially corrective interventions (eg, discontinuing uterotonic drugs, maternal position change, IV fluids, oxygen). We recommend expeditious delivery for persistent nonreassuring FHR patterns associated with acidosis or if the presence of acidosis cannot be excluded (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Management of nonreassuring FHR patterns'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/1\">",
"      Freeman RK. Problems with intrapartum fetal heart rate monitoring interpretation and patient management. Obstet Gynecol 2002; 100:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/2\">",
"      WALKER N. The case for conservatism in management of foetal distress. Br Med J 1959; 2:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/3\">",
"      Benson RC, Shubeck F, Deutschberger J, et al. Fetal heart rate as a predictor of fetal distress. A report from the collaborative project. Obstet Gynecol 1968; 32:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/4\">",
"      Young BK. Monitoring the fetal heart: a continuing controversy. Obstet Gynecol Surv 1995; 50:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/5\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol 2009; 114:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/6\">",
"      Alfirevic Z, Devane D, Gyte GM. Continuous cardiotocography (CTG) as a form of electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database Syst Rev 2006; :CD006066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/7\">",
"      Graham EM, Petersen SM, Christo DK, Fox HE. Intrapartum electronic fetal heart rate monitoring and the prevention of perinatal brain injury. Obstet Gynecol 2006; 108:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/8\">",
"      Thacker SB, Stroup DF, Peterson HB. Efficacy and safety of intrapartum electronic fetal monitoring: an update. Obstet Gynecol 1995; 86:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/9\">",
"      Vintzileos AM, Nochimson DJ, Antsaklis A, et al. Comparison of intrapartum electronic fetal heart rate monitoring versus intermittent auscultation in detecting fetal acidemia at birth. Am J Obstet Gynecol 1995; 173:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/10\">",
"      Larma JD, Silva AM, Holcroft CJ, et al. Intrapartum electronic fetal heart rate monitoring and the identification of metabolic acidosis and hypoxic-ischemic encephalopathy. Am J Obstet Gynecol 2007; 197:301.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/11\">",
"      Chen HY, Chauhan SP, Ananth CV, et al. Electronic fetal heart rate monitoring and its relationship to neonatal and infant mortality in the United States. Am J Obstet Gynecol 2011; 204:491.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/12\">",
"      Vintzileos AM, Nochimson DJ, Guzman ER, et al. Intrapartum electronic fetal heart rate monitoring versus intermittent auscultation: a meta-analysis. Obstet Gynecol 1995; 85:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/13\">",
"      Nelson KB, Dambrosia JM, Ting TY, Grether JK. Uncertain value of electronic fetal monitoring in predicting cerebral palsy. N Engl J Med 1996; 334:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/14\">",
"      Phelan JP, Kim JO. Fetal heart rate observations in the brain-damaged infant. Semin Perinatol 2000; 24:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/15\">",
"      MacDonald D, Grant A, Sheridan-Pereira M, et al. The Dublin randomized controlled trial of intrapartum fetal heart rate monitoring. Am J Obstet Gynecol 1985; 152:524.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Preventive Services Task Force. Intrapartum Electronic Fetal Monitoring. www.ahcpr.gov/clinic/uspstf/uspsiefm.htm. (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     Canadian Task Force on Preventive Health Care. www.ctfphc.org/. (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence (NICE). Intrapartum Care: management and delivery of care to women in labour. London, NICE, 2007.",
"    </li>",
"    <li>",
"     Antenatal Diagnosis III. NIH publ. #79-1973, Wash DC. 1979.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/20\">",
"      Bakker JJ, Janssen PF, van Halem K, et al. Internal versus external tocodynamometry during induced or augmented labour. Cochrane Database Syst Rev 2012; 12:CD006947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/21\">",
"      McCartney PR. Computer analysis of the fetal heart rate. J Obstet Gynecol Neonatal Nurs 2000; 29:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/22\">",
"      Agrawal SK, Doucette F, Gratton R, et al. Intrapartum computerized fetal heart rate parameters and metabolic acidosis at birth. Obstet Gynecol 2003; 102:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/23\">",
"      Li X, Zheng D, Zhou S, et al. Approximate entropy of fetal heart rate variability as a predictor of fetal distress in women at term pregnancy. Acta Obstet Gynecol Scand 2005; 84:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/24\">",
"      Van Laar JO, Porath MM, Peters CH, Oei SG. Spectral analysis of fetal heart rate variability for fetal surveillance: review of the literature. Acta Obstet Gynecol Scand 2008; 87:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/25\">",
"      Costa A, Ayres-de-Campos D, Costa F, et al. Prediction of neonatal acidemia by computer analysis of fetal heart rate and ST event signals. Am J Obstet Gynecol 2009; 201:464.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/26\">",
"      Nielsen PV, Stigsby B, Nickelsen C, Nim J. Intra- and inter-observer variability in the assessment of intrapartum cardiotocograms. Acta Obstet Gynecol Scand 1987; 66:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/27\">",
"      Beaulieu MD, Fabia J, Leduc B, et al. The reproducibility of intrapartum cardiotocogram assessments. Can Med Assoc J 1982; 127:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/28\">",
"      Chauhan SP, Klauser CK, Woodring TC, et al. Intrapartum nonreassuring fetal heart rate tracing and prediction of adverse outcomes: interobserver variability. Am J Obstet Gynecol 2008; 199:623.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/29\">",
"      Electronic fetal heart rate monitoring: research guidelines for interpretation. National Institute of Child Health and Human Development Research Planning Workshop. Am J Obstet Gynecol 1997; 177:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/30\">",
"      Blackwell SC, Grobman WA, Antoniewicz L, et al. Interobserver and intraobserver reliability of the NICHD 3-Tier Fetal Heart Rate Interpretation System. Am J Obstet Gynecol 2011; 205:378.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/31\">",
"      Macones GA, Hankins GD, Spong CY, et al. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Obstet Gynecol 2008; 112:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/32\">",
"      Clark SL, Gimovsky ML, Miller FC. The scalp stimulation test: a clinical alternative to fetal scalp blood sampling. Am J Obstet Gynecol 1984; 148:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/33\">",
"      Krebs HB, Petres RE, Dunn LJ, Smith PJ. Intrapartum fetal heart rate monitoring. VI. Prognostic significance of accelerations. Am J Obstet Gynecol 1982; 142:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/34\">",
"      Powell OH, Melville A, MacKenna J. Fetal heart rate acceleration in labor: excellent prognostic indicator. Am J Obstet Gynecol 1979; 134:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/35\">",
"      Young BK, Weinstein HM. Moderate fetal bradycardia. Am J Obstet Gynecol 1976; 126:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/36\">",
"      Young BK, Katz M, Klein SA. Intrapartum fetal cardiac arrhythmias. Obstet Gynecol 1979; 54:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/37\">",
"      Cahill AG, Roehl KA, Odibo AO, Macones GA. Association and prediction of neonatal acidemia. Am J Obstet Gynecol 2012; 207:206.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/38\">",
"      Westgate JA, Wibbens B, Bennet L, et al. The intrapartum deceleration in center stage: a physiologic approach to the interpretation of fetal heart rate changes in labor. Am J Obstet Gynecol 2007; 197:236.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/39\">",
"      Myers RE, Mueller-Heubach E, Adamsons K. Predictability of the state of fetal oxygenation from a quantitative analysis of the components of late deceleration. Am J Obstet Gynecol 1973; 115:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/40\">",
"      Frasch MG, Grasch MG, Frasch MG, et al. Measures of acidosis with repetitive umbilical cord occlusions leading to fetal asphyxia in the near-term ovine fetus. Am J Obstet Gynecol 2009; 200:200.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/41\">",
"      Ross MG, Jessie M, Amaya K, et al. Correlation of arterial fetal base deficit and lactate changes with severity of variable heart rate decelerations in the near-term ovine fetus. Am J Obstet Gynecol 2013; 208:285.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/42\">",
"      Krebs HB, Petres RE, Dunn LJ. Intrapartum fetal heart rate monitoring. VIII. Atypical variable decelerations. Am J Obstet Gynecol 1983; 145:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/43\">",
"      Cahill AG, Roehl KA, Odibo AO, Macones GA. Association of atypical decelerations with acidemia. Obstet Gynecol 2012; 120:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/44\">",
"      Hamilton E, Warrick P, O'Keeffe D. Variable decelerations: do size and shape matter? J Matern Fetal Neonatal Med 2012; 25:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/45\">",
"      Katz M, Wilson SJ, Young BK. Sinusoidal fetal heart rate. II. Continuous tissue pH studies. Am J Obstet Gynecol 1980; 136:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/46\">",
"      Young BK, Katz M, Wilson SJ. Sinusoidal fetal heart rate. I. Clinical significance. Am J Obstet Gynecol 1980; 136:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/47\">",
"      Johnson TR Jr, Compton AA, Rotmensch J, et al. Significance of the sinusoidal fetal heart rate pattern. Am J Obstet Gynecol 1981; 139:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/48\">",
"      Murotsuki J, Kimura Y, Iwamoto M, et al. [Power spectral analysis of spontaneous rhythm in peripheral blood flow in fetal lamb]. Nihon Sanka Fujinka Gakkai Zasshi 1993; 45:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/49\">",
"      van Woerden EE, van Geijn HP, Swartjes JM, et al. Fetal heart rhythms during behavioural state 1F. Eur J Obstet Gynecol Reprod Biol 1988; 28:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/50\">",
"      Lustig-Gillman I, Young BK, Silverman F, et al. Fetal intraventricular hemorrhage: sonographic diagnosis and clinical implications. J Clin Ultrasound 1983; 11:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/51\">",
"      Schifrin BS, Hamilton-Rubinstein T, Shields JR. Fetal heart rate patterns and the timing of fetal injury. J Perinatol 1994; 14:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/52\">",
"      Phelan JP, Ahn MO. Perinatal observations in forty-eight neurologically impaired term infants. Am J Obstet Gynecol 1994; 171:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/53\">",
"      Ahn MO, Korst LM, Phelan JP. Normal Fetal Heart Rate Pattern in the Brain-damaged Infant: A Failure of Intrapartum Fetal Monitoring? J Matern Fetal Investig 1998; 8:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/54\">",
"      Terao T, Kawashima Y, Noto H, et al. Neurological control of fetal heart rate in 20 cases of anencephalic fetuses. Am J Obstet Gynecol 1984; 149:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/55\">",
"      McWhinney NA, Knowles S, Green HL, Gordon H. Transmission of the maternal electrocardiograph via a fetal scalp electrode in the presence of intrauterine death. Case report. Br J Obstet Gynaecol 1984; 91:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/56\">",
"      Phelan JP. Labor admission test. Clin Perinatol 1994; 21:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/57\">",
"      Mires G, Williams F, Howie P. Randomised controlled trial of cardiotocography versus Doppler auscultation of fetal heart at admission in labour in low risk obstetric population. BMJ 2001; 322:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/58\">",
"      Impey L, Reynolds M, MacQuillan K, et al. Admission cardiotocography: a randomised controlled trial. Lancet 2003; 361:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/59\">",
"      Blix E, Sviggum O, Koss KS, &Oslash;ian P. Inter-observer variation in assessment of 845 labour admission tests: comparison between midwives and obstetricians in the clinical setting and two experts. BJOG 2003; 110:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/60\">",
"      Devane D, Lalor JG, Daly S, et al. Cardiotography versus intermittent auscultation of fetal heart on admission to labour ward for assessment of fetal wellbeing. Cochrane Database Syst Rev 2012; :CD005122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/61\">",
"      Hofmeyr GJ, Kulier R. Operative versus conservative management for 'fetal distress' in labour. Cochrane Database Syst Rev 2012; :CD001065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/62\">",
"      American College of Obstetricians and Gynecologists. Practice bulletin no. 116: Management of intrapartum fetal heart rate tracings. Obstet Gynecol 2010; 116:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/63\">",
"      Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Number 326, December 2005. Inappropriate use of the terms fetal distress and birth asphyxia. Obstet Gynecol 2005; 106:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/64\">",
"      Parer JT, Ikeda T. A framework for standardized management of intrapartum fetal heart rate patterns. Am J Obstet Gynecol 2007; 197:26.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/65\">",
"      Skupski DW, Rosenberg CR, Eglinton GS. Intrapartum fetal stimulation tests: a meta-analysis. Obstet Gynecol 2002; 99:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/66\">",
"      Edersheim TG, Hutson JM, Druzin ML, Kogut EA. Fetal heart rate response to vibratory acoustic stimulation predicts fetal pH in labor. Am J Obstet Gynecol 1987; 157:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/67\">",
"      Trochez RD, Sibanda T, Sharma R, Draycott T. Fetal monitoring in labor: are accelerations good enough? J Matern Fetal Neonatal Med 2005; 18:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/68\">",
"      Nicolaides KH, Economides DL, Soothill PW. Blood gases, pH, and lactate in appropriate- and small-for-gestational-age fetuses. Am J Obstet Gynecol 1989; 161:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/69\">",
"      Mansano RZ, Beall MH, Ross MG. Fetal ST segment heart rate analysis in labor: improvement of intervention criteria using interpolated base deficit. J Matern Fetal Neonatal Med 2007; 20:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/70\">",
"      Vayssiere C, Haberstich R, Sebahoun V, et al. Fetal electrocardiogram ST-segment analysis and prediction of neonatal acidosis. Int J Gynaecol Obstet 2007; 97:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/71\">",
"      Nor&eacute;n H, Luttkus AK, Stupin JH, et al. Fetal scalp pH and ST analysis of the fetal ECG as an adjunct to cardiotocography to predict fetal acidosis in labor--a multi-center, case controlled study. J Perinat Med 2007; 35:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/72\">",
"      Neilson JP. Fetal electrocardiogram (ECG) for fetal monitoring during labour. Cochrane Database Syst Rev 2012; 4:CD000116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/73\">",
"      Becker JH, Bax L, Amer-W&aring;hlin I, et al. ST analysis of the fetal electrocardiogram in intrapartum fetal monitoring: a meta-analysis. Obstet Gynecol 2012; 119:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/74\">",
"      Salmelin A, Wiklund I, Bottinga R, et al. Fetal monitoring with computerized ST analysis during labor: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2013; 92:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/75\">",
"      Schuit E, Amer-Wahlin I, Ojala K, et al. Effectiveness of electronic fetal monitoring with additional ST analysis in vertex singleton pregnancies at &gt;36 weeks of gestation: an individual participant data metaanalysis. Am J Obstet Gynecol 2013; 208:187.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/76\">",
"      Garite TJ. The search for an adequate back-up test for intrapartum fetal heart rate monitoring. Am J Obstet Gynecol 2013; 208:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/77\">",
"      Zalar RW Jr, Quilligan EJ. The influence of scalp sampling on the cesarean section rate for fetal distress. Am J Obstet Gynecol 1979; 135:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/78\">",
"      SALING E. [BLOOD GAS RELATIONS AND THE ACID-BASE EQUILIBRIUM OF THE FETUS IN AN UNCOMPLICATED COURSE OF DELIVERY]. Z Geburtshilfe Gynakol 1964; 161:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/79\">",
"      Banta HD, Thacker SB. Assessing the costs and benefits of electronic fetal monitoring. Obstet Gynecol Surv 1979; 34:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/80\">",
"      Kruger K, Hallberg B, Blennow M, et al. Predictive value of fetal scalp blood lactate concentration and pH as markers of neurologic disability. Am J Obstet Gynecol 1999; 181:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/81\">",
"      Perkins RP. Requiem for a heavyweight: the demise of scalp blood pH sampling. J Matern Fetal Med 1997; 6:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/82\">",
"      Young DC, Gray JH, Luther ER, Peddle LJ. Fetal scalp blood pH sampling: its value in an active obstetric unit. Am J Obstet Gynecol 1980; 136:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/83\">",
"      Westgren M, Kruger K, Ek S, et al. Lactate compared with pH analysis at fetal scalp blood sampling: a prospective randomised study. Br J Obstet Gynaecol 1998; 105:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/84\">",
"      Wiberg-Itzel E, Lipponer C, Norman M, et al. Determination of pH or lactate in fetal scalp blood in management of intrapartum fetal distress: randomised controlled multicentre trial. BMJ 2008; 336:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/85\">",
"      Westgren M, Kublickas M, Kruger K. Role of lactate measurements during labor. Obstet Gynecol Surv 1999; 54:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/86\">",
"      Suidan JS, Wasserman JF, Young BK. Placental contribution to lactate production by the human fetoplacental unit. Am J Perinatol 1984; 1:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/87\">",
"      Suidan JS, Antoine C, Silverman F, et al. Human maternal-fetal lactate relationships. J Perinat Med 1984; 12:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/88\">",
"      Suidan JS, Young BK. Outcome of fetuses with lactic acidemia. Am J Obstet Gynecol 1984; 150:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/89\">",
"      Dildy GA. Fetal pulse oximetry. Clin Obstet Gynecol 2011; 54:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/90\">",
"      Dildy GA, van den Berg PP, Katz M, et al. Intrapartum fetal pulse oximetry: fetal oxygen saturation trends during labor and relation to delivery outcome. Am J Obstet Gynecol 1994; 171:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/91\">",
"      Nonnenmacher A, Hopp H, Dudenhausen J. Predictive value of pulse oximetry for the development of fetal acidosis. J Perinat Med 2010; 38:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/92\">",
"      K&uuml;hnert M, Seelbach-G&ouml;ebel B, Butterwegge M. Predictive agreement between the fetal arterial oxygen saturation and fetal scalp pH: results of the German multicenter study. Am J Obstet Gynecol 1998; 178:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/93\">",
"      Seelbach-G&ouml;bel B, Heupel M, K&uuml;hnert M, Butterwegge M. The prediction of fetal acidosis by means of intrapartum fetal pulse oximetry. Am J Obstet Gynecol 1999; 180:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/94\">",
"      Garite TJ, Dildy GA, McNamara H, et al. A multicenter controlled trial of fetal pulse oximetry in the intrapartum management of nonreassuring fetal heart rate patterns. Am J Obstet Gynecol 2000; 183:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/95\">",
"      Klauser CK, Christensen EE, Chauhan SP, et al. Use of fetal pulse oximetry among high-risk women in labor: a randomized clinical trial. Am J Obstet Gynecol 2005; 192:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/96\">",
"      East CE, Brennecke SP, King JF, et al. The effect of intrapartum fetal pulse oximetry, in the presence of a nonreassuring fetal heart rate pattern, on operative delivery rates: a multicenter, randomized, controlled trial (the FOREMOST trial). Am J Obstet Gynecol 2006; 194:606.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/97\">",
"      Bloom SL, Spong CY, Thom E, et al. Fetal pulse oximetry and cesarean delivery. N Engl J Med 2006; 355:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/98\">",
"      Kulier R, Hofmeyr GJ. Tocolytics for suspected intrapartum fetal distress. Cochrane Database Syst Rev 2000; :CD000035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/99\">",
"      Simpson KR, James DC. Efficacy of intrauterine resuscitation techniques in improving fetal oxygen status during labor. Obstet Gynecol 2005; 105:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/100\">",
"      Clark SL, Cotton DB, Pivarnik JM, et al. Position change and central hemodynamic profile during normal third-trimester pregnancy and post partum. Am J Obstet Gynecol 1991; 164:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/101\">",
"      Althabe O Jr, Schwarcz RL, Pose SV, et al. Effects on fetal heart rate and fetal pO2 of oxygen administration to the mother. Am J Obstet Gynecol 1967; 98:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/102\">",
"      Tomimatsu T, Pereyra Pena J, Hatran DP, Longo LD. Maternal oxygen administration and fetal cerebral oxygenation: studies on near-term fetal lambs at both low and high altitude. Am J Obstet Gynecol 2006; 195:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/103\">",
"      Haydon ML, Gorenberg DM, Nageotte MP, et al. The effect of maternal oxygen administration on fetal pulse oximetry during labor in fetuses with nonreassuring fetal heart rate patterns. Am J Obstet Gynecol 2006; 195:735.",
"     </a>",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynaecologists. The use of electronic fetal monitoring. The use and interpretation of cardiotocography in intrapartum fetal surveillance. London: RCOG Press; 2001. p.136 (Evidence-based clinical guidelines; no. 8).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/105\">",
"      Pullen KM, Riley ET, Waller SA, et al. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. Am J Obstet Gynecol 2007; 197:414.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/106\">",
"      Egarter CH, Husslein PW, Rayburn WF. Uterine hyperstimulation after low-dose prostaglandin E2 therapy: tocolytic treatment in 181 cases. Am J Obstet Gynecol 1990; 163:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/107\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists, Number 70, December 2005 (Replaces Practice Bulletin Number 62, May 2005). Intrapartum fetal heart rate monitoring. Obstet Gynecol 2005; 106:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/108\">",
"      Smith CV, Nguyen HN, Phelan JP, Paul RH. Intrapartum assessment of fetal well-being: a comparison of fetal acoustic stimulation with acid-base determinations. Am J Obstet Gynecol 1986; 155:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/7/23674/abstract/109\">",
"      Parer JT, King T, Flanders S, et al. Fetal acidemia and electronic fetal heart rate patterns: is there evidence of an association? J Matern Fetal Neonatal Med 2006; 19:289.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 418 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-192C8F5B95-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23674=[""].join("\n");
var outline_f23_7_23674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECTIVENESS OF INTRAPARTUM FHR MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EQUIPMENT AND TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Doppler ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fetal electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Artificial intelligence computer programs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION OF THE FETAL HEART RATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Standards for interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Reassuring patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonreassuring patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Absent or minimal variability with decelerations or bradycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1059913\">",
"      Recurrent late decelerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1059921\">",
"      Recurrent variable decelerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1059929\">",
"      Bradycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Sinusoidal heart rate pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Indeterminate patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pre-existing fetal neurological injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LABOR ADMISSION TEST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT OF FETAL HEART RATE PATTERNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Three tier approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Further evaluation of nonreassuring patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - FHR response to stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - STAN fetal heart monitor (ST analysis)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Fetal scalp blood sampling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Fetal pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Management of nonreassuring FHR patterns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/418\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/418|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/5/3165\" title=\"table 1\">",
"      NICHHD FHR interpretation guide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/43/11964\" title=\"table 2\">",
"      Category I II and III FHR tracings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/38/9838\" title=\"table 3\">",
"      Management of intrapartum fetal heart rate tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/418|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?21/10/21673\" title=\"waveform 1\">",
"      R R interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?20/10/20647\" title=\"waveform 2\">",
"      Normal variability and accelerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/37/29272\" title=\"waveform 3\">",
"      Tachysystole with low normal variability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?6/62/7144\" title=\"waveform 4\">",
"      Early deceleration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?23/19/23861\" title=\"waveform 5\">",
"      Late decelerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?17/46/18152\" title=\"waveform 6\">",
"      Variable decelerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?16/33/16920\" title=\"waveform 7\">",
"      Severe variable decelerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?3/35/3639\" title=\"waveform 8\">",
"      Tachycardia and variable decels with late recovery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?33/43/34487\" title=\"waveform 9\">",
"      Variable decelerations with shoulder pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?12/38/12902\" title=\"waveform 10\">",
"      Sinusoidal FHR pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?39/56/40836\" title=\"waveform 11\">",
"      Premature atrial contractions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/14/1253?source=related_link\">",
"      Fetal acid-base physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38311?source=related_link\">",
"      Management of intrapartum category I, II, and III fetal heart rate tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=related_link\">",
"      Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35702?source=related_link\">",
"      Umbilical cord blood acid-base analysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_7_23675="Evaluation of infants with WNV";
var content_f23_7_23675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended clinical evaluation of infants with clinical or laboratory evidence of possible congenital West Nile virus (WNV) infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Computerized tomography (CT) scan of the head and",
"brain. If abnormal, a pediatric neurologist should be consulted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pediatric ophthalmologic evaluation, including",
"examination of the retina.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete blood count, platelet count, and liver",
"function tests, including alanine aminotransferase (ALT) and aspartate",
"aminotransferase (AST). Examination of the CSF should be considered,",
"and if done, should include testing of the CSF for IgM to WNV.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluation by a dysmorphologist or clinical geneticist.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Further evaluation of any congenital abnormalities to",
"determine alternative causes, including genetic, infectious, or other",
"teratogenic causes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Repeat hearing screen at age 6 months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Careful evaluation of head circumference, physical",
"characteristics, and developmental milestones throughout the first year",
"of life.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Repeat examination of infant serum for IgG and IgM",
"antibody to WNV at age 6 months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histopathologic examination of the placenta and",
"umbilical cord, testing of frozen placental tissue and cord tissue for",
"WNV nucleic acid, and testing of cord serum for IgM and IgG antibody to",
"WNV.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     www.cdc.gov.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23675=[""].join("\n");
var outline_f23_7_23675=null;
var title_f23_7_23676="Differential dx of arthritis";
var content_f23_7_23676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of some systemic causes of arthritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reactive arthritis (formerly Reiter's syndrome)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rheumatoid arthritis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gonococcal arthritis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Psoriatic arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age",
"       </td>",
"       <td>",
"        Young",
"       </td>",
"       <td>",
"        Middle",
"       </td>",
"       <td>",
"        Young",
"       </td>",
"       <td>",
"        Middle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gender",
"       </td>",
"       <td>",
"        Male&gt;female",
"       </td>",
"       <td>",
"        Female&gt;male",
"       </td>",
"       <td>",
"        Female&gt;male",
"       </td>",
"       <td>",
"        No effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onset",
"       </td>",
"       <td>",
"        Abrupt",
"       </td>",
"       <td>",
"        Insidious",
"       </td>",
"       <td>",
"        Abrupt",
"       </td>",
"       <td>",
"        Insidious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Joint number",
"       </td>",
"       <td>",
"        Oligoarthritis",
"       </td>",
"       <td>",
"        Polyarthritis",
"       </td>",
"       <td>",
"        Monoarthritis or oligoarthritis",
"       </td>",
"       <td>",
"        Oligoarthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symmetry of arthritis",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sausage digits",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Back pain",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urethritis",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin lesions",
"       </td>",
"       <td>",
"        Palms and soles in 10 percent",
"       </td>",
"       <td>",
"        Subcutaneous nodules",
"       </td>",
"       <td>",
"        Pustular, nodular or vesicular",
"       </td>",
"       <td>",
"        Psoriasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonococcus",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23676=[""].join("\n");
var outline_f23_7_23676=null;
var title_f23_7_23677="IP ABX intermittent dosing";
var content_f23_7_23677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intraperitoneal antibiotic dosing recommendations for intermittent administration in peritoneal dialysis patients (adult)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         IP dose*",
"        </p>",
"        <p>",
"         For patients with residual renal function (defined as greater than 100 mL per day urine output): empirically increase dose shown by twenty-five percent",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Aminoglycosides",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"        &Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amikacin",
"       </td>",
"       <td>",
"        2 mg/kg in one exchange per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gentamicin",
"       </td>",
"       <td>",
"        0.6 mg/kg in one exchange per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Netilmicin&loz;",
"       </td>",
"       <td>",
"        0.6 mg/kg in one exchange per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tobramycin",
"       </td>",
"       <td>",
"        0.6 mg/kg in one exchange per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cephalosporins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefazolin",
"       </td>",
"       <td>",
"        15 mg/kg in one exchange per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cefepime",
"       </td>",
"       <td>",
"        1 gram in one exchange per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cephalothin&loz;",
"       </td>",
"       <td>",
"        15 mg/kg in one exchange per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cephradine&loz;",
"       </td>",
"       <td>",
"        15 mg/kg in one exchange per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ceftazidime",
"       </td>",
"       <td>",
"        1 to 1.5 grams in one exchange per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ceftizoxime",
"       </td>",
"       <td>",
"        1 gram in one exchange per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Penicillins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Intermittent IP administration of penicillins is not recommended. See text and accompanying table on continuous IP antibiotic administration and dosing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vancomycin",
"       </td>",
"       <td>",
"        15 to 30 mg/kg repeat every 3 to 7 days, based on serum drug levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Linezolid",
"       </td>",
"       <td>",
"        ORAL: 200 to 300 mg once per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Teicoplanin&loz;",
"       </td>",
"       <td>",
"        15 mg/kg in one exchange per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Combinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ampicillin-sulbactam&sect;",
"       </td>",
"       <td>",
"        2 grams in one exchange every twelve hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Imipenem-cilastatin&yen;",
"       </td>",
"       <td>",
"        1 gram in one exchange every twelve hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quinupristin-dalfopristin",
"       </td>",
"       <td>",
"        25 mg per liter of dialysate in alternate bags������",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trimethoprim-sulfamethoxazole (co-trimoxazole)",
"       </td>",
"       <td>",
"        ORAL: one 960 mg double strength tablet (trimethoprim 160 mg and sulfamethoxazole 800 mg) two times per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Antifungal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluconazole",
"       </td>",
"       <td>",
"        200 mg in one exchange every 24 to 48 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Table shows suggested dose of antibiotics for intermittent IP administration (except as noted otherwise) in peritoneal dialysate for continuous ambulatory PD associated peritonitis. For dosing of antibiotics administered continuously (with each dialysate exchange), see text and accompanying table.",
"    <div class=\"footnotes\">",
"     IP: intraperitoneal; PD: peritoneal dialysis.",
"     <br>",
"      * Dwell time for dialysate exchange containing antibiotic(s) must be at least six hours.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Penicillins and some cephalosporins may inactivate aminoglycosides. Mixture in the same dialysate should be minimized or avoided.",
"       <br>",
"        &Delta; Repeated or prolonged courses of aminoglycosides are not recommended if an alternative is available. See text.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Not available in United States.",
"         <br>",
"          &sect; Based on ampicillin component.",
"          <br>",
"           &yen; Based on imipenem component.",
"           <br>",
"            ������ Given in conjunction with 500 mg intravenous twice daily.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Li, PK, Szeto, CC, Piraino, B, et al. Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. Perit Dial Int 2010; 30:393. Published in Peritoneal Dialysis International. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23677=[""].join("\n");
var outline_f23_7_23677=null;
var title_f23_7_23678="Survival estimates for glioblastoma by risk group";
var content_f23_7_23678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival estimates for glioblastoma by risk group",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 291px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Group 1: Age &le;40, frontal tumor.",
"    <br>",
"     Group 2: Age &le;40, other tumor sites.",
"     <br>",
"      Group 3: Age &gt;40 and &lt;65; KPS &gt;70 and gross or subtotal resection.",
"      <br>",
"       Group 4: Age &ge;65 or age &lt;40; or KPS &le;70; or biopsy only.",
"       <br>",
"        Fourteen patients in group 1, 12 patients in group 2, and 9 patients in group 3 lived beyond 5 years (260 weeks). Fifty-three patients were censored (13 in group 1, 14 in group 2, 21 in group 3, and 5 in group 4).",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reproduced with permission from: Lamborn, KR, Chang, SM, Prados, MD. Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis. Neuro-oncology 2004; 6:231. Copyright &copy; 2004 Duke University Press.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23678=[""].join("\n");
var outline_f23_7_23678=null;
var title_f23_7_23679="Diphtheria epidemiology US";
var content_f23_7_23679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72244&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diphtheria cases in the United States",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 670px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Diphtheria. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book, 12th ed, Atkinson W, Wolfe S, Hamborsky J (Eds), Public Health Foundation, Washington, DC 2011. Available at:",
"     <a href=\"file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/dip.pdf\">",
"      www.cdc.gov/vaccines/pubs/pinkbook/downloads/dip.pdf",
"     </a>",
"     (Accessed on September 12, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_7_23679=[""].join("\n");
var outline_f23_7_23679=null;
